<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Intratympanic corticosteroids for sudden sensorineural hearing loss - Plontke, SK - 2022 | Cochrane Library</title> <meta content="Intratympanic corticosteroids for sudden sensorineural hearing loss - Plontke, SK - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008080.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Intratympanic corticosteroids for sudden sensorineural hearing loss - Plontke, SK - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008080.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008080.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Intratympanic corticosteroids for sudden sensorineural hearing loss" name="citation_title"/> <meta content="Stefan K Plontke&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Martin Luther University Halle-Wittenberg" name="citation_author_institution"/> <meta content="stefan.plontke@uk-halle.de" name="citation_author_email"/> <meta content="Christoph Meisner&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Robert Bosch Hospital" name="citation_author_institution"/> <meta content="Sumit Agrawal" name="citation_author"/> <meta content="Western University" name="citation_author_institution"/> <meta content="Per Cayé-Thomasen" name="citation_author"/> <meta content="Copenhagen University Hospital Rigshospitalet" name="citation_author_institution"/> <meta content="Kevin Galbraith" name="citation_author"/> <meta content="Cochrane ENT" name="citation_author_institution"/> <meta content="Anthony A Mikulec" name="citation_author"/> <meta content="St. Louis University" name="citation_author_institution"/> <meta content="Lorne Parnes" name="citation_author"/> <meta content="Western University" name="citation_author_institution"/> <meta content="Yaamini Premakumar" name="citation_author"/> <meta content="Guy's Hospital" name="citation_author_institution"/> <meta content="Julia Reiber" name="citation_author"/> <meta content="Martin Luther University Halle-Wittenberg" name="citation_author_institution"/> <meta content="Anne GM Schilder" name="citation_author"/> <meta content="Arne Liebau&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Martin Luther University Halle-Wittenberg" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD008080.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/07/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008080.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008080.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008080.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenal Cortex Hormones [adverse effects]; Dizziness; *Hearing Loss, Sensorineural [drug therapy]; Pain [drug therapy]; *Tympanic Membrane Perforation [drug therapy]; Vertigo [drug therapy]" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008080.pub2&amp;doi=10.1002/14651858.CD008080.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="PMzGcYGP";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008080\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008080\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008080\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008080\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ko","ms","hr","fr","hu","zh_HANS","zh_HANT","ja","fa","pl"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD008080.pub2",title:"Intratympanic corticosteroids for sudden sensorineural hearing loss",firstPublishedDate:"Jul 22, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane ENT Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PMzGcYGP&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008080.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008080.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008080.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008080.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008080.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008080.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008080.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008080.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008080.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008080.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10301 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008080.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-sec-0145"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-sec-0130"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/appendices#CD008080-sec-0157"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/supinfo/CD008080StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/supinfo/CD008080StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Intratympanic corticosteroids for sudden sensorineural hearing loss</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="Stefan K. Plontke, Christoph Meisner and Arne Liebau contributed equally to this study."><a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/information#CD008080-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Stefan K Plontke</a><sup>a</sup></li> <li class="author custom-tooltip" title="Stefan K. Plontke, Christoph Meisner and Arne Liebau contributed equally to this study."><a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/information#CD008080-cr-0005">Christoph Meisner</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/information#CD008080-cr-0006">Sumit Agrawal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/information#CD008080-cr-0007">Per Cayé-Thomasen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/information#CD008080-cr-0008">Kevin Galbraith</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/information#CD008080-cr-0009">Anthony A Mikulec</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/information#CD008080-cr-0010">Lorne Parnes</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/information#CD008080-cr-0011">Yaamini Premakumar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/information#CD008080-cr-0012">Julia Reiber</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/information#CD008080-cr-0013">Anne GM Schilder</a></li> <li class="author custom-tooltip" title="Stefan K. Plontke, Christoph Meisner and Arne Liebau contributed equally to this study."><a href="/cdsr/doi/10.1002/14651858.CD008080.pub2/information#CD008080-cr-0014">Arne Liebau</a><sup>a</sup></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/information/en#CD008080-sec-0161">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 July 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008080.pub2">https://doi.org/10.1002/14651858.CD008080.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008080-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008080-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008080-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008080-abs-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008080-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008080-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008080-abs-0014">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008080-abs-0001" lang="en"> <section id="CD008080-sec-0001"> <h3 class="title" id="CD008080-sec-0001">Background</h3> <p>Idiopathic sudden sensorineural hearing loss (ISSNHL) is common, and defined as a sudden decrease in sensorineural hearing sensitivity of unknown aetiology. Systemic corticosteroids are widely used, however their value remains unclear. Intratympanic injections of corticosteroids have become increasingly common in the treatment of ISSNHL. </p> </section> <section id="CD008080-sec-0002"> <h3 class="title" id="CD008080-sec-0002">Objectives</h3> <p>To assess the effects of intratympanic corticosteroids in people with ISSNHL.</p> </section> <section id="CD008080-sec-0003"> <h3 class="title" id="CD008080-sec-0003">Search methods</h3> <p>The Cochrane ENT Information Specialist searched the Cochrane ENT Trials Register; CENTRAL (2021, Issue 9); PubMed; Ovid Embase; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials (search date 23 September 2021). </p> </section> <section id="CD008080-sec-0004"> <h3 class="title" id="CD008080-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) involving people with ISSNHL and follow‐up of over a week. Intratympanic corticosteroids were given as primary or secondary treatment (after failure of systemic therapy). </p> </section> <section id="CD008080-sec-0005"> <h3 class="title" id="CD008080-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods, including GRADE to assess the certainty of the evidence. Our primary outcome was change in hearing threshold with pure tone audiometry. Secondary outcomes included the proportion of people whose hearing improved, final hearing threshold, speech audiometry, frequency‐specific hearing changes and adverse effects. </p> </section> <section id="CD008080-sec-0006"> <h3 class="title" id="CD008080-sec-0006">Main results</h3> <p>We included 30 studies, comprising 2133 analysed participants. Some studies had more than two treatment arms and were therefore relevant to several comparisons. Studies investigated intratympanic corticosteroids as either primary (initial) therapy or secondary (rescue) therapy after failure of initial treatment. </p> <p><b><i>1. Intratympanic corticosteroids versus systemic corticosteroids as primary therapy</i> </b> </p> <p>We identified 16 studies (1108 participants). Intratympanic therapy may result in little to no improvement in the change in hearing threshold (mean difference (MD) ‐5.93 dB better, 95% confidence interval (CI) ‐7.61 to ‐4.26; 10 studies; 701 participants; low‐certainty). We found little to no difference in the proportion of participants whose hearing was improved (risk ratio (RR) 1.04, 95% CI 0.97 to 1.12; 14 studies; 972 participants; moderate‐certainty). Intratympanic therapy may result in little to no difference in the final hearing threshold (MD ‐3.31 dB, 95% CI ‐6.16 to ‐0.47; 7 studies; 516 participants; low‐certainty). Intratympanic therapy may increase the number of people who experience vertigo or dizziness (RR 2.53, 95% CI 1.41 to 4.54; 1 study; 250 participants; low‐certainty) and probably increases the number of people with ear pain (RR 15.68, 95% CI 6.22 to 39.49; 2 studies; 289 participants; moderate‐certainty). It also resulted in persistent tympanic membrane perforation (range 0% to 3.9%; 3 studies; 359 participants; very low‐certainty), vertigo/dizziness at the time of injection (1% to 21%, 3 studies; 197 participants; very low‐certainty) and ear pain at the time of injection (10.5% to 27.1%; 2 studies; 289 participants; low‐certainty). </p> <p><b><i>2. Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as primary therapy</i> </b> </p> <p>We identified 10 studies (788 participants). Combined therapy may have a small effect on the change in hearing threshold (MD ‐8.55 dB better, 95% CI ‐12.48 to ‐4.61; 6 studies; 435 participants; low‐certainty). The evidence is very uncertain as to whether combined therapy changes the proportion of participants whose hearing is improved (RR 1.27, 95% CI 1.15 to 1.41; 10 studies; 788 participants; very low‐certainty). Combined therapy may result in slightly lower (more favourable) final hearing thresholds but the evidence is very uncertain, and it is not clear whether the change would be important to patients (MD ‐9.11 dB, 95% CI ‐16.56 to ‐1.67; 3 studies; 194 participants; very low‐certainty). Some adverse effects only occurred in those who received combined therapy. These included persistent tympanic membrane perforation (range 0% to 5.5%; 5 studies; 474 participants; very low‐certainty), vertigo or dizziness at the time of injection (range 0% to 8.1%; 4 studies; 341 participants; very low‐certainty) and ear pain at the time of injection (13.5%; 1 study; 73 participants; very low‐certainty).  </p> <p><b><i>3. Intratympanic corticosteroids versus no treatment or placebo as secondary therapy</i> </b> </p> <p>We identified seven studies (279 participants). Intratympanic therapy may have a small effect on the change in hearing threshold (MD ‐9.07 dB better, 95% CI ‐11.47 to ‐6.66; 7 studies; 280 participants; low‐certainty). Intratympanic therapy may result in a much higher proportion of participants whose hearing is improved (RR 5.55, 95% CI 2.89 to 10.68; 6 studies; 232 participants; low‐certainty). Intratympanic therapy may result in lower (more favourable) final hearing thresholds (MD ‐11.09 dB, 95% CI ‐17.46 to ‐4.72; 5 studies; 203 participants; low‐certainty). Some adverse effects only occurred in those who received intratympanic injection. These included persistent tympanic membrane perforation (range 0% to 4.2%; 5 studies; 185 participants; very low‐certainty), vertigo or dizziness at the time of injection (range 6.7% to 33%; 3 studies; 128 participants; very low‐certainty) and ear pain at the time of injection (0%; 1 study; 44 participants; very low‐certainty).  </p> <p><b><i>4. Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as secondary therapy</i> </b> </p> <p>We identified one study with 76 participants. Change in hearing threshold was not reported. Combined therapy may result in a higher proportion with hearing improvement, but the evidence is very uncertain (RR 2.24, 95% CI 1.10 to 4.55; very low‐certainty). Adverse effects were poorly reported with only data for persistent tympanic membrane perforation (rate 8.1%, very low‐certainty). </p> </section> <section id="CD008080-sec-0007"> <h3 class="title" id="CD008080-sec-0007">Authors' conclusions</h3> <p>Most of the evidence in this review is low‐ or very low‐certainty, therefore it is likely that further studies may change our conclusions.   </p> <p>For primary therapy, intratympanic corticosteroids may have little or no effect compared with systemic corticosteroids. There may be a slight benefit from combined treatment when compared with systemic treatment alone, but the evidence is uncertain. </p> <p>For secondary therapy, there is low‐certainty evidence that intratympanic corticosteroids, when compared to no treatment or placebo, may result in a much higher proportion of participants whose hearing is improved, but may only have a small effect on the change in hearing threshold. It is very uncertain whether there is additional benefit from combined treatment over systemic steroids alone. </p> <p>Although adverse effects were poorly reported, the different risk profiles of intratympanic treatment (including tympanic membrane perforation, pain and dizziness/vertigo) and systemic treatment (for example, blood glucose problems) should be considered when selecting appropriate treatment.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008080-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008080-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD008080-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD008080-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008080-abs-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008080-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008080-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/hu#CD008080-abs-0011">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008080-abs-0017">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008080-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008080-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD008080-abs-0020">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008080-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008080-abs-0015">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008080-abs-0016">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008080-abs-0002" lang="en"> <h3>Treatment of sudden hearing loss with corticosteroids applied into the middle ear</h3> <p><b>What is sudden hearing loss?</b> </p> <p>Sudden hearing loss is a condition characterised by the sudden onset (usually within 72 hours) of reduced or absent hearing. </p> <p><b>How is it treated?</b> </p> <p>People have often used corticosteroids – a type of anti‐inflammatory medicine ‐ to treat the condition. These medicines are usually taken by mouth or injected into the body (known as systemic corticosteroids), but can also be given as an injection directly into the middle ear, through the eardrum (known as intratympanic corticosteroids). </p> <p><b>What did we want to find out?</b> </p> <p>It is not clear whether intratympanic treatment with corticosteroids is effective, or which of these treatments (intratympanic or systemic) is best for treating this condition. </p> <p><b>What did we do?</b> </p> <p>We searched for all relevant studies in the medical literature, compared the results and summarised the evidence. We also assessed how certain the evidence was, considering factors such as study size and the way studies were conducted. Based on our assessments, we categorised the evidence as being of very low, low, moderate or high certainty. </p> <p><b>What did we find?</b> </p> <p>We found 30 studies that included 2133 people. These studies compared intratympanic treatment with corticosteroids with no treatment, with placebo (sham or dummy treatment) and with corticosteroids that were taken by mouth or injection into the body (systemic corticosteroids). We took into account whether people were having their first treatment for sudden deafness or whether they had previously had some other kind of treatment (which had not worked). </p> <p><b><i>For people having their first treatment for sudden deafness</i> </b> </p> <p>We did not find any studies that compared intratympanic corticosteroids to no treatment or placebo (dummy) treatment.  </p> <p>Intratympanic corticosteroids might result in little or no difference in hearing when compared to people who receive systemic corticosteroids, and might make little to no difference in the number of people whose hearing improves. The side effects may be different with these two types of treatment. With intratympanic treatment, people may have an increase in the risk of dizziness or ear pain as compared to systemic corticosteroids, typically at the time of injection, and some may develop a small hole in the ear drum. However, systemic treatment may also cause an increased risk of different side effects, such as problems with sugar levels in the blood.  </p> <p>Taking intratympanic corticosteroids <i>as well as</i> systemic corticosteroids might result in a small improvement in hearing compared to systemic corticosteroids alone, but it is uncertain how many people would notice an improvement. As above, intratympanic treatment may cause some side effects, but we cannot be certain of the number of people who may experience these.  </p> <p><b><i>For people having additional treatment for sudden deafness (when their first treatment did not work)</i> </b> </p> <p>When compared to no treatment or a placebo (dummy) treatment, intratympanic corticosteroids may result in a much larger number of people having an improvement in their hearing but may only improve hearing slightly. As with first treatment, intratympanic injections might cause some side effects, such as pain or dizziness at the time of the injection, or development of a small hole in the ear drum. We are not certain how often these side effects will happen.  </p> <p>We are very uncertain whether adding intratympanic treatment to systemic treatment will result in an improvement in hearing.  </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We considered most of the evidence we found to be of low or very low certainty. This was because there were often some problems with how the studies had been carried out, there may have been few people included in the studies and sometimes results from different studies were conflicting. Therefore, the conclusions of this review may change as new studies are published.  </p> <p><b>How up‐to‐date is this evidence?</b> </p> <p>The evidence in this Cochrane Review is current to 23 September 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008080-sec-0145" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008080-sec-0145"></div> <h3 class="title" id="CD008080-sec-0146">Implications for practice</h3> <section id="CD008080-sec-0146"> <p>For <b>primary therapy</b>, we identified no evidence on the efficacy of intratympanic therapy compared to placebo/no treatment.  </p> <p>Intratympanic corticosteroids probably result in little to no difference when compared to systemic corticosteroids in primary therapy for idiopathic sudden sensorineural hearing loss (ISSNHL). The evidence regarding adverse events was very uncertain. </p> <p>The evidence regarding combined corticosteroid therapy was very uncertain. There may be a slight benefit to combined therapy when compared to systemic corticosteroids alone, but the difference may be small. For change in hearing threshold and for final hearing threshold, the mean difference between the two groups is close to the threshold for a minimally important difference (estimates of ‐8.55 dB and ‐9.11 dB, respectively) and it is unclear whether it would be important to patients. The evidence regarding adverse events was very uncertain. </p> <p>For <b>secondary therapy</b>, intratympanic corticosteroid therapy may be more effective than no treatment or placebo for ISSNHL. Intratympanic therapy may result in a much higher proportion of participants whose hearing is improved and for final hearing threshold the difference exceeds the threshold for a minimally important difference (estimates of ‐11.09 dB HL). For change in hearing threshold, the mean difference between the two groups is close to the threshold for a minimally important difference (estimates of ‐9.07 dB). </p> <p>The evidence regarding adverse events was very uncertain.</p> <p>We are very uncertain about the effect of combined therapy on hearing outcome for secondary therapy of ISSNHL when compared to systemic therapy. The change in hearing threshold may be slightly increased, but it is not clear whether the extent of change would be important to patients. The evidence regarding adverse events was very uncertain. </p> <p>Further research is likely to have an important impact on the estimates of effect and may change the estimates in the respective comparisons. </p> </section> <h3 class="title" id="CD008080-sec-0147">Implications for research</h3> <section id="CD008080-sec-0147"> <section id="CD008080-sec-0148"> <h5 class="title">Suggestions for future trials</h5> <section id="CD008080-sec-0149"> <h6 class="title">Design and methods</h6> <p>Where the intent is to assess the effectiveness of interventions, randomised controlled trials should be conducted. Trials should use appropriate methods for randomisation and allocation concealment to avoid selection bias, and they should be adequately powered. Attempts should be made by the investigators to blind participants, healthcare professionals and study personnel to the treatment allocation. This could be through the use of a placebo and ensuring that the treatment regimens are the same between treatment arms. A double placebo design should be used where dosage form and/or regimen are different. Where it is not possible to blind participants and/or clinicians to the treatment received, efforts to blind the outcome assessment and analysis personnel should be made. </p> </section> <section id="CD008080-sec-0150"> <h6 class="title">Populations</h6> <p>Populations should be clearly described with respect to the degree of initial hearing loss and additional symptoms. A standardised and evidence‐based definition for ISSNHL, especially with respect to audiological criteria, still needs to be established. </p> </section> <section id="CD008080-sec-0151"> <h6 class="title">Interventions</h6> <p>There should be clear reporting of the therapies used, including the drug, dose, frequency and duration, and clear descriptions of any adjunctive therapies used across the treatment groups. Publications should make it clear exactly which form of the drug (the exact chemical composition) was used in the study. This should apply to any drug used, not just corticosteroids (<a href="./references#CD008080-bbs2-0137" title="SaltAN , PlontkeSK . Steroid nomenclature in inner ear therapy. Otology &amp; Neurotology2020;41(6):722-6. [PMID: 32195918]">Salt 2020</a>). We recommend gathering evidence on the various corticosteroid treatment regimens including various concentrations/dosages, forms of corticosteroids, injection frequencies and intervals, drug formulations and delivery systems, and (other) methods for enhancing uptake into the cochlea. </p> </section> <section id="CD008080-sec-0152"> <h6 class="title">Outcomes</h6> <p>Primary and secondary outcomes should be clearly defined and these parameters should also be evaluated later on. The development of core outcome sets for ISSNHL would be beneficial for future trials. This would help to ensure that trials are consistent, high‐quality and examine appropriate outcomes. Fixed levels of improvement may not always be adequate, since benefit for patients depends on the initial degree of hearing loss and the final outcome, respectively. Speech audiometry in quiet and noise are preferable over pure tone thresholds. Internationally comparable speech audiometry tests should be further developed and applied if possible (<a href="./references#CD008080-bbs2-0055" title="AkeroydMA , ArlingerS , BentlerRA , BoothroydA , DillierN , DreschlerWA , et al. International Collegium of Rehabilitative Audiology (ICRA) recommendations for the construction of multilingual speech tests. ICRA Working Group on Multilingual Speech Tests. International Journal of Audiology2015;54 Suppl 2:17-22. [PMID: 25922886]">Akeroyd 2015</a>; <a href="./references#CD008080-bbs2-0100" title="KollmeierB , WarzybokA , HochmuthS , ZokollMA , UslarV , BrandT , et al. The multilingual matrix test: Principles, applications, and comparison across languages: a review. International journal of audiology2015;54 Suppl 2:3-16. [PMID: 26383182]">Kollmeier 2015</a>). Other categorical criteria of high patient relevance, such as the necessity of an ear still being a cochlear implant or hearing aid candidate after partial recovery, should be considered (see <a href="#CD008080-sec-0130">Discussion</a> and <a href="./references#CD008080-bbs2-0067" title="ChandrasekharSS , Tsai DoBS , SchwartzSR , BontempoLJ , FaucettEA , FinestoneSA , et al. Clinical practice guideline: sudden hearing loss (Update). Otolaryngology - Head and Neck Surgery2019;161(1 Suppl):S1-S45. [PMID: 31369359]">Chandrasekhar 2019</a>). Consensus should also be reached on the appropriate minimally importance difference (appreciable or clinically relevant benefit and harm) to be used when assessing hearing outcomes.  </p> <p>The primary endpoint should not be too early for ISSNHL studies. We suggest a primary outcome assessment between four weeks and three months, and studies should follow up patients for at least six months. Efforts should be made to establish internationally comparable speech audiometry tests including speech understanding in noise. </p> <p>The assessment of adverse effects should be defined in the protocol and these should be systematically sought during trials. A validated patient‐reported outcome measure (PROM) or quality of life measurement instrument should be used whenever possible. </p> </section> <section id="CD008080-sec-0153"> <h6 class="title">Reporting</h6> <p>Trials should be registered in a regional or international clinical trials registry and, when published, adhere to reporting guidelines such as CONSORT (<a href="./references#CD008080-bbs2-0139" title="SchulzKF , AltmanDG , MoherD . CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials2010;11:32. [PMID: 20334632]">Schulz 2010</a>). </p> </section> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008080-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008080-sec-0008"></div> <div class="table" id="CD008080-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Intratympanic corticosteroids versus systemic corticosteroids as primary therapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Intratympanic corticosteroids versus systemic corticosteroids as primary therapy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> sudden sensorineural hearing loss </p> <p><b>Settings:</b> initial therapy </p> <p><b>Intervention:</b> intratympanic steroid therapy </p> <p><b>Comparison:</b> systemic steroid therapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Systemic therapy</b> </p> <p><b>(assumed risk)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intratympanic therapy</b> </p> <p><b>(corresponding risk)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in hearing threshold determined by PTA</p> <p> </p> <p>Range 0 dB to 140 dB</p> <p> </p> <p>Negative values represent lowering and positive values represent raising of the hearing threshold. A lower hearing threshold represents hearing improvement). </p> <p> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in PTA ranged across control groups from ‐30.07 dB to ‐15.1 dB</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in PTA in the intervention groups was on average ‐5.93 dB greater (from ‐4.26 greater to ‐7.61 greater) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>701</p> <p>(10 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐5.93  dB</p> <p>(95% CI ‐7.61 to ‐4.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intratympanic therapy may have a trivial/no effect on the change in hearing threshold when compared to systemic steroids (as primary therapy). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of patients whose hearing is improved</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>731 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>760 per 1000 (709 to 818)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>972</p> <p>(14 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04</p> <p>(95% CI 0.97 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intratympanic therapy probably results in little to no difference in the proportion of patients whose hearing is improved compared to systemic corticosteroids (as primary therapy). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final hearing threshold determined by PTA (a lower value represents better hearing)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final PTA ranged across control groups from 25.1 dB to 59 dB </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final PTA in the intervention groups was on average ‐3.31 dB lower (‐6.16 lower to ‐0.47 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>516</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐3.31 dB</p> <p>(95% CI ‐6.16 to ‐0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intratympanic therapy may result in little to no difference in the final hearing threshold (as primary therapy). </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse events<sup>b</sup> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events in control group</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events in intervention group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tympanic membrane perforation</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not applicable<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Ranged from 0% (0/30) to 3.9% (5/129) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>463 (4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain regarding the risk of tympanic membrane perforation for those who received intratympanic corticosteroid as primary treatment.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness: timing not reported<sup>d</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13/121 (10.7%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35/129 (27.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.53 (1.41 to 4.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intratympanic therapy may increase the risk of vertigo/dizziness of unspecified timing as compared to systemic corticosteroid. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness: at the time of injection </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not applicable<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 studies reported a rate between 1.5% (1/67) and 21% (4/19) for those who received an intratympanic injection<sup>e</sup>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301 (4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain regarding the risk of vertigo/dizziness at the time of intratympanic injection of corticosteroid as primary treatment.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain: timing not reported<sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4/141 (2.8%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74/148 (50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>289 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 15.68 (95% CI 6.22 to 39.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intratympanic corticosteroid injection probably increases the risk of ear pain of unspecified timing as compared to systemic corticosteroid when used as primary treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain: at the time of injection<sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not applicable<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 studies reported a rate between 4.8% (5/104) and 27.1% (35/129)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>393 (3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence suggests that there may be a risk of ear pain at the time of intratympanic injection of corticosteroid as primary treatment.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>PTA:</b> pure tone audiometry; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><sup>a</sup>Fourteen studies recruited participants suffering from sudden sensorineural hearing loss. The incidence of improvement for the systemic corticosteroid group in these 14 studies was 73.07%. We have used 731 per 1000 to express the assumed risk. </p> <p><sup>b</sup>Only the most widely reported adverse events are described here. For adverse events that could feasibly occur in either group, we have only included the studies that provided a rate for both groups. For adverse events that could only occur in one group, we have only included the studies that reported the rate in that group, and presented these as a range. A full description of adverse event data is available for reference in <a href="./full#CD008080-tbl-0002">Table 1</a>. </p> <p><sup>c</sup>Comparisons between patients receiving intratympanic therapy and those receiving only systemic therapy were regarded as invalid for the following adverse events: persistent tympanic membrane perforation, vertigo observed at the time of intratympanic injection and ear pain observed at the time of intratympanic injection. This is explained in <a href="#CD008080-sec-0028">Data extraction and management</a>.  </p> <p><sup>d</sup>A single study reported a rate for both intratympanic and systemic corticosteroid (<a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>). However, it is not specified whether all of the patients in the intratympanic corticosteroid group experiencing vertigo did so at the time of injection. We have therefore reported this outcome separately from vertigo/dizziness interpreted as having occurred specifically at the time of injection. </p> <p><sup>e</sup>In two studies, two groups received intratympanic injection: in <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>, one group received intratympanic corticosteroid and the other received intratympanic and systemic corticosteroid; in <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>, one group received intratympanic corticosteroid and the other received intravenous followed by intratympanic corticosteroid. </p> <p><sup>f</sup>In each study contributing data, the number of participants with ear pain/earache was presented separately from the numbers with ear pain at intratympanic injection. It was assumed, therefore that those participants with pain at injection were not included among those with ear pain/earache.  </p> <p> </p> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate.  </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level due to risk of bias: eight studies were at high risk of other bias, three studies were at risk of attrition bias and three studies were at risk of selection bias. Downgraded one level due to inconsistency: the size and direction of effect varied between the studies and the I<sup>2</sup> value was 80%. </p> <p><sup>2</sup>Downgraded one level due to risk of bias: we judged 11 of 14 studies to be at unclear or high risk of selection bias and we judged 12 of 14 studies to be at high risk of other bias. </p> <p><sup>3</sup>Downgraded one level due to risk of bias: we judged six studies to be at high risk of other bias; two studies were at high risk of selection bias. Downgraded one level due to inconsistency: the I<sup>2</sup> value was moderate (41%). </p> <p><sup>4</sup>Downgraded one level due to risk of bias: we judged one study to be at high risk of bias because of concern about random sequence generation and allocation concealment. Downgraded two levels due to imprecision: the number of events is smaller than the optimal information size (taken as 300 events) and an effect estimate could not be calculated. </p> <p><sup>5</sup>Downgraded one level due to imprecision: the number of events is smaller than the optimal information size (taken as 300 events). Downgraded one level because of indirectness: provision of data by only a single study from a single setting, which may not adequately represent all patients with ISSNHL. </p> <p><sup>6</sup>Downgraded two levels due to risk of bias: we judged two studies to be at high risk of bias because of incomplete outcome data; we judged one study to be at high risk of bias because of concern about random sequence generation and allocation concealment. Downgraded two levels due to imprecision: the number of events is smaller than the optimal information size (taken as 300 events) and an effect estimate could not be calculated. </p> <p><sup>7</sup>Downgraded one level due to imprecision: the number of events is smaller than the optimal information size (taken as 300 events). </p> <p><sup>8</sup>Downgraded two levels because of imprecision: the number of events is smaller than the optimal information size (taken as 300 events) and an effect estimate could not be calculated. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008080-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">1.</span> <span class="table-title">Adverse events: intratympanic compared to systemic corticosteroids as primary therapy</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse event reported</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>How reported</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Details of recovery</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rate in intervention group (%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rate in comparator group (%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RR (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tympanic membrane (TM) perforation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no cases of [...] perforation of the tympanic membrane</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52 (0)*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No residual TM perforations</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All patients demonstrated a complete healing of TM after the tympanostomy tube removal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/24 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent TM perforation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/129 (3.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No residual tympanic membrane perforations were observed in any of the individuals at their final visit </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/30 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0010" title="ErmutluG , SüslüN , YılmazT , SaraçS . Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. European Archives of Oto-rhino-laryngology2017;274(10):3585-91. ">Ermutlu 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Four patients in the ITS group had transient vertigo during the procedure</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/19 (21)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>[...] complained of brief dizziness after IT injection [...]</p> <p> </p> <p> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No patients stopped the treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/52 (13.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/52 (15.4)*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The intratympanic group experienced adverse effects typical of local injection, most often transient pain at the injection site and brief caloric vertigo. Note, it is unclear whether all reported instances of vertigo in the intervention group occurred at the time of injection. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35/129 (27.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/121 (10.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.53 (1.41 to 4.54); favours systemic corticosteroid; P = 0.002</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temporary adverse events in 22.7% of patients treated with oral prednisolone which included [...] and dizziness. In 35% of patients treated with intratympanic corticosteroid, adverse events occurred including [...] and dizziness. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six of 30 patients in the intratympanic injection group complained of a transient dizziness lasting about a minute during treatment </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/30 (20)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient experienced transient dizziness as a result of caloric stimulation from the injected steroid solution (unclear which of 2 groups receiving intratympanic injection) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptoms resolved completely within 15 minutes and there was no need to discontinue the treatment. The injections that followed caused no further side effect. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinnitus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 35% of patients treated with intratympanic corticosteroid, adverse events occurred including [...] ringing sensation in the ear </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain due to injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/19 (10.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Earache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/19 (21.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.45 (0.54 to 164.49); favours systemic corticosteroid; P = 0.12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>[...] refused repeated IT injections due to unbearable pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/52 (5.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/52 (3.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The intratympanic group experienced adverse effects typical of local injection, most often transient pain at the injection site [...] </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35/129 (27.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Experienced ear pain at least once</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70/129 (54.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/121 (3.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.41 (6.18 to 43.59); favours systemic corticosteroid;  P &lt; 0.00001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 35% of patients treated with intratympanic corticosteroid adverse events occurred including […] mild ear pain, severe ear pain (3 patients) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/20 (15) severe ear pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some patients had a tolerable pain reaction after the injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mood change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/19 (10.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/20 (40)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.26 (0.06 to 1.08); favours IT corticosteroid; P = 0.06</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood glucose problem</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/19 (15.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/20 (30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.53 (0.15 to 1.81); favours IT corticosteroid; P = 0.31</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleep change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/19 (5.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/20 (30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.18 (0.02 to 1.32); favours IT corticosteroid; P = 0.09</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased appetite</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/19 (5.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/20 (25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.21 (0.03 to 1.64); favours IT corticosteroid; P = 0.14  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mouth dryness/thirst</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/20 (25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.10 (0.01 to 1.62); favours IT corticosteroid; P = 0.10</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weight gain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/20 (15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.15 (0.01 to 2.72); favours IT corticosteroid; P = 0.20  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No complications related to the treatment were noted in both the groups</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/21 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0010" title="ErmutluG , SüslüN , YılmazT , SaraçS . Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. European Archives of Oto-rhino-laryngology2017;274(10):3585-91. ">Ermutlu 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No long‐term complications were observed in any of the patients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/16 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0013" title="HongSM , ParkCH , LeeJH . Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngology - Head and Neck Surgery2009;141(5):579-83. ">Hong 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No side effects were observed in either group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/32 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/31 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Apparent bleeding at intratympanic injection site</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>External otitis or myringitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Otitis media</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluctuation of basal blood pressure (&gt; 10 mmHg)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/52 (3.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/52 (13.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluctuation of fasting blood glucose (&gt; 2 mmol/L)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/52 (9.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/52 (23.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Emotional change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/52 (15.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/52 (28.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appetite change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/52 (25.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/52 (48.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dyssomnia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/52 (44.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/52 (73.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Water‐sodium retention</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/52 (17.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/52 (46.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne on face and body</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/52 (3.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/52 (11.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irregular menstruation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/21 (23.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/23 (47.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cushing's syndrome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/52 (1.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Osteoporotic fracture</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In one case an acute suppurative otitis media developed that was eliminated by local antibacterial therapy. This patient was excluded from the study. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nine patients in the ST (standard therapy) group and 12 patients in the intravenous corticosteroid group complained of sleep loss </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completely corrected after withdrawal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/24 (37.5) in ST group and 12/25 (48) in intravenous corticosteroid group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No systemic adverse effects related to intratympanic application of steroids were noticed </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/24 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious side effects related to systemic administration of steroids were observed in the study </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/49 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0022" title="QuY , ChenH , ZhangH , GuoM . Analysis the treatment of sudden sensorineural hearing loss with steroid from different administration routes [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery [Chinese]2015;29(4):324-6. ">Qu 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No complications were seen in patients (unclear which group), including those with hypertension or diabetes </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mood change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/129 (9.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54/121 (44.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.21 (0.12 to 0.37); favours IT corticosteroid; P &lt; 0.00001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood glucose problem</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/129 (16.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/121 (29.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.55 (0.34 to 0.88); favours IT corticosteroid; P = 0.01</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleep change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/129 (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/121 (36.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19 (0.1 to 0.38); favours IT corticosteroid; P &lt; 0.00001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appetite change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/129 (4.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/121 (23.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 (0.09 to 0.47); favours IT corticosteroid; P = 0.0002</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dry mouth/thirst</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/129 (3.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/121 (24.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.16 (0.06 to 0.39); favours IT corticosteroid; P &lt; 0.0001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weight change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/129 (5.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/121 (18.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 (0.13 to 0.67); favours IT corticosteroid; P = 0.004</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/129 (5.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/121 (1.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.28 (0.7 to 15.49); favours systemic corticosteroid; P = 0.13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse event: "Adverse events were reported by 87.6% (106 of 121) of participants in the oral group and 89.9% (116 of 129) in the intratympanic group." Note: it is unclear whether 'adverse events' refers to those already reported (and listed for this study in this table).  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116/129 (89.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106/121 (87.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03 (0.94 to 1.12); favours systemic corticosteroid;</p> <p>P = 0.56 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events: "In the intratympanic treatment group, these included osteomyelitis of the toe, leukemia, myocardial infarction, bladder cancer, chest pain due to possible endocarditis, and exacerbation of pre‐existing chronic obstructive pulmonary disease. In the oral treatment group, the serious adverse events were myocardial infarction, cerebral hemorrhage, hyponatremia, hospitalization for possible transient ischemic attack, and syncope. The case of hyponatremia arose from worsening of pre‐existent mild renal insufficiency in a patient with type 2 diabetes that was deemed study‐related." </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/129 (4.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/121 (4.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.13 (0.35 to 3.59); favours systemic corticosteroid;</p> <p>P = 0.84 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adverse effects were reported in either study group during the study period</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temporary adverse events: temporary adverse events in 22.7% of patients treated with oral prednisolone which included puffiness of face, ulcers in mouth, increased appetite, diarrhea [...] </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/22 (22.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: in 35% of patients treated with intratympanic methylprednisolone adverse events occurred including mild ear pain, severe ear pain (3 patients), ringing sensation in ear and dizziness </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/20 (35)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No otitis media […] observed in any of the individuals at their final visit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/30 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/30 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant complications during the intratympanic injections or the follow‐up period </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/33 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Patients in the comparator group for this trial also received intratympanic (IT) corticosteroid at a later time point in the trial, therefore complications of IT treatment are included here (<a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>). The intervention group received 24 days of IT corticosteroid and the comparator group received 12 days of systemic (intravenous corticosteroid) followed by 12 days of IT corticosteroid. Rate ratios are not presented as they are not applicable to the comparison of interest (IT compared to systemic as primary therapy).  </p> <p>CI: confidence interval; IT: intratympanic; NA: not applicable; NR: not reported; RR: risk ratio; TM: tympanic membrane </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008080-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as primary therapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as primary therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> sudden sensorineural hearing loss </p> <p><b>Settings:</b> initial therapy </p> <p><b>Intervention:</b> combination of intratympanic and systemic steroid therapy </p> <p><b>Comparison:</b> systemic steroid therapy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants</b> <br/><b>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Systemic therapy</b> </p> <p><b>(assumed risk)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Combined therapy</b> </p> <p><b>(corresponding risk)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in hearing threshold determined by PTA</p> <p>Range 0 dB to 140 dB</p> <p>Negative values represent lowering and positive values represent raising of the hearing threshold. A lower hearing threshold represents hearing improvement. </p> <p> </p> <p> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in PTA ranged across control groups from<br/>‐33.0 dB to ‐13.0 dB </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in PTA in the intervention groups was on average ‐8.55 dB greater (‐4.61 greater to ‐12.48 greater) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>435</p> <p>(6 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐8.55 dB</p> <p>(95% CI ‐12.48 to ‐4.61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The change in hearing threshold may be slightly increased in participants who receive combined therapy. However, it is unclear whether this increase would be noticeable to patients.  </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of patients whose hearing is improved</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>579 per 1000<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>735 per 1000 (666 to 816)<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>788</p> <p>(10 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.27</p> <p>(95% CI 1.15 to 1.41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain as to whether combined therapy changes the proportion of participants whose hearing is improved. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final hearing threshold determined by PTA</p> <p>A lower value represents better hearing</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final PTA ranged across control groups from 39.1 dB to 59 dB </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final PTA in the intervention groups was on average 9.11 dB lower (1.67 lower to 16.56 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> <p>(3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐9.11 dB</p> <p>(95% CI ‐16.56 to ‐1.67)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>3</sup> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combined therapy may result in slightly lower (more favourable) final hearing thresholds compared to systemic corticosteroids alone (as primary therapy) but the evidence is very uncertain, and it is not clear whether the change would be of importance to patients. </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse events<sup>b</sup> </b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events in control group</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events in intervention group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of Participants</b> <br/><b>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent tympanic membrane perforation</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not applicable<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 studies reported a rate between 0% (0/85) and 5.5% (2/36) for those who received an intratympanic injection  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>474 (5 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain regarding the risk of tympanic membrane perforation for those who received intratympanic steroids.  </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness: timing not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No study reported on this outcome for both the intervention and comparator groups. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness: at the time of injection </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not applicable<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 studies reported a rate between 0% (0/60) and 8.1% (3/37) for those who received an intratympanic injection<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341 (4 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain regarding the risk of vertigo/dizziness at the time of intratympanic injection for those who received intratympanic corticosteroid as primary treatment. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain: timing not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No study reported on this outcome for both the intervention and comparator groups. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain: at the time of injection</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not applicable<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>One study reported a rate of 5/37 (13.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain regarding the risk of ear pain at the time of intratympanic injection for those who received combined treatment as primary treatment. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>PTA:</b> pure tone audiometry; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><sup>a</sup>Ten studies recruited participants suffering from sudden sensorineural hearing loss. The incidence of improvement for the 10 studies was 57.86%. We have used 579 per 1000 to express the assumed risk. </p> <p><sup>b</sup>Only the most widely reported adverse events are described here. For adverse events that could feasibly occur in either group, we have only included the studies that provided a rate for both groups. For adverse events that could only occur in one group, we have only included the studies that reported the rate in that group, and presented these as a range. A full description of adverse event data is available for reference in <a href="./full#CD008080-tbl-0004">Table 2</a>. </p> <p><sup>c</sup>Comparisons between patients receiving intratympanic therapy and those receiving only systemic therapy were regarded as invalid for the following adverse events: persistent tympanic membrane perforation, vertigo observed at the time of intratympanic injection and ear pain observed at the time of intratympanic injection. This is explained in <a href="#CD008080-sec-0028">Data extraction and management</a>.  </p> <p><sup>d</sup>In one study, two groups received intratympanic injection: one group received intratympanic corticosteroid and the other received intratympanic and systemic corticosteroid (<a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>).  </p> <p> </p> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level due to risk of bias: we rated a study contributing moderate weight to the overall effect estimate as high risk of bias due to concern about random sequence generation and allocation concealment. Five studies were at high risk of other bias, and one study was at risk of attrition bias. Downgraded one level due to imprecision: the 95% CI overlaps the threshold for clinical relevance, taken to be 10 dB. </p> <p><sup>2</sup>Downgraded one level due to risk of bias: we judged 8 of 10 studies to be at high or unclear risk of selection bias and at high risk of other bias. Downgraded one level due to imprecision: the 95% CI overlaps the threshold for clinical relevance. Downgraded one level due to inconsistency: the I<sup>2</sup> value was moderate (47%). </p> <p><sup>3</sup>Downgraded two levels due to risk of bias: we judged all three studies to be at high or unclear risk of selection bias and high risk of other bias. We also judged one of three studies to be at high risk of bias for incomplete outcome data and selective reporting. Downgraded one level due to imprecision: the 95% CI overlaps the threshold for clinical relevance and the sample size is smaller than the optimal information size (taken as 400 participants). </p> <p><sup>4</sup>Downgraded two levels due to risk of bias: we judged two studies to be at high risk of bias because of concern about random sequence generation, two studies because of selective reporting, one study because of concern about blinding and one study because of concern about allocation concealment. </p> <p><sup>5</sup>Downgraded two levels due to risk of bias: we judged one study to be at high risk of bias because of concern about random sequence generation and blinding, one study because of selective reporting and one study because of incomplete outcome data. Downgraded two levels due to imprecision: the number of events is smaller than the optimal information size (taken as 300 events) and an effect estimate could not be calculated. </p> <p><sup>6</sup>Downgraded two levels due to imprecision: the number of events is smaller than the optimal information size (taken as 300 events) and an effect estimate could not be calculated. Downgraded one level because of indirectness: provision of data by only a single study from a single setting, which may not adequately represent all patients with ISSNHL. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008080-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">2.</span> <span class="table-title">Adverse events: combined compared to systemic as primary therapy</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse event reported</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>How reported</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Details of recovery</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rate in intervention group (%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rate in comparator group (%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RR (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TM perforation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant complications during or after IT dexamethasone, including TM perforation […] </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/60 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two patients developed tympanic perforation (reported as 2.6% of whole study sample; unclear how many from each group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treated with cauterisation and paper patch (n = 1) and tympanoplasty (n = 1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the patients had an important complication, namely […] TM perforation (unclear which group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant complications during or after IT steroid injection including TM perforation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No case of residual TM perforation […] was noted</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No long‐term complications resulting from either oral steroid or IT steroid in any of the patients </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/37 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant complications during or after IT dexamethasone, including […] vertigo […] </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/60 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the patients had an important complication, namely, […] vertigo […] (unclear which group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant complications during or after IT steroid injection, including […] vertigo […] </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three patients complained of vertigo immediately after injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovered after 2 hours of rest</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/37 (8.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient experienced transient dizziness as a result of caloric stimulation from the injected steroid solution (unclear which of two groups receiving intratympanic injection) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptoms resolved completely within 15 minutes and there was no need to discontinue the treatment. The injections that followed caused no further side effects. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinnitus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant<br/>complications during or after IT dexamethasone, including […] and tinnitus </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/60 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the patients had an important complication, namely, […] tinnitus […] (unclear which group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant complications during or after IT steroid injection, including […] tinnitus […] </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the patients had an important complication, namely, […] otalgia […] (unclear which group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Otalgia occurred in 5 patients after IT corticosteroid injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relieved after 1 hour</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/37 (13.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant complications during or after IT dexamethasone, including […] otitis media […] </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/60 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the patients had an important complication, namely, […]  nystagmus, otitis media […] (unclear which group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No long‐term complications resulted from either the prednisone taper or the IT corticosteroid in any of the patients enrolled in the study </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/16 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/18 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant complications during or after IT steroid injection, including […] otitis media […] </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No case of […] otitis media was noted</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No long‐term complications resulted from either oral steroid or IT steroid in any of the patients </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No long‐ term complications resulted from either oral steroid or IT steroid in any of the patients </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/37 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/36 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant complications during the intratympanic injections or the follow‐up period </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/33 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0015" title="KoltsidopoulosP , BibasA , SismanisA , TzonouA , SeggasI . Intratympanic and systemic steroids for sudden hearing loss. Otology &amp; Neurotology2013;34:771-6. ">Koltsidopoulos 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant complications occurred during IT injections or the follow‐up period. One case of otitis media was encountered (unclear which group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/46 (0) (significant complications)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>IT: intratympanic; NA: not applicable; NR: not reported; TM: tympanic membrane</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008080-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Intratympanic corticosteroids versus no treatment or versus placebo as secondary therapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Intratympanic corticosteroids versus no treatment or versus placebo as secondary therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> sudden sensorineural hearing loss </p> <p><b>Settings:</b> after treatment failure with systemic steroids </p> <p><b>Intervention:</b> intratympanic steroid therapy </p> <p><b>Comparison:</b> no treatment/placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants</b> <br/><b>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No treatment/placebo</b> </p> <p><b>(assumed risk)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intratympanic therapy</b> </p> <p><b>(corresponding risk)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in hearing threshold determined by PTA</p> <p>Range 0 dB to 140 dB</p> <p>Negative values represent lowering and positive values represent raising of the hearing threshold. A lower hearing threshold represents hearing improvement. </p> <p> </p> <p> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in PTA ranged across control groups from<br/>‐13.21 dB to 0.8 dB </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in PTA in the intervention groups was on average ‐9.07 dB greater (‐6.66 greater to ‐11.47 greater)<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280</p> <p>(7 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐9.07 dB (95% CI ‐11.47 to ‐6.66)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low<sup>1</sup> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intratympanic therapy may have a small effect on hearing threshold compared to no treatment or placebo (as secondary therapy), but it is not clear whether this change would be important to patients. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of patients whose hearing is improved</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>70 per 1000<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>385 per 1000 (203 to 747)<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232</p> <p>(6 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.55</p> <p>(95% CI 2.89 to 10.68)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intratympanic therapy may result in a much higher proportion of patients whose hearing is improved, compared to no treatment or placebo (as secondary therapy). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final hearing threshold determined by PTA (a lower value represents better hearing)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final PTA ranged across control groups from 59.9 to 90.5 dB HL</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final PTA in the intervention groups was on average ‐11.09 dB lower (‐4.72 lower to ‐17.46 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203</p> <p>(5 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐11.09 dB</p> <p>(95% CI ‐17.46 to ‐4.72)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intratympanic therapy may result in lower (more favourable) final hearing thresholds compared to no treatment or placebo (as secondary therapy). </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse events<sup>b</sup> </b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events in control group</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events in intervention group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of Participants (studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent tympanic membrane perforation</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not applicable<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 studies reported a rate between 0% (0/19) and 4.2% (1/24) for those who received an intratympanic injection<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185 (5 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain regarding the risk of tympanic membrane perforation for those who received intratympanic injection (either corticosteroid or placebo) as secondary treatment. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness: timing not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No study reported on this outcome for both the intervention and comparator groups.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness at the time of intratympanic injection</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not applicable<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 studies reported a rate between 6.7% (1/15) and 33% (number not reported) for those who received an intratympanic injection.<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128 (3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low<sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain regarding the risk of vertigo/dizziness at the time of intratympanic injection (either corticosteroid or placebo) as secondary treatment. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain: timing not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No study reported on this outcome for both the intervention and comparator groups.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain at the time of intratympanic injection</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not applicable<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>One study reported no participants with ear pain at the time of intratympanic injection (0/24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (one study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low<sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain regarding the risk of ear pain at the time of intratympanic corticosteroid injection as secondary treatment. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>PTA:</b> pure tone audiometry; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><sup>a</sup>Six studies recruited participants suffering from sudden sensorineural hearing loss after treatment failure with systemic steroids. The incidence of improvement for the control group in these six studies was 6.96%. We have used 70 per 1000 to express the assumed risk. </p> <p><sup>b</sup>Only the most widely reported adverse events are described here. For adverse events that could feasibly occur in either group, we have only included the studies that provided a rate for both groups. For adverse events that could only occur in one group, we have only included the studies that reported the rate in that group, and presented these as a range. A full description of adverse event data is available for reference in <a href="./full#CD008080-tbl-0006">Table 3</a>. </p> <p><sup>c</sup>Comparisons between patients receiving intratympanic therapy and those receiving only systemic therapy were regarded as invalid for the following adverse events: persistent tympanic membrane perforation, vertigo observed at the time of intratympanic injection and ear pain observed at the time of intratympanic injection. This is explained in <a href="#CD008080-sec-0028">Data extraction and management</a>.  </p> <p><sup>d</sup>This includes participants who received placebo intratympanic injection. </p> <p> </p> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level due to risk of bias: we rated one study contributing moderate weight to the overall effect estimate as having high risk of bias due to incomplete outcome data. All studies were at high risk of other bias. Downgraded one level due to imprecision: the 95% CI for the effect overlaps the threshold for clinical relevance and the sample size is smaller than the optimal information size (taken as 400 participants). One study included treatment in the comparator arm with vitamin B, vasodilators and benzodiazepines (<a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a>). However, as the weight of this study in the meta‐analysis was low and exclusion of the study made little difference to the effect estimate we did not downgrade for indirectness. </p> <p><sup>2</sup>Downgraded one level due to risk of bias: we rated two studies as being at high risk of bias due to selective reporting and one study was at high risk of bias for incomplete outcome data. All studies were at high risk of other bias. Downgraded one level due to imprecision: the total number of events is smaller than the optimal information size (taken as 300 events). </p> <p><sup>3</sup>Downgraded one level due to risk of bias: we rated one study contributing moderate weight to the overall effect estimate as high risk of bias due to incomplete outcome data, and one other study as high risk of bias because of selective reporting. All studies were at high risk of other bias. Downgraded one level due to imprecision: the 95% CI for the effect overlaps the threshold for clinical relevance and the sample size is smaller than the optimal information size (taken as 400 participants). </p> <p><sup>4</sup>Downgraded one level due to risk of bias: we rated one study as high risk of bias because of selective reporting; we rated one study as high risk of bias because of incomplete outcome data; we rated three studies as uncertain for random sequence generation, allocation concealment and blinding. Downgraded two levels because of imprecision: the number of events is smaller than the optimal information size (taken as 300 events) and an effect estimate could not be calculated. </p> <p><sup>5</sup>Downgraded one level due to risk of bias: we rated one study as high risk of bias because of selective reporting; we rated one study as high risk of bias because of incomplete outcome data; we rated two studies as uncertain for random sequence generation, allocation concealment and blinding. Downgraded two levels because of imprecision: the number of events is smaller than the optimal information size (taken as 300 events) and an effect estimate could not be calculated. </p> <p><sup>6</sup>Downgraded two levels because of imprecision: the number of events is smaller than the optimal information size (taken as 300 events) and an effect estimate could not be calculated. Downgraded one level due to indirectness: single study from a single setting, which may not adequately represent all patients with ISSNHL. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008080-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">3.</span> <span class="table-title">Adverse events: intratympanic compared to no treatment/placebo as secondary therapy</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse event reported</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>How reported</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Details of recovery</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rate in intervention group (%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rate in comparator group (%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RR (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TM perforation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No residual TM perforation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/15 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent TM perforation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No hearing loss in the affected ear. The perforation was treated successfully with a paper patch. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/24 (4.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient (unclear which group) had a major catheter dislocation with perforation of ear drum. Note: both groups received IT injection, either corticosteroid or normal saline.   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small ear drum perforation was closed with a myringoplasty</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient TM perforation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healed spontaneously by follow‐up 1 month later</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/27 (3.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No TM perforation was noticed at last visit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complained of vertigo immediately after injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovered after 2 hours of rest</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/15 (6.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three patients complained of vertigo [...] during the injections</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resolved within minutes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/24 (12.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No disequilibrium</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/24 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No dizziness for more than 24 hours</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/24 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient (unclear which group) with increase in vertigo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temporary dizziness experienced by one‐third of subjects (unclear how many each group). Note: both groups received IT injection, either corticosteroid or normal saline. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relieved by resting for a short time. Three participants quit the trial because of uncomfortable dizziness (unclear how many each group). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinnitus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three patients complained of vertigo or an increase in tinnitus during the injections</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resolved within minutes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/24 (12.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hearing loss</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The injection did not induce an increase in […] hearing loss […] for greater than 24 h </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/24 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No participant experienced a decrease in hearing of 10 dB or more</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The injection did not induce an increase in ear pain […]</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/24 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two patients (unclear how many each group) with ear pain. Note: both groups received IT injection, either corticosteroid or normal saline. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A mild ear pain occurring the first hour post‐injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Easily controlled with common analgesics</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One of 15 patients had acne</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/15 (6.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious complications such as chronic otitis media, disequilibrium or dysgeusia developed </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/24 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient (unclear which group) with each of: ear canal skin defect, steroid acne, nausea after antibiotic intake, gastroenteritis, hypokalaemia, pump battery failure and viral conjunctivitis. Three patients with headache (unclear how many in each group; one considered as 'possibly', 'probably' or 'very likely' related to the study) and 3 (unclear how many each group) with increased liver function tests (probably due to antibiotics). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe nausea or vomiting was not experienced by any of the participants after the injection therapy </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No infection was noticed in any of the patients at their last visit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/18 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>TM: tympanic membrane; NA: not applicable; NR: not reported; IT: intratympanic</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008080-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as secondary therapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as secondary therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> sudden sensorineural hearing loss </p> <p><b>Settings:</b> after treatment failure with systemic steroids </p> <p><b>Intervention:</b> combination of intratympanic and systemic steroid therapy </p> <p><b>Comparison:</b> systemic steroid therapy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants</b> <br/><b>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Systemic therapy</b> </p> <p><b>(assumed risk)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Combined therapy</b> </p> <p><b>(corresponding risk)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in hearing threshold determined by PTA</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of patients whose hearing is improved</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>205 per 1000<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>459 per 1000 (226 to 933)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.24</p> <p>(95% CI 1.10 to 4.55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combined therapy may increase the proportion of patients whose hearing is improved compared to systemic corticosteroids alone (as secondary therapy), but the evidence is very uncertain.  </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final hearing threshold determined by PTA</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse events<sup>b</sup> </b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events in control group</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events in intervention group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants</b> <br/><b>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent tympanic membrane perforation</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not appropriate<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>One study reported a rate of 8.1% (3/37)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The risk of tympanic membrane perforation among those who receive intratympanic corticosteroid combined with systemic corticosteroid as primary treatment is very uncertain.    </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness:</p> <p>timing not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness:</p> <p>at the time of injection </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not appropriate<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No study reported a rate in the intervention group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain:</p> <p>timing not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain: </p> <p>at the time of injection</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not appropriate<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No study reported a rate in the intervention group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>PTA:</b> pure tone audiometry; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><sup>a</sup>One study recruited participants suffering from sudden sensorineural hearing loss after treatment failure with systemic steroids. The incidence of improvements was 20.51%. We have used 205 per 1000 to express the assumed risk. </p> <p><sup>b</sup>Only the most widely reported adverse events are described here. For adverse events that could feasibly occur in either group, we have only included the studies that provided a rate for both groups. For adverse events that could only occur in one group, we have only included the studies that reported the rate in that group, and presented these as a range. A full description of adverse event data is available for reference in <a href="./full#CD008080-tbl-0008">Table 4</a>. </p> <p><sup>c</sup>Comparisons between patients receiving intratympanic therapy and those receiving only systemic therapy were regarded as invalid for the following adverse events: persistent tympanic membrane perforation, vertigo observed at the time of intratympanic injection and ear pain observed at the time of intratympanic injection. This is explained in <a href="#CD008080-sec-0028">Data extraction and management</a>.  </p> <p> </p> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels due to risk of bias: we judged the study to be at high risk of selection bias, performance bias, incomplete outcome data, selective reporting and other bias. Downgraded two levels due to imprecision: the 95% CI overlaps the threshold for clinical relevance and the total number of events is smaller than the optimal information size (taken as 300 events). </p> <p><sup>2</sup>Downgraded two levels due to risk of bias: we judged the study to be at high risk of bias because of selection bias, concern about blinding, incomplete outcome data and selective reporting. Downgraded two levels due to imprecision: the number of events is smaller than the optimal information size (taken as 300 events) and an effect estimate could not be calculated. Downgraded one level because of indirectness: provision of data by only a single study from a single setting, which may not adequately represent all patients with ISSNHL. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008080-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">4.</span> <span class="table-title">Adverse events: combined compared to systemic as secondary treatment</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse event reported</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>How reported</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Details of recovery</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rate in intervention group (%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rate in comparator group (%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RR (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TM perforation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three patients had small eardrum perforations</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Successful closure by simple treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/37 (8.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Second frequent complaint: transient vertigo after the drug had been injected into the ear </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not a severe problem if the drug was heated in 37°C water before injection and the vertigo disappeared after a few minutes or under 30 minutes </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most frequent complaint</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Easily controlled by the oral administration of paracetamol 30 minutes before the local infusion of the methylprednisolone </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hearing loss*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No loss in hearing related to the treatment (in either group)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/37 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/39 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient had tongue paresthesia (unclear which group)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resolved after 2 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No infections were observed (unclear which group)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term complications did not occur in any patients who received the transtympanic injections </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/37 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Hearing loss defined as ≥ 15 dB worsening in pure tone audiometry or ≥ 15% worsening of speech discrimination score. </p> <p>NA: not applicable; NR: not reported; TM: tympanic membrane</p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008080-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008080-sec-0009"></div> <section id="CD008080-sec-0010"> <h3 class="title" id="CD008080-sec-0010">Description of the condition</h3> <p>Idiopathic sudden sensorineural hearing loss (ISSNHL) is a sudden decrease in sensorineural hearing sensitivity of unknown aetiology. It is usually unilateral and the degree of severity can vary from mild hearing loss to total deafness. It may also be accompanied by vertigo and tinnitus. </p> <p>There is no international consensus on the definition of ISSNHL in terms of the degree of hearing threshold change or the number of specific frequencies that are affected on pure tone audiological testing. A definition that is commonly used is "loss of at least 30 dB in three connected frequencies within 72 hours" (<a href="./references#CD008080-bbs2-0067" title="ChandrasekharSS , Tsai DoBS , SchwartzSR , BontempoLJ , FaucettEA , FinestoneSA , et al. Clinical practice guideline: sudden hearing loss (Update). Otolaryngology - Head and Neck Surgery2019;161(1 Suppl):S1-S45. [PMID: 31369359]">Chandrasekhar 2019</a>; <a href="./references#CD008080-bbs2-0119" title="NIDCD. National Institute on Deafness and Other Communication Disorders. NIDCD Fact Sheet: Sudden Deafness. Washington, DC: US Department of Health and Human Services; 2018. https://www.nidcd.nih.gov (accessed 20 April 2022).">NIDCD 2018</a>). However, this definition is not universally accepted. It does not specify the frequencies and the frequency range, the rational for choosing this threshold is not known and it is often not used as an inclusion criterion in clinical trials on ISSNHL. Although for mild and moderate hearing losses, statistical floor effects complicate the evaluation of recovery (<a href="./references#CD008080-bbs2-0068" title="ChenCY , HalpinC , RauchSD . Oral steroid treatment of sudden sensorineural hearing loss: a ten year retrospective analysis. Otology &amp; Neurotology2003;24(5):728-33. [PMID: 14501447]">Chen 2003</a>), it appears justified to expand the definition to cases with less than 30 dB of hearing loss (<a href="./references#CD008080-bbs2-0067" title="ChandrasekharSS , Tsai DoBS , SchwartzSR , BontempoLJ , FaucettEA , FinestoneSA , et al. Clinical practice guideline: sudden hearing loss (Update). Otolaryngology - Head and Neck Surgery2019;161(1 Suppl):S1-S45. [PMID: 31369359]">Chandrasekhar 2019</a>; <a href="./references#CD008080-bbs2-0128" title="PlontkeSK , BauerM , MeisnerC . Comparison of pure tone audiometry analysis in sudden hearing loss studies: lack of agreement for different outcome measures. Otology &amp; Neurotology2007;28(6):753-63.">Plontke 2007</a>). There is also a lack of consensus on the most appropriate outcome criteria for clinical studies (<a href="./references#CD008080-bbs2-0128" title="PlontkeSK , BauerM , MeisnerC . Comparison of pure tone audiometry analysis in sudden hearing loss studies: lack of agreement for different outcome measures. Otology &amp; Neurotology2007;28(6):753-63.">Plontke 2007</a>). </p> <p>The incidence of sudden sensorineural hearing loss has been estimated to be 5 to 20 per 100,000 per year in industrial countries (<a href="./references#CD008080-bbs2-0064" title="BylFM . Seventy-six cases of presumed sudden hearing loss occurring in 1973: prognosis and incidence. Laryngoscope1977;87(5 Pt 1):817-25.">Byl 1977</a>; <a href="./references#CD008080-bbs2-0092" title="HughesGB , FreedmanMA , HaberkampTJ , GuayME . Sudden sensorineural hearing loss. Otolaryngologic Clinics of North America1996;29(3):393-405.">Hughes 1996</a>; <a href="./references#CD008080-bbs2-0146" title="StokroosRJ , AlbersFW . Therapy of idiopathic sudden sensorineural hearing loss. A review of the literature. Acta Oto-Rhino-Laryngologica Belgica1996;50(1):77-84.">Stokroos 1996</a>). However, according to studies in Germany, the incidence may be much higher: <a href="./references#CD008080-bbs2-0122" title="OlzowyB , OsterkornD , SuckfüllM . The incidence of sudden hearing loss is greater than previously assumed [German]. MMW Fortschritte der Medizin2005;147(14):37-8.">Olzowy 2005</a> estimated the incidence at 160 per 100,000 per year and <a href="./references#CD008080-bbs2-0099" title="KlemmE , DeutscherA , MosgesR . A present investigation of the epidemiology in idiopathic sudden sensorineural hearing loss. Laryngo- Rhino- Otologie2009;88(8):524-7.">Klemm 2009</a> estimated it at 400 per 100,000 per year. This discrepancy may be due to the absence of international consensus on the audiological definition and outcome criteria. The mean age of patients included in randomised controlled trials (RCTs) is between 45 and 55. Men and women are equally affected. ISSNHL in childhood is rare (<a href="./references#CD008080-bbs2-0072" title="DesloovereC , Meyer-BreitingE , vonIlbergC . Randomized double-blind study of therapy of sudden deafness: initial results [Randomisierte Doppelblindstudie zur Hörsturztherapie: Erste Ergebnisse]. HNO1988;36(10):417-22.">Desloovere 1988</a>; <a href="./references#CD008080-bbs2-0098" title="KlemmE , BepperlingF , BurschkaMA , MösgesR , Study Group. Hemodilution therapy with hydroxyethyl starch solution (130/0.4) in unilateral idiopathic sudden sensorineural hearing loss: a dose-finding, double-blind, placebo-controlled, international multicenter trial with 210 patients. Otology &amp; Neurotology2007;28(2):157-70.">Klemm 2007</a>; <a href="./references#CD008080-bbs2-0116" title="MösgesR , KöberleinJ , HeibgesA , ErdtrachtB , KlingelR , LehmacherW , RHEO-ISHL Study Group. Rheopheresis for idiopathic sudden hearing loss: results from a large prospective, multicenter, randomized, controlled clinical trial. European Archives of Oto-Rhino-Laryngology2009;266(7):943-53.">Mösges 2009</a>; <a href="./references#CD008080-bbs2-0128" title="PlontkeSK , BauerM , MeisnerC . Comparison of pure tone audiometry analysis in sudden hearing loss studies: lack of agreement for different outcome measures. Otology &amp; Neurotology2007;28(6):753-63.">Plontke 2007</a>; <a href="./references#CD008080-bbs2-0130" title="ProbstR , TschoppK , LüdinE , KellerhalsB , PodvinecM , PfaltzCR . A randomized, double-blind, placebo-controlled study of dextran/pentoxifylline medication in acute acoustic trauma and sudden hearing loss. Acta Oto-Laryngologica1992;112(3):435-43.">Probst 1992</a>; <a href="./references#CD008080-bbs2-0152" title="TucciDL , Farmer JC Jr, KitchRD , WitsellDL . Treatment of sudden sensorineural hearing loss with systemic steroids and valacyclovir. Otology &amp; Neurotology2002;23(3):301-8.">Tucci 2002</a>; <a href="./references#CD008080-bbs2-0149" title="Tran Ba HuyPT , SauvagetE . Idiopathic sudden sensorineural hearing loss is not an otologic emergency. Otology &amp; Neurotology2005;26(5):896-902.">Tran Ba Huy 2005</a>). Idiopathic sudden sensorineural hearing loss, particularly when accompanied by tinnitus and dizziness, results in a significant reduction in quality of life (<a href="./references#CD008080-bbs2-0065" title="CarlssonPI , HallM , LindKJ , DanermarkB . Quality of life, psychosocial consequences, and audiological rehabilitation after sudden sensorineural hearing loss. International Journal of Audiology2011;50(2):139-44. [PMID: 21265640]">Carlsson 2011</a>; <a href="./references#CD008080-bbs2-0145" title="StachlerRJ , ChandrasekharSS , ArcherSM , RosenfeldRM , SchwartzSR , BarrsDM , et al. Clinical practice guideline: sudden hearing loss. Otolaryngology - Head and Neck Surgery2012;146(3 Suppl):1-35.">Stachler 2012</a>). </p> <p>Various theories to explain ISSNHL have been proposed, for example viral infection, vascular occlusion, breakdown of labyrinthine membranes or barriers, immune‐mediated mechanisms (<a href="./references#CD008080-bbs2-0153" title="VambutasA , DaviaDV . Biologics for immune-mediated sensorineural hearing loss. Otolaryngologic clinics of North America2021;54(4):803-13. [PMID: 34119332]">Vambutas 2021</a>) and abnormal cellular stress responses within the cochlea. However, none of these hypotheses has been proven convincingly in humans (<a href="./references#CD008080-bbs2-0113" title="MerchantSN , AdamsJC , Nadol JB Jr. Pathology and pathophysiology of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2005;26(2):151-60.">Merchant 2005</a>; <a href="./references#CD008080-bbs2-0114" title="MerchantSN , DurandML , AdamsJC . Sudden deafness: is it viral?ORL: Journal of Oto-Rhino-Laryngology and its Related Specialties2008;70(1):52-60; discussion 60-2.">Merchant 2008</a>). </p> <p>Treatment modalities for ISSNHL are mostly based on the above etiopathogenetic hypotheses and include (gluco)corticosteroids, rheological drugs (e.g. dextran, hydroxyethyl starch, pentoxifylline and naftidrofuryl), vasodilators, anaesthetics, osmotically active substances, antioxidants, thrombocyte aggregation inhibitors, fibrinogen reduction through drugs or apheresis or rheopheresis (<a href="./references#CD008080-bbs2-0148" title="SuckfüllM , Hearing Loss Study Group. Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial. Lancet2002;360(9348):1811-7.">Suckfüll 2002</a>), hyperbaric oxygen therapy, antiviral therapy, N‐methyl‐D‐aspartate (NMDA) receptor antagonists, immunosuppressants, anti‐apoptotic substances (<a href="./references#CD008080-bbs2-0147" title="SuckfuellM , LisowskaG , DomkaW , KabacinskaA , MorawskiK , BodlajR , et al. Efficacy and safety of AM-111 in the treatment of acute sensorineural hearing loss: a double-blind, randomized, placebo-controlled phase II study. Otology &amp; Neurotology2014;35(8):1317-26.">Suckfuell 2014</a>), and other substances (see reviews in: <a href="./references#CD008080-bbs2-0069" title="ConlinAE , ParnesLS . Treatment of sudden sensorineural hearing loss: I. A systematic review. Archives of Otolaryngology - Head and Neck Surgery2007a;133(6):573-81.">Conlin 2007a</a>; <a href="./references#CD008080-bbs2-0101" title="LabusJ , BreilJ , StutzerH , MichelO . Meta-analysis for the effect of medical therapy vs. placebo on recovery of idiopathic sudden hearing loss. Laryngoscope2010;120(9):1863-71.">Labus 2010</a>; <a href="./references#CD008080-bbs2-0104" title="LawrenceR , ThevasagayamR . Controversies in the management of sudden sensorineural hearing loss: an evidence-based review. Clinical Otolaryngology2015;40(3):176-82.">Lawrence 2015</a>; <a href="./references#CD008080-bbs2-0127" title="PlontkeS . Therapy of hearing disorders - conservative procedures. In: BeleitesE , GudziolH , editors(s). Restoring Methods of Functional Defects in Head and Neck. 1st edition. Köln, Germany: Scientias Verlag, 2005:1-65.">Plontke 2005</a>). Cochrane Reviews have assessed treatment of ISSNHL with systemic corticosteroids (<a href="./references#CD008080-bbs2-0156" title="WeiBPC , MubiruS , O'LearyS . Steroids for idiopathic sudden sensorineural hearing loss. Cochrane Database of Systematic Reviews2006, Issue 1. Art. No: CD003998. [DOI: 10.1002/14651858.CD003998.pub2]">Wei 2006</a>; <a href="./references#CD008080-bbs2-0157" title="WeiBP , StathopoulosD , O'LearyS . Steroids for idiopathic sudden sensorineural hearing loss. Cochrane Database of Systematic Reviews2013, Issue 7. Art. No: CD003998. [DOI: 10.1002/14651858.CD003998.pub3]">Wei 2013</a>), hyperbaric oxygen (<a href="./references#CD008080-bbs2-0060" title="BennettMH , KerteszT , YeungP . Hyperbaric oxygen for idiopathic sudden sensorineural hearing loss and tinnitus. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD004739. [DOI: 10.1002/14651858.CD004739.pub3]">Bennett 2007</a>; <a href="./references#CD008080-bbs2-0061" title="BennettMH , KerteszT , PerlethM , YeungP , LehmJP . Hyperbaric oxygen for idiopathic sudden sensorineural hearing loss and tinnitus. Cochrane Database of Systematic Reviews2012, Issue 10. Art. No: CD004739. [DOI: 10.1002/14651858.CD004739.pub4]">Bennett 2012</a>), and vasodilators (<a href="./references#CD008080-bbs2-0053" title="AgarwalL , PothierDD . Vasodilators and vasoactive substances for idiopathic sudden sensorineural hearing loss. Cochrane Database of Systematic Reviews2009, Issue 4. Art. No: CD003422. [DOI: 10.1002/14651858.CD003422.pub3]">Agarwal 2009</a>), without demonstrating clear efficacy. </p> <p>Systemic corticosteroids are widely used for ISSNHL worldwide (<a href="./references#CD008080-bbs2-0127" title="PlontkeS . Therapy of hearing disorders - conservative procedures. In: BeleitesE , GudziolH , editors(s). Restoring Methods of Functional Defects in Head and Neck. 1st edition. Köln, Germany: Scientias Verlag, 2005:1-65.">Plontke 2005</a>). A Cochrane Review on systemic corticosteroids for ISSNHL found that there was uncertainty about the value of corticosteroids in the treatment of ISSNHL, "since the evidence from randomised controlled trials is contradictory in outcome, in part because the studies are based upon too small a number of patients" (<a href="./references#CD008080-bbs2-0156" title="WeiBPC , MubiruS , O'LearyS . Steroids for idiopathic sudden sensorineural hearing loss. Cochrane Database of Systematic Reviews2006, Issue 1. Art. No: CD003998. [DOI: 10.1002/14651858.CD003998.pub2]">Wei 2006</a>). These findings were supported by another meta‐analysis (<a href="./references#CD008080-bbs2-0070" title="ConlinAE , ParnesLS . Treatment of sudden sensorineural hearing loss: II. A meta-analysis. Archives of Otolaryngology - Head and Neck Surgery2007;133(6):582-6.">Conlin 2007b</a>). The updated version of the Cochrane Review also included a randomised, placebo‐controlled, multicentre trial published in 2012 comparing the effect of prednisolone and placebo (<a href="./references#CD008080-bbs2-0121" title="Nosrati-ZarenoeR , HultcrantzE . Corticosteroid treatment of idiopathic sudden sensorineural hearing loss: randomized triple-blind placebo-controlled trial. Otology &amp; Neurotology2012;33(4):523-31.">Nosrati‐Zarenoe 2012</a>); again the review found that there was uncertainty about the value of systemic corticosteroids in the treatment ISSNHL (<a href="./references#CD008080-bbs2-0157" title="WeiBP , StathopoulosD , O'LearyS . Steroids for idiopathic sudden sensorineural hearing loss. Cochrane Database of Systematic Reviews2013, Issue 7. Art. No: CD003998. [DOI: 10.1002/14651858.CD003998.pub3]">Wei 2013</a>). </p> <p>In general, possible side effects of systemic corticosteroid medication include metabolic complications, such as glucose intolerance and diabetes mellitus, hypertension, increased intraocular pressure and glaucoma, psychotropic effects, hypothalamic‐pituitary‐adrenal‐axis suppression, gastrointestinal bleeding, bone loss, avascular necrosis of the femoral or humeral head and potential infections. A study investigating the risk of corticosteroid‐induced hyperglycaemia concluded that prevalence during systemic therapy is high and rises as the dose increases (<a href="./references#CD008080-bbs2-0134" title="RohrmeierC , KoemmN , BabilasP , PrahsP , StrutzJ , BuettnerR . Sudden sensorineural hearing loss: systemic steroid therapy and the risk of glucocorticoid-induced hyperglycemia. European Archives of Oto-rhino-laryngology2012;270(4):1255-61.">Rohrmeier 2012</a>). Although the rate of occurrence of side effects with systemic corticosteroid therapy appears low (<a href="./references#CD008080-bbs2-0079" title="Garcia-BerrocalJR , Ramirez-CamachoR , LoboD , TrinidadA , VerdaguerJM . Adverse effects of glucocorticoid therapy for inner ear disorders. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2008;70(4):271-4.">Garcia‐Berrocal 2008</a>), systematic data recording and publication of the proposed side effects are still insufficient, and adverse effects from a short course of high‐dose systemic corticosteroids have not been documented with good evidence. It is only possible, therefore, to speculate as to whether these known side effects occur during (longer) systemic corticosteroid treatment of ISSNHL and, if so, to what degree. </p> <p>The terms 'steroids', 'corticosteroids', 'glucocorticoids' are unfortunately used imprecisely and interchangeably in the literature on ISSNHL. The term 'corticosteroid' is used throughout this review, since this term is more often used and generally accepted in the literature on ISSNHL (<a href="./references#CD008080-bbs2-0067" title="ChandrasekharSS , Tsai DoBS , SchwartzSR , BontempoLJ , FaucettEA , FinestoneSA , et al. Clinical practice guideline: sudden hearing loss (Update). Otolaryngology - Head and Neck Surgery2019;161(1 Suppl):S1-S45. [PMID: 31369359]">Chandrasekhar 2019</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>). </p> </section> <section id="CD008080-sec-0011"> <h3 class="title" id="CD008080-sec-0011">Description of the intervention</h3> <p>The rationale for local intratympanic application of drugs for the treatment of inner ear diseases is based on the expected advantages over systemic treatment. These are 1) the bypassing of the blood‐labyrinthine barrier, resulting in 2) higher concentrations in the inner ear fluids despite the lower total amount of drug given, and 3) avoiding the major unwanted effects of systemically administered medications due to lower systemic drug levels. </p> <p>Pharmacokinetic studies in animals and humans have shown that high doses of systemic corticosteroids are needed to achieve detectable drug levels in the inner ear perilymph and that substances applied to the round window membrane lead to significantly higher drug levels in the inner ear fluids compared to systemic application (<a href="./references#CD008080-bbs2-0057" title="BachmannG , SuJ , ZumegenC , WittekindtC , MichelO . Permeability of the round window membrane for prednisolone-21-hydrogen succinate. Prednisolone content of the perilymph after local administration vs. systemic injection [German]. HNO2001;49(7):538-42.">Bachmann 2001</a>; <a href="./references#CD008080-bbs2-0062" title="BirdPA , BeggEJ , ZhangM , KeastAT , MurrayDP , BalkanyTJ . Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. Otology &amp; Neurotology2007;28(8):1124-30.">Bird 2007</a>; <a href="./references#CD008080-bbs2-0063" title="BirdPA , MurrayDP , ZhangM , BeggEJ . Intratympanic versus intravenous delivery of dexamethasone and dexamethasone sodium phosphate to cochlear perilymph. Otology &amp; Neurotology2011;32(6):933-6.">Bird 2011</a>; <a href="./references#CD008080-bbs2-0066" title="ChandrasekharSS , RubinsteinRY , KwartlerJA , GatzM , ConnellyPE , HuangE , et al. Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of facilitating agents. Otolaryngology - Head and Neck Surgery2000;122(4):521-8.">Chandrasekhar 2000</a>; <a href="./references#CD008080-bbs2-0120" title="NiedermeyerHP , ZahneisenG , LuppaP , BuschR , ArnoldW . Cortisol levels in the human perilymph after intravenous administration of prednisolone. Audiology &amp; Neuro-otology2003;8(6):316-21.">Niedermeyer 2003</a>; <a href="./references#CD008080-bbs2-0124" title="ParnesLS , SunAH , FreemanDJ . Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope1999;109(7 Pt 2):1-17. [PMID: 10399889]">Parnes 1999</a>). Thus, applying drugs locally may be more effective in treating sudden sensorineural hearing loss and may avoid systemic complications and side effects. The introduction of this drug delivery approach has triggered a large number of pre‐clinical studies focused on the pharmacokinetics of local drug delivery to the inner ear and the development of drug delivery systems (reviewed, for example, in: <a href="./references#CD008080-bbs2-0091" title="HoskisonE , DanielM , Al-ZahidS , ShakesheffKM , BaystonR , BirchallJP . Drug delivery to the ear. Therapeutic Delivery2013;4(1):115-24.">Hoskison 2013</a>; <a href="./references#CD008080-bbs2-0117" title="NakagawaT , ItoJ . Local drug delivery to the inner ear using biodegradable materials. Therapeutic Delivery2011;2(6):807-14.">Nakagawa 2011</a>; <a href="./references#CD008080-bbs2-0123" title="PararasEE , BorkholderDA , BorensteinJT . Microsystems technologies for drug delivery to the inner ear. Advanced Drug Delivery Reviews2012;64(14):1650-60.">Pararas 2012</a>; <a href="./references#CD008080-bbs2-0135" title="SaltAN , PlontkeSK . Principles of local drug delivery to the inner ear. Audiology &amp; Neuro-otology2009;14(6):350-60.">Salt 2009</a>; <a href="./references#CD008080-bbs2-0136" title="SaltAN , PlontkeSK . Pharmacokinetic principles in the inner ear: influence of drug properties on intratympanic applications. Hearing Research2018;368:28-40. [PMID: 29551306]">Salt 2018</a>). </p> <p>Intratympanic injection of corticosteroids for ISSNHL in humans was pioneered by Silverstein (<a href="./references#CD008080-bbs2-0143" title="SilversteinH , ChooD , RosenbergSI , KuhnJ , SeidmanM , SteinI . Intratympanic steroid treatment of inner ear disease and tinnitus (preliminary report). Ear, Nose, and Throat Journal1996;75(8):468-71, 474, 476 passim.">Silverstein 1996</a>) and Parnes (<a href="./references#CD008080-bbs2-0124" title="ParnesLS , SunAH , FreemanDJ . Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope1999;109(7 Pt 2):1-17. [PMID: 10399889]">Parnes 1999</a>). Since then, a rapidly growing number of reports have been published on treatment results of intratympanic application of corticosteroids for inner ear disorders (<a href="./references#CD008080-bbs2-0103" title="LavigneP , LavigneF , SalibaI . Intratympanic corticosteroids injections: a systematic review of literature. European Archives of Oto-rhino-laryngology2016;273(9):2271-8.">Lavigne 2016</a>; <a href="./references#CD008080-bbs2-0107" title="LiebauA , PogorzelskiO , SaltAN , PlontkeSK . Hearing changes after intratympanically applied steroids for primary therapy of sudden hearing loss: a meta-analysis using mathematical simulations of drug delivery protocols. Otology &amp; Neurotology2017;38(1):19-30.">Liebau 2017</a>; <a href="./references#CD008080-bbs2-0108" title="LiebauA , PogorzelskiO , SaltAN , PlontkeSK . Hearing changes after intratympanic steroids for secondary (salvage) therapy of sudden hearing loss: a meta-analysis using mathematical simulations of drug delivery protocols. Otology &amp; Neurotology2018;39(7):803-15.">Liebau 2018</a>). Intratympanic injection of corticosteroids is used not only as a single treatment approach but also in combination with systemic administration of corticosteroids. In a Cochrane meta‐analysis, <a href="./references#CD008080-bbs2-0125" title="PhillipsJS , WesterbergB . Intratympanic steroids for Meniere's disease or syndrome. Cochrane Database of Systematic Reviews2011, Issue 7. Art. No: CD008514. [DOI: 10.1002/14651858.CD008514.pub2]">Phillips 2011</a> assessed the efficacy of intratympanic corticosteroids for Ménière's disease. The majority of clinical reports, however, described the use of intratympanic corticosteroids for sudden hearing loss and more studies, including randomised controlled trials, are ongoing. So far, mainly dexamethasone or methylprednisolone preparations have been used as a primary or a second‐line ('rescue', 'salvage', 'reserve') intratympanic therapy for ISSNHL. Although these studies have shown intratympanic treatment with corticosteroids to be relatively safe, efficacy is difficult to assess since many studies did not compared their findings with a control group, and an even smaller number were randomised trials (reviewed in: <a href="./references#CD008080-bbs2-0067" title="ChandrasekharSS , Tsai DoBS , SchwartzSR , BontempoLJ , FaucettEA , FinestoneSA , et al. Clinical practice guideline: sudden hearing loss (Update). Otolaryngology - Head and Neck Surgery2019;161(1 Suppl):S1-S45. [PMID: 31369359]">Chandrasekhar 2019</a>; <a href="./references#CD008080-bbs2-0071" title="CraneRA , CamilonM , NguyenS , MeyerTA . Steroids for treatment of sudden sensorineural hearing loss: a meta-analysis of randomized controlled trials. Laryngoscope2015;125(1):209-17.">Crane 2015</a>; <a href="./references#CD008080-bbs2-0077" title="GaoY , LiuD . Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss: a meta-analysis. European Archives of Oto-rhino-laryngology2016;273(11):3699-711.">Gao 2016</a>; <a href="./references#CD008080-bbs2-0078" title="GaravelloW , GalluzziF , GainiRM , ZanettiD . Intratympanic steroid treatment for sudden deafness: a meta-analysis of randomized controlled trials. Otology &amp; Neurotology2012;33(5):724-9.">Garavello 2012</a>; <a href="./references#CD008080-bbs2-0089" title="HaynesDS , O'MalleyM , CohenS , WatfordK , LabadieRF . Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope2007;117(1):3-15.">Haynes 2007</a>; <a href="./references#CD008080-bbs2-0103" title="LavigneP , LavigneF , SalibaI . Intratympanic corticosteroids injections: a systematic review of literature. European Archives of Oto-rhino-laryngology2016;273(9):2271-8.">Lavigne 2016</a>; <a href="./references#CD008080-bbs2-0104" title="LawrenceR , ThevasagayamR . Controversies in the management of sudden sensorineural hearing loss: an evidence-based review. Clinical Otolaryngology2015;40(3):176-82.">Lawrence 2015</a>; <a href="./references#CD008080-bbs2-0105" title="LiH , FengG , WangH , FengY . Intratympanic steroid therapy as a salvage treatment for sudden sensorineural hearing loss after failure of conventional therapy: a meta-analysis of randomized, controlled trials. Clinical Therapeutics2015;37(1):178-87.">Li 2015</a>; <a href="./references#CD008080-bbs2-0112" title="MarxM , YounesE , ChandrasekharSS , ItoJ , PlontkeS , O'LearyS , et al. International consensus (ICON) on treatment of sudden sensorineural hearing loss. European Annals of Otorhinolaryngology, Head and Neck Diseases2018;135(1S):S23-8. [PMID: 29396226]">Marx 2018</a> <a href="./references#CD008080-bbs2-0118" title="NgJH , HoRC , CheongCS , NgA , YuenHW , NgoRY . Intratympanic steroids as a salvage treatment for sudden sensorineural hearing loss? A meta-analysis. European Archives of Oto-rhino-laryngology2015;272(10):2777-82.">Ng 2015</a>; <a href="./references#CD008080-bbs2-0140" title="SeggasI , KoltsidopoulosP , BibasA , TzonouA , SismanisA . Intratympanic steroid therapy for sudden hearing loss: a review of the literature. Otology &amp; Neurotology2011;32(1):29-35.">Seggas 2011</a>; <a href="./references#CD008080-bbs2-0144" title="SpearSA , SchwartzSR . Intratympanic steroids for sudden sensorineural hearing loss: a systematic review. Otolaryngology - Head and Neck Surgery2011;145(4):534-43.">Spear 2011</a>; <a href="./references#CD008080-bbs2-0145" title="StachlerRJ , ChandrasekharSS , ArcherSM , RosenfeldRM , SchwartzSR , BarrsDM , et al. Clinical practice guideline: sudden hearing loss. Otolaryngology - Head and Neck Surgery2012;146(3 Suppl):1-35.">Stachler 2012</a>; <a href="./references#CD008080-bbs2-0155" title="VlastarakosPV , PapacharalampousG , MaragoudakisP , KampessisG , MaroudiasN , CandilorosD , et al. Are intra-tympanically administered steroids effective in patients with sudden deafness? Implications for current clinical practice. European Archives of Oto-rhino-laryngology2012;269(2):363-80.">Vlastarakos 2012</a>; <a href="./references#CD008080-bbs2-0163" title="ZhaoD , TongB , WangQ , HellstromS , DuanM . A comparison of effects of systemic and intratympanic steroid therapies for sudden sensorineural hearing loss: a meta-analysis. Journal of Otology2016;11:18-23.">Zhao 2016</a>). </p> <p>Several methods for intratympanic application of corticosteroids haven been developed in recent years. Most are single or repeated intratympanic injections with or without visualisation of the round window membrane. In some studies additional substances like hyaluronic acid are used for volume stabilisation to increase the persistence of the drug in the middle ear. Another strategy is continuous or discontinuous drug application via partly or fully implantable pump systems, allowing adjustment of drug concentrations over time. Potential adverse events in the intratympanic application of corticosteroids are in principle the same as in systemic drug administration, but to a lesser extent. Some of the intratympanically applied drug may be lost from the middle ear by drainage through the Eustachian tube and then swallowed. However, the dose is much lower than with systemic application. Persistent perforation of the tympanic membrane can develop after injection if there is an impaired healing process. Also, temporary pain may be observed, or temporary vertigo or dizziness due to caloric stimulation. </p> </section> <section id="CD008080-sec-0012"> <h3 class="title" id="CD008080-sec-0012">How the intervention might work</h3> <p>Corticosteroids were originally implemented in the treatment of ISSNHL because of their anti‐inflammatory effect. It is assumed that the main cause of sudden deafness is a harmful effect of the immune system on the inner ear in response to viral infection (<a href="./references#CD008080-bbs2-0158" title="WilsonWR , BylFM , LairdN . The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double-blind clinical study. Archives of Otolaryngology1980;106(12):772-6.">Wilson 1980</a>). However, corticosteroids have further effects, mainly mediated by activation of the glucocorticoid receptor, which could play a role in the treatment of sudden hearing loss. One important effect is an increase in anti‐apoptotic transcription factors in cells and the blocking of apoptosis signalling pathways. This could protect the sensory hair cells and other neural and non‐neural structures in the inner ear (<a href="./references#CD008080-bbs2-0076" title="EshraghiAA , Van de WaterTR . Cochlear implantation trauma and noise-induced hearing loss: apoptosis and therapeutic strategies. The Anatomical Record. Part A, Discoveries in Molecular, Cellular, and Evolutionary biology2006;288(4):473-81.">Eshraghi 2006</a>; <a href="./references#CD008080-bbs2-0090" title="HoangKN , DinhCT , BasE , ChenS , EshraghiAA , Van De WaterTR . Dexamethasone treatment of naive organ of Corti explants alters the expression pattern of apoptosis-related genes. Brain Research2009;1301:1-8.">Hoang 2009</a>; <a href="./references#CD008080-bbs2-0151" title="TruneDR , CanlonB . Corticosteroid therapy for hearing and balance disorders. Anatomical Record (Hoboken, N.J.: 2007)2012;295(11):1928-43.">Trune 2012</a>). However, probably the most important effect of corticosteroids is their property of reducing the impact of oxidative stress in cells (<a href="./references#CD008080-bbs2-0151" title="TruneDR , CanlonB . Corticosteroid therapy for hearing and balance disorders. Anatomical Record (Hoboken, N.J.: 2007)2012;295(11):1928-43.">Trune 2012</a>). Recent studies point out that oxidative stress plays an important role in the aetiology of sudden hearing loss (<a href="./references#CD008080-bbs2-0081" title="GulF , MuderrisT , YalcinerG , SevilE , BercinS , ErginM , et al. A comprehensive study of oxidative stress in sudden hearing loss. European Archives of Oto-rhino-laryngology2016;274(3):1301-8.">Gul 2016</a>; <a href="./references#CD008080-bbs2-0131" title="QuarantaN , De CeglieV , D'EliaA . Endothelial dysfunction in idiopathic sudden sensorineural hearing loss: a review. Audiology Research2016;6(1):151.">Quaranta 2016</a>). Glucocorticoids also bind to the mineralocorticoid receptor (<a href="./references#CD008080-bbs2-0080" title="GrossmannC , ScholzT , RochelM , Bumke-VogtC , OelkersW , PfeifferAF , et al. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. European Journal of Endocrinology2004;151(3):397-406.">Grossmann 2004</a>). Additional effects of corticosteroids are mediated by activation of the mineralocorticoid receptor, which has an impact on cochlear ion transport (<a href="./references#CD008080-bbs2-0150" title="TruneDR , KemptonJB , GrossND . Mineralocorticoid receptor mediates glucocorticoid treatment effects in the autoimmune mouse ear. Hearing Research2006;212(1-2):22-32.">Trune 2006</a>). This may help to restore a disturbed homeostasis in the inner ear and ensure hair cell function driven by the endocochlear potential (<a href="./references#CD008080-bbs2-0109" title="MacArthurC , HausmanF , KemptonB , TruneDR . Intratympanic steroid treatments may improve hearing via ion homeostasis alterations and not immune suppression. Otology &amp; Neurotology2015;36(6):1089-95.">MacArthur 2015</a>). For some of these effects, especially the anti‐apoptotic and anti‐oxidative effects, a high drug concentration in the inner ear might be necessary (<a href="./references#CD008080-bbs2-0085" title="HaakeSM , DinhCT , ChenS , EshraghiAA , Van De WaterTR . Dexamethasone protects auditory hair cells against TNFalpha-initiated apoptosis via activation of PI3K/Akt and NFkappaB signaling. Hearing Research2009;255(1-2):22-32.">Haake 2009</a>). Since there is no accumulation of corticosteroids in the inner ear, and as corticoid entrance to the inner ear structures is limited by the blood‐labyrinth barrier, drug concentration in the inner ear with systemic application will not exceed the systemic plasma concentration. Local application of corticosteroids to the inner ear by intratympanic injection achieves a short‐duration, high concentration of the drug in the middle ear cavity, from where the drug can diffuse through the boundaries to the inner ear, i.e. the round window and the oval window (<a href="./references#CD008080-bbs2-0097" title="KingEB , SaltAN , EastwoodHT , O'LearySJ . Direct entry of gadolinium into the vestibule following intratympanic applications in Guinea pigs and the influence of cochlear implantation. Journal of the Association for Research in Otolaryngology: JARO2011;12(6):741-51.">King 2011</a>; <a href="./references#CD008080-bbs2-0135" title="SaltAN , PlontkeSK . Principles of local drug delivery to the inner ear. Audiology &amp; Neuro-otology2009;14(6):350-60.">Salt 2009</a>). Thus, higher corticosteroid concentrations can be achieved in the inner ear, which might be necessary for successful treatment of sudden hearing loss (<a href="./references#CD008080-bbs2-0062" title="BirdPA , BeggEJ , ZhangM , KeastAT , MurrayDP , BalkanyTJ . Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. Otology &amp; Neurotology2007;28(8):1124-30.">Bird 2007</a>; <a href="./references#CD008080-bbs2-0063" title="BirdPA , MurrayDP , ZhangM , BeggEJ . Intratympanic versus intravenous delivery of dexamethasone and dexamethasone sodium phosphate to cochlear perilymph. Otology &amp; Neurotology2011;32(6):933-6.">Bird 2011</a>). </p> <p>Hearing recovery in patients with ISSNHL mostly occurs early, within a few days of onset, but can also occur after several weeks (<a href="./references#CD008080-bbs2-0107" title="LiebauA , PogorzelskiO , SaltAN , PlontkeSK . Hearing changes after intratympanically applied steroids for primary therapy of sudden hearing loss: a meta-analysis using mathematical simulations of drug delivery protocols. Otology &amp; Neurotology2017;38(1):19-30.">Liebau 2017</a>; <a href="./references#CD008080-bbs2-0108" title="LiebauA , PogorzelskiO , SaltAN , PlontkeSK . Hearing changes after intratympanic steroids for secondary (salvage) therapy of sudden hearing loss: a meta-analysis using mathematical simulations of drug delivery protocols. Otology &amp; Neurotology2018;39(7):803-15.">Liebau 2018</a>). It has been observed that the time course of hearing recovery can extend to six months (<a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>). However, most of the hearing improvement will take place during the first weeks after onset. To estimate the treatment effect of an intervention for ISSNHL, it is desirable that the final outcome assessment is conducted after several weeks of follow‐up. Short evaluation periods may risk underestimation of treatment effects (<a href="./references#CD008080-bbs2-0159" title="WycherlyBJ , ThompkinsJJ , Jeffrey KimH . Early posttreatment audiometry underestimates hearing recovery after intratympanic steroid treatment of sudden sensorineural hearing loss. International Journal of Otolaryngology2011;2011:465831. [DOI: 10.1155/2011/465831]">Wycherly 2011</a>). After the recovery period, the hearing thresholds reached can be assumed to be stable in most patients. A large randomised controlled trial (published protocol) assessed the primary outcome 30 days after onset with an initial assessment after 10 days and a follow‐up at six months (<a href="./references#CD008080-bbs2-0129" title="PlontkeSK , GirndtM , MeisnerC , ProbstR , OerleckeI , RichterM , et al. Multicenter trial for sudden hearing loss therapy - planning and concept [Multizentrische Studie zur Hörsturztherapie - Planung und Konzeption]. HNO2016;64(4):227-36. [PMID: 27038034]">Plontke 2016</a>). </p> </section> <section id="CD008080-sec-0013"> <h3 class="title" id="CD008080-sec-0013">Why it is important to do this review</h3> <p>There is still uncertainty as to 1) whether intratympanic corticosteroids are better than placebo or no treatment, 2) whether intratympanic administration of corticosteroids alone or in combination with systemic application of steroids will lead to better results than systemic drug administration alone, 3) if so, which treatment protocol will lead to the best outcome and 4) what risks of adverse events are associated with this approach in inner ear therapy. This Cochrane Review was therefore warranted to assess the benefits and harms of intratympanic corticosteroids treatment for ISSNHL. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008080-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008080-sec-0014"></div> <p>To assess the effects of intratympanic corticosteroids in people with idiopathic sudden sensorineural hearing loss (ISSNHL). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008080-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008080-sec-0015"></div> <section id="CD008080-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008080-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) and quasi‐randomised controlled trials according to the Cochrane definition (<a href="./references#CD008080-bbs2-0088" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Handbook 2021</a>). Cross‐over trials were not included. Cross‐over trials are not feasible for the evaluation of interventions in the treatment of ISSNHL as there is no possibility to return to the baseline situation after the first intervention. </p> </section> <section id="CD008080-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included adults and children, female and male, of any ethnic origin, with unilateral ISSNHL (i.e. sudden sensorineural hearing loss of unknown aetiology) with or without vertigo, and with or without tinnitus. </p> <p>Studies in patients with non‐idiopathic conditions or diagnoses were excluded (e.g. acoustic trauma, Ménière's disease, fluctuating hearing loss, endolymphatic hydrops, suspected retro‐cochlear lesion, hearing loss due to ear surgery, perilymph fistula or barotrauma, middle ear inflammation or effusion, or conductive hearing loss). </p> </section> <section id="CD008080-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Corticosteroids (also referred to as steroids), which were applied by intratympanic application for the treatment of ISSNHL as one of two treatment strategies: </p> <p> <ul id="CD008080-list-0001"> <li> <p>as primary (first‐line) treatment; or</p> </li> <li> <p>as secondary (rescue/salvage/reserve/second‐line) treatment after failure of primary therapy. </p> </li> </ul> </p> <p>Corticosteroids were administered using one of the following drug delivery systems:</p> <p> <ul id="CD008080-list-0002"> <li> <p>single or repeated intratympanic injection with or without volume stabilisation and with or without visualisation of the round window membrane; or </p> </li> <li> <p>continuous or discontinuous drug application via partly or fully implantable pump systems. </p> </li> </ul> </p> <p>The different methods of intratympanic drug delivery were considered together as intratympanic application. </p> <p>We included studies of the following comparisons:</p> <p> <ul id="CD008080-list-0003"> <li> <p>intratympanic corticosteroids versus no treatment or versus placebo;</p> </li> <li> <p>intratympanic corticosteroids versus systemic corticosteroids;</p> </li> <li> <p>intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone; </p> </li> <li> <p>intratympanic plus systemic corticosteroids (combined therapy) versus no treatment or versus placebo. </p> </li> </ul> </p> <p>Studies were included regardless of the precise details of the treatment protocol (e.g. type of corticosteroid used, injection procedure, dose, frequency of application and duration of treatment). </p> </section> <section id="CD008080-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We did not use the outcomes selected for the review as a basis for including or excluding studies. We conducted analyses on outcome data collected more than one week (eight days or more) after the start of treatment. </p> <p>The primary outcome was the change in mean hearing threshold determined by pure tone audiometry (pure tone average) between treatment arms and measured in decibels (dB). A lowering of the mean hearing threshold represents an improvement in hearing. To indicate the direction of change, we denoted a lowering of mean threshold as a negative value, and an elevation of the mean threshold as a positive value. There was no restriction on frequencies or number of frequencies used for generation the pure tone average. </p> <p>Secondary outcome measures included final hearing threshold (pure tone average at the study endpoint), frequency‐specific changes in mean hearing threshold, the proportion of patients whose hearing improved (based on pure tone average and/or speech audiometry and without restriction on definition) and changes in hearing threshold based on speech audiometry (without restriction on type or language of speech test).  </p> <p>Also among the secondary outcomes were minor and serious adverse events.  </p> <section id="CD008080-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008080-list-0004"> <li> <p>Change in hearing threshold with pure tone audiometry (pure tone average (PTA)).</p> </li> </ul> </p> </section> <section id="CD008080-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008080-list-0005"> <li> <p>Proportion of patients whose hearing is improved (criteria for improvement were defined by the included studies). </p> </li> <li> <p>Final hearing threshold with pure tone audiometry.</p> </li> <li> <p>Change in hearing threshold with speech audiometry.</p> </li> <li> <p>Frequency‐specific changes in hearing threshold with pure tone audiometry.</p> </li> <li> <p>Mean level of improvement in those whose hearing is improved.</p> </li> <li> <p>For patients with profound pre‐treatment hearing loss: percentage of patients reaching serviceable hearing (defined as maximum percentage of correctly understood monosyllables equal or greater than 50%). </p> </li> <li> <p>Effect on tinnitus and vertigo.</p> </li> <li> <p>Minor and serious adverse events.</p> </li> </ul> </p> </section> </section> </section> <section id="CD008080-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>The Cochrane ENT Information Specialist conducted systematic searches for randomised controlled trials and controlled clinical trials. There were no language, publication year or publication status restrictions. The date of the search was 23 September 2021. </p> <section id="CD008080-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Information Specialist searched:</p> <p> <ul id="CD008080-list-0006"> <li> <p>the Cochrane ENT Trials Register (searched via the Cochrane Register of Studies 23 September 2021); </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (searched via the Cochrane Register of Studies) (CENTRAL 2021, Issue 9); </p> </li> <li> <p>PubMed (1946 to 23 September 2021);</p> </li> <li> <p>Ovid Embase (1974 to 23 September 2021);</p> </li> <li> <p>LILACS, <a href="http://lilacs.bvsalud.org" target="_blank">lilacs.bvsalud.org</a> (searched 23 September 2021); </p> </li> <li> <p>Web of Knowledge, Web of Science (1945 to 23 September 2021);</p> </li> <li> <p>CNKI, <a href="http://www.cnki.com.cn" target="_blank">www.cnki.com.cn</a> (searched via Google Scholar 23 September 2021); </p> </li> <li> <p>ClinicalTrials.gov (searched via the Cochrane Register of Studies and clinicaltrials.gov 23 September 2021); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), <a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a> (searched 23 September 2021). </p> </li> </ul> </p> <p>The Information Specialist modelled subject strategies for databases on the search strategy designed for CENTRAL. Where appropriate, they were combined with subject strategy adaptations of the highly sensitive search strategy designed by Cochrane for identifying randomised controlled trials and controlled clinical trials (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Version 5.1.0, Box 6.4.b. (<a href="./references#CD008080-bbs2-0087" title="Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org.">Handbook 2011</a>). Search strategies for major databases including CENTRAL are provided in <a href="./appendices#CD008080-sec-0158">Appendix 1</a>. </p> </section> <section id="CD008080-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We scanned the reference lists of identified publications for additional trials and contacted trial authors where necessary. In addition, the Information Specialist searched PubMed, the Cochrane Library and Google to retrieve existing systematic reviews relevant to this systematic review, so that we could scan their reference lists for additional trials. </p> </section> </section> <section id="CD008080-sec-0026"> <h3 class="title" id="CD008080-sec-0026">Data collection and analysis</h3> <p>Data collection and analysis for this review were specified in a pre‐published protocol (<a href="./references#CD008080-bbs2-0164" title="PlontkeSK , MeisnerC , Caye‐ThomasenP , ParnesL , AgrawalS , MikulecT . Intratympanic glucocorticoids for sudden sensorineural hearing loss. Cochrane Database of Systematic Reviews2009, Issue 4. Art. No: CD008080. [DOI: 10.1002/14651858.CD008080]">Plontke 2009</a>). Changes that have been made since the protocol are specified in the section <a href="#CD008080-sec-0165">Differences between protocol and review</a>. </p> <section id="CD008080-sec-0027"> <h4 class="title">Selection of studies</h4> <p>After scanning all search results and independent screening of titles and abstracts, we retrieved the full texts of reports that loosely met the inclusion criteria and where exclusion of studies could not be clearly inferred from the abstract. At least two authors reviewed these and applied the inclusion criteria independently. These were 1) intratympanic corticosteroid treatment of ISSNHL, 2) clinical study, 3) stated randomisation process and 4) studying at least one comparison included in the review. </p> <p>Final decisions on inclusion were based on full‐text analysis of preselected studies for the following criteria: 1) a reported randomisation process in the main text of the study report, 2) studying comparisons included in the review, 3) the diagnosis of included patients was ISSNHL, 4) the proportion of included patients with bilateral ISSNHL was below 5%, and 5) the time point of final outcome assessment was at least one week (eight days or more) after the start of treatment. In order to include a high number of studies, we also included those performing outcome assessments with short follow‐up (less than four weeks). However, we considered a short follow‐up duration of two weeks or less to represent a high risk of bias in these studies. </p> <p>We openly discussed any differences of opinion about which studies to include in the review. If consensus could not be reached, we planned to refer these studies to the Cochrane ENT Co‐ordinating Editor. However, this was not necessary in any case. Publications in languages that could not be read by the authors were fully translated by a professional translator. Further, if such studies were included in the meta‐analyses, two native speakers independently performed extraction of key data, co‐ordinated by Cochrane ENT. </p> </section> <section id="CD008080-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Study characteristics and data related to participants from each study were always independently extracted by at least three authors. Any discrepancies among the extracted data were discussed and resolved by consensus. Only treatment arms that met the comparisons defined in the review were included. If a study had more than one treatment arm matching the same type of intervention, we selected the one most widely used among included studies. In most studies, we extracted outcome data from the defined primary endpoint. When no time point was defined as the primary endpoint, we selected the latest time point for inclusion. Exceptionally, if the number of participants lost to follow‐up was very high at the final time point and the necessary outcome parameters and numbers of participants were reported for an earlier time point, we chose this earlier time point. This is documented in the <a href="./references#CD008080-sec-0167" title="">Characteristics of included studies</a> table. </p> <p>We documented the following details for each study:</p> <p> <ul id="CD008080-list-0007"> <li> <p>Methods (study design, country, year, setting, allocation, blinding).</p> </li> <li> <p>Participants (inclusion and exclusion criteria, number of included participants, baseline parameters). </p> </li> <li> <p>Interventions (treatment arms, time point of start of intervention, whether primary therapy or secondary/rescue therapy, dosage and type of steroid, drug delivery strategy, injection regime, duration of intervention, time to follow‐up, concomitant treatments). </p> </li> <li> <p>Outcomes (defined primary and secondary outcomes in the review (see above), definition of PTA and successful hearing improvement, number of completed and analysed participants, type of analysis). </p> </li> <li> <p>Funding sources and declarations of interest.</p> </li> </ul> </p> <p>We always extracted outcome data based on intention‐to‐treat (ITT) analysis when they were reported, in preference to data based on per‐protocol (PP) analysis. We extracted the following summary statistics for each study and each outcome: </p> <p> <ul id="CD008080-list-0008"> <li> <p>For continuous data: the mean values, standard deviations and number of patients for each treatment group. </p> </li> <li> <p>For binary data: the number of participants experiencing an event and the number of patients assessed at the time point. </p> </li> </ul> </p> <p>We took an exploratory approach to assessing adverse events and extracted data on all adverse events reported by the trialists.  </p> </section> <section id="CD008080-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Assessment of the risk of bias of the included studies was undertaken independently by four authors with the following domains taken into consideration, as guided by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008080-bbs2-0087" title="Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org.">Handbook 2011</a>): </p> <p> <ul id="CD008080-list-0009"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective reporting; and</p> </li> <li> <p>other sources of bias.</p> </li> </ul> </p> <p>We used the Cochrane risk of bias tool in RevMan 5 (<a href="./references#CD008080-bbs2-0133" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">RevMan 2020</a>), which involves scrutiny of each domain as reported in the trial and judgement about the adequacy of each entry. Discrepancies between raters' judgements were discussed and resolved by consensus. We judged the risk of bias to be 'high', 'low' or 'unclear' and documented this together with an explanation in the risk of bias tables in <a href="./references#CD008080-sec-0167" title="">Characteristics of included studies</a>. In non‐placebo‐controlled studies, we generally considered the risk of bias derived from a lack of blinding to be 'low' because we assumed that the ascertainment of outcomes was not influenced by open (non‐blind) administration. Studies that met the inclusion criteria after screening were included in the review independent of their risk of bias classification. The assigned risk of bias in studies had an influence on the assessment of the certainty of the evidence (GRADE). </p> </section> <section id="CD008080-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We summarised the effects of dichotomous outcomes (e.g. proportion of patients with hearing improvement measured by pure tone audiometry) as risk ratios (RR) with a 95% confidence interval (CI). For the key dichotomous outcomes presented in the summary of findings tables, we also expressed the results as absolute numbers (the assumed risk in the comparator group and the corresponding risk associated with the experimental intervention, based on its pooled relative effect and 95% CI).  </p> <p>For outcomes measured on a continuous scale (e.g. change in PTA, final PTA), we calculated the mean difference (MD) with a 95% CI. The summary statistic in the meta‐analysis for the primary outcome was the mean difference (MD) of the mean change in dB (baseline/post‐therapy) in hearing threshold between two groups in each study, measured by pure tone audiometry. The summary statistic in the meta‐analysis of the secondary outcome 'final hearing threshold' was the mean difference (MD) of the mean final hearing threshold in dB HL (post‐therapy) between two groups in each study, measured by pure tone audiometry. We used RevMan 5 to compute the measures of treatment effect for each individual study (<a href="./references#CD008080-bbs2-0133" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">RevMan 2020</a>). </p> <p>For hearing outcomes measured on a continuous scale (e.g. change in PTA, final PTA), we assumed a difference of 10 dB to be a clinically relevant effect. This decision was based on the test‐retest reliability of pure tone audiometric measurements, established minimal criteria for improvement in individual patients (<a href="./references#CD008080-bbs2-0067" title="ChandrasekharSS , Tsai DoBS , SchwartzSR , BontempoLJ , FaucettEA , FinestoneSA , et al. Clinical practice guideline: sudden hearing loss (Update). Otolaryngology - Head and Neck Surgery2019;161(1 Suppl):S1-S45. [PMID: 31369359]">Chandrasekhar 2019</a>; <a href="./references#CD008080-bbs2-0083" title="GurgelRK , JacklerRK , DobieRA , PopelkaGR . A new standardized format for reporting hearing outcome in clinical trials. Otolaryngology--Head and Neck Surgery2012;147(5):803-7. [PMID: 22931898]">Gurgel 2012</a>; <a href="./references#CD008080-bbs2-0145" title="StachlerRJ , ChandrasekharSS , ArcherSM , RosenfeldRM , SchwartzSR , BarrsDM , et al. Clinical practice guideline: sudden hearing loss. Otolaryngology - Head and Neck Surgery2012;146(3 Suppl):1-35.">Stachler 2012</a>), and on a large RCT on this topic with low risk of bias (<a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>). </p> <p>For dichotomous outcomes (e.g. proportion of patients with hearing improvement), we used a threshold of 25% or more in RR increase for appreciable benefit as suggested in the GRADE guideline (<a href="./references#CD008080-bbs2-0084" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93. [PMID: 21839614]">Guyatt 2011</a>). The 10 dB difference and the 25% criteria were agreed upon by all authors. </p> </section> <section id="CD008080-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant. We intended to include only studies in which the individual participant was the unit of analysis, regardless of whether they had unilateral or bilateral hearing loss. However, we did identify one study in which the unit of analysis was a single ear (<a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>). As only a very small number of participants had bilateral hearing loss, we decided to include these data in the review. Although we were unable to account for the correlation between the ears, treating the data as independent is likely to produce a more conservative estimate of the treatment effect.  </p> </section> <section id="CD008080-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We considered missing information about the methods of the included studies (e.g. when the method of randomisation was not reported) in the risk of bias assessment. Where data relating to an outcome of interest were not reported, we contacted the study authors. If the study authors could not provide the missing data or did not respond we excluded the study from the analysis of that outcome. If standard deviation data were not available, we approximated them using standard estimation methods from P values, standard errors or 95% CIs if these were reported, as detailed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008080-bbs2-0088" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Handbook 2021</a>). </p> </section> <section id="CD008080-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed both clinical and statistical heterogeneity. Clinical heterogeneity may be present even in the absence of statistical heterogeneity. For assessment of clinical heterogeneity we examined the included studies for evidence of major differences in the types of participants recruited, interventions, controls or outcomes measured. </p> <p>We assessed statistical heterogeneity by visually inspecting the forest plots and by considering the Chi² test and the I² statistic. The latter calculates the percentage of variability that is not due to chance. I² values over 50% suggest the presence of substantial heterogeneity (<a href="./references#CD008080-bbs2-0088" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Handbook 2021</a>). Due to the low power of the Chi² test we set a significance level of P &lt; 0.1. </p> </section> <section id="CD008080-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed two aspects of reporting bias: between‐study publication bias and within‐study outcome reporting bias. </p> <section id="CD008080-sec-0035"> <h5 class="title">Publication bias (between‐study reporting bias)</h5> <p>Where sufficient studies (10 or more) were available for an outcome, we used a funnel plot to assess publication bias. </p> </section> <section id="CD008080-sec-0036"> <h5 class="title">Outcome reporting bias (within‐study reporting bias)</h5> <p>We assessed within‐study reporting bias by comparing the outcomes reported in the published report with those listed in the methods section. If a study protocol was available, we compared the reported outcomes with the pre‐specified outcomes in the study protocol. When results were not reported in a statistically correct way this was reflected in a designation of high risk of bias due to selective outcome reporting. </p> </section> </section> <section id="CD008080-sec-0037"> <h4 class="title">Data synthesis</h4> <p>We used RevMan 5 to carry out meta‐analyses (<a href="./references#CD008080-bbs2-0133" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">RevMan 2020</a>). Where possible we analysed data to give a summary measure of effect. We always used a fixed‐effect model for meta‐analysis to measure the effect. For dichotomous data, we analysed treatment differences as a risk ratio (RR). For continuous outcomes, if all the data were from the same scale, we pooled mean differences between values obtained at follow‐up and at baseline and reported this as a MD. We performed separate analyses for studies assessing primary and secondary therapy respectively. </p> <p>Few studies reported the outcomes 'change in hearing threshold with speech audiometry' and 'frequency‐specific hearing loss'. Furthermore, studies often used different methods of speech audiometry and it was not clear if these were directly comparable. Therefore we have not conducted any meta‐analyses for these outcomes, but have instead shown the available data on a forest plot without pooling.  </p> <p>The type of adverse events varied widely between the different studies and it was often unclear whether these events had been systematically assessed and reported. Few studies reported an event rate for each randomised group. More often, a rate was reported for only one group, or a broad statement was made that 'no adverse events were observed'. Sometimes it was unclear to which group a statement applied. The lack of comparable data across groups and across studies meant we were unable to synthesise the data for many types of event and permitted few meta‐analyses.  </p> <p>We considered some adverse events to be directly related to the procedure of intratympanic injection, which may have explained why these events were not always assessed or reported in the comparator group. We considered people with ISSNHL to be very unlikely to experience tympanic membrane perforation, sudden‐onset vertigo (at the time of intratympanic injection) or sudden‐onset ear pain (at the time of intratympanic injection) unless directly attributable to the procedure. For these events we have provided a narrative synthesis of the event rate in the relevant group and presented these as a range.   </p> <p>For adverse events that could feasibly occur in either group, we have only included the studies that provided a rate for both groups, which allowed a comparison between the groups. A full description of all reported adverse event data is available for reference in <a href="./full#CD008080-tbl-0002">Table 1</a>, <a href="./full#CD008080-tbl-0004">Table 2</a>, <a href="./full#CD008080-tbl-0006">Table 3</a> and <a href="./full#CD008080-tbl-0008">Table 4</a>. </p> </section> <section id="CD008080-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We did not perform subgroup analysis, due to insufficient data for our planned analyses. We had planned to consider the following subgroups in the review: </p> <p> <ul id="CD008080-list-0010"> <li> <p>Degree of hearing loss at initial presentation.</p> </li> <li> <p>Age of patients.</p> </li> <li> <p>Presence of vertigo and/or tinnitus.</p> </li> <li> <p>Time before start of intratympanic treatment.</p> </li> <li> <p>Duration of intratympanic treatment.</p> </li> <li> <p>Drug delivery strategy/system used (e.g. intratympanic injection or continuous delivery etc). </p> </li> <li> <p>Dose of intratympanic treatment.</p> </li> </ul> </p> </section> <section id="CD008080-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out sensitivity analyses to determine whether or not the findings were robust, based on the decisions made in undertaking the review. We planned analyses excluding studies with high risk of bias. Studies with high risk of bias were defined as those that had a high risk of selection bias (bias in randomisation or concealment, or both), an overall loss to follow‐up of &gt; 25%, or unclear or imbalanced baseline parameters (e.g. treatment delay in <a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>). </p> </section> <section id="CD008080-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Two independent authors (AL and CM) used the GRADE approach to rate the overall certainty of evidence. The certainty of evidence reflects the extent to which we are confident that an estimate of effect is correct and we considered this in the interpretation of results. There are four possible ratings: high, moderate, low and very low. A rating of high certainty of evidence implies that we are confident in our estimate of effect and that further research is very unlikely to change our confidence in the estimate of effect. A rating of very low certainty implies that any estimate of effect obtained is very uncertain. </p> <p>The GRADE approach rates evidence from RCTs that do not have serious limitations as high certainty. However, several factors can lead to the downgrading of the evidence to moderate, low or very low. The degree of downgrading is determined by the seriousness of these factors: </p> <p> <ul id="CD008080-list-0011"> <li> <p>study limitations (risk of bias);</p> </li> <li> <p>inconsistency (heterogeneity);</p> </li> <li> <p>indirectness of evidence (characteristics of participant population);</p> </li> <li> <p>imprecision (variance of the outcome within studies); and</p> </li> <li> <p>publication bias.</p> </li> </ul> </p> <p>We included a summary of findings table, constructed according to the recommendations described in Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008080-bbs2-0088" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Handbook 2021</a>), for the following comparisons: </p> <p> <ul id="CD008080-list-0012"> <li> <p>Intratympanic corticosteroids versus systemic corticosteroids as primary therapy.</p> </li> <li> <p>Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as primary therapy. </p> </li> <li> <p>Intratympanic corticosteroids versus no treatment or versus placebo as secondary therapy.</p> </li> <li> <p>Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as secondary therapy.  </p> </li> </ul> </p> <p>We included the following outcomes in the summary of findings tables: </p> <p> <ul id="CD008080-list-0013"> <li> <p>Change in hearing threshold with pure tone audiometry (pure tone average (PTA)).</p> </li> <li> <p>Proportion of patients whose hearing is improved.</p> </li> <li> <p>Final hearing threshold.</p> </li> <li> <p>Adverse events.</p> </li> </ul> </p> <p>As described above, adverse events were inconsistently reported across the studies, and a wide range of different adverse events were described. For the summary of findings tables, we therefore prioritised events that were considered to be of most relevance to intratympanic injection, namely tympanic membrane perforation, ear pain and vertigo/dizziness. All other adverse events are described in the text of the review and additional tables (<a href="./full#CD008080-tbl-0002">Table 1</a>; <a href="./full#CD008080-tbl-0004">Table 2</a>; <a href="./full#CD008080-tbl-0006">Table 3</a>; <a href="./full#CD008080-tbl-0008">Table 4</a>), but not included in the summary of findings tables.  </p> <p>The wording in the comments of the summary of findings tables, in the abstract, the results and the authors’ conclusion sections was based on the <i>'GRADE guidelines informative statements to communicate the findings of systematic reviews of interventions'</i> (<a href="./references#CD008080-bbs2-0138" title="SantessoN , GlentonC , DahmP , GarnerP , AklEA , AlperB , et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. Journal of Clinical Epidemiology2020;119:126-35. [PMID: 31711912]">Santesso 2020</a>). In this guideline, producers and users of systematic reviews found statements to communicate findings combining size and certainty of an effect acceptable. The <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Chapter 15.6.4) also suggests using these narrative statements for drawing conclusions based on the effect estimate from the meta‐analysis and the certainty of the evidence (<a href="./references#CD008080-bbs2-0088" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Handbook 2021</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008080-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008080-sec-0041"></div> <section id="CD008080-sec-0042"> <h3 class="title">Description of studies</h3> <section id="CD008080-sec-0043"> <h4 class="title">Results of the search</h4> <p>The flow of records from the number of references identified in the search to the number of studies included in the review is shown in <a href="#CD008080-fig-0001">Figure 1</a>. The database search yielded 1720 records after duplicates were removed. We identified 59 additional records through other sources. We screened 1779 records for initial inclusion and discarded 1399 records because they did not study intratympanic corticosteroid treatment of ISSNHL. We discarded a further 328 articles because they were reviews, case reports, study protocols or not randomised controlled studies (i.e. randomised controlled trials and quasi‐randomised controlled trials). Finally, we assessed 52 randomised and quasi‐randomised trials for eligibility. We excluded 20 studies because either the study was carried out in the wrong population (n = 3), or used the wrong intervention (n = 4) or wrong comparator (n = 12). We excluded one study because the duration of follow‐up was seven days or less. See <a href="#CD008080-sec-0061">Excluded studies</a> and <a href="./references#CD008080-sec-0168" title="">Characteristics of excluded studies</a>. </p> <div class="figure" id="CD008080-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Process of selection of studies for inclusion in the review." data-id="CD008080-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Process of selection of studies for inclusion in the review.</p> </div> </div> </div> <p>Two studies are ongoing. See <a href="./references#CD008080-sec-0169" title="">Characteristics of ongoing studies</a>. </p> <p>We included the remaining 30 studies in the review.</p> </section> <section id="CD008080-sec-0044"> <h4 class="title">Included studies</h4> <p>Thirty studies met the criteria for inclusion with 2133 analysed patients in total. See the <a href="./references#CD008080-sec-0167" title="">Characteristics of included studies</a> table for full details.  </p> <section id="CD008080-sec-0045"> <h5 class="title">Study design</h5> <p>All included studies were parallel‐group RCTs. The majority of studies were open‐label trials. Only four studies reported blinding of participants, personnel and outcome assessors (<a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>; <a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>; <a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>; <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>).  </p> </section> <section id="CD008080-sec-0046"> <h5 class="title">Participants</h5> <p>All included studies recruited adult participants. Studies were conducted in a number of locations, including China (<a href="./references#CD008080-bbs2-0007" title="ChangWX , ZhongHL , CaiX , GanQ . Dexamethasone injection in the middle ear for high altitude refractory sudden deafness. Sichuan Medical Journal2010;31(1):71. ">Chang 2010</a>; <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>; <a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a>; <a href="./references#CD008080-bbs2-0020" title="PengY , XiongS , ChengY , QiYF , YangY . Clinical investigation of different routes of administration of dexamethasone on sudden deafness [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery (Chinese)2008;22(10):442-5. ">Peng 2008</a>; <a href="./references#CD008080-bbs2-0022" title="QuY , ChenH , ZhangH , GuoM . Analysis the treatment of sudden sensorineural hearing loss with steroid from different administration routes [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery [Chinese]2015;29(4):324-6. ">Qu 2015</a>; <a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a>; <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>; <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>), the Republic of Korea (<a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a>; <a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a>; <a href="./references#CD008080-bbs2-0013" title="HongSM , ParkCH , LeeJH . Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngology - Head and Neck Surgery2009;141(5):579-83. ">Hong 2009</a>; <a href="./references#CD008080-bbs2-0017" title="LeeJB , ChoiSJ , ParkK , ParkHY , ChooOS , ChoungYH . The efficiency of intratympanic dexamethasone injection as a sequential treatment after initial systemic steroid therapy for sudden sensorineural hearing loss. European Archives of Oto-rhino-laryngology2011;268(6):833-9. ">Lee 2011</a>; <a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a>), Greece (<a href="./references#CD008080-bbs2-0015" title="KoltsidopoulosP , BibasA , SismanisA , TzonouA , SeggasI . Intratympanic and systemic steroids for sudden hearing loss. Otology &amp; Neurotology2013;34:771-6. ">Koltsidopoulos 2013</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>; <a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a>), Turkey (<a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>; <a href="./references#CD008080-bbs2-0010" title="ErmutluG , SüslüN , YılmazT , SaraçS . Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. European Archives of Oto-rhino-laryngology2017;274(10):3585-91. ">Ermutlu 2017</a>; <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>), Iran (<a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a>; <a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>), the USA (<a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>), Germany (<a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>), India (<a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a>), Italy (<a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a>), Russia (<a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>), Saudi Arabia (<a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>), Sri Lanka (<a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a>), and Taiwan (<a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a>). </p> <section id="CD008080-sec-0047"> <h6 class="title">Baseline hearing loss</h6> <p>All participants had SSNHL, but the specific hearing threshold required by the studies did differ. The most common threshold was a hearing loss of &gt; 30 dB in three contiguous frequencies, occurring over the course of &lt; 72 hours (<a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a>; <a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a>; <a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a>; <a href="./references#CD008080-bbs2-0010" title="ErmutluG , SüslüN , YılmazT , SaraçS . Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. European Archives of Oto-rhino-laryngology2017;274(10):3585-91. ">Ermutlu 2017</a>; <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>; <a href="./references#CD008080-bbs2-0013" title="HongSM , ParkCH , LeeJH . Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngology - Head and Neck Surgery2009;141(5):579-83. ">Hong 2009</a>; <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>; <a href="./references#CD008080-bbs2-0015" title="KoltsidopoulosP , BibasA , SismanisA , TzonouA , SeggasI . Intratympanic and systemic steroids for sudden hearing loss. Otology &amp; Neurotology2013;34:771-6. ">Koltsidopoulos 2013</a>; <a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>; <a href="./references#CD008080-bbs2-0017" title="LeeJB , ChoiSJ , ParkK , ParkHY , ChooOS , ChoungYH . The efficiency of intratympanic dexamethasone injection as a sequential treatment after initial systemic steroid therapy for sudden sensorineural hearing loss. European Archives of Oto-rhino-laryngology2011;268(6):833-9. ">Lee 2011</a>; <a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a>; <a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a>; <a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>; <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>; <a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a>; <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>). Three studies did not describe the use of these thresholds in their methods, but defined SSNHL according to these criteria elsewhere in the article, therefore it is presumed that the same criteria were used (<a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a>; <a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>; <a href="./references#CD008080-bbs2-0020" title="PengY , XiongS , ChengY , QiYF , YangY . Clinical investigation of different routes of administration of dexamethasone on sudden deafness [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery (Chinese)2008;22(10):442-5. ">Peng 2008</a>). Some studies used a smaller change in hearing threshold, such as &gt; 20 dB hearing loss in three contiguous frequencies (<a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>; <a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a>), or &gt; 10 dB hearing loss in three contiguous frequencies (<a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a>). Again, one study did not describe the definition of SSNHL in the methods of the paper, but referred elsewhere to a definition of &gt; 20 dB hearing loss in three contiguous frequencies, therefore we presumed this threshold was used (<a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>).  </p> <p>Two studies required participants to have a pure tone average of 50 dB or higher and the affected ear having hearing at least 30 dB worse than the contralateral (unaffected) ear (<a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>). One study required a hearing threshold of ≥ 50 dB hearing loss for three or more frequencies (PTA including 0.5 kHz, 1 kHz, 2 kHz, 3 kHz and 4 kHz) or ≥ 60 dB for two frequencies, or ≥ 70 dB for any frequency within this range, or a speech reception threshold of ≥ 70 dB SPL or a speech discrimination score of ≥ 30% (<a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>). Three studies did not provide a hearing threshold at which participants were included in the study (<a href="./references#CD008080-bbs2-0007" title="ChangWX , ZhongHL , CaiX , GanQ . Dexamethasone injection in the middle ear for high altitude refractory sudden deafness. Sichuan Medical Journal2010;31(1):71. ">Chang 2010</a>; <a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a>; <a href="./references#CD008080-bbs2-0022" title="QuY , ChenH , ZhangH , GuoM . Analysis the treatment of sudden sensorineural hearing loss with steroid from different administration routes [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery [Chinese]2015;29(4):324-6. ">Qu 2015</a>).  </p> </section> <section id="CD008080-sec-0048"> <h6 class="title">Time to initial treatment</h6> <p>For studies that were concerned with primary treatment, the majority enrolled and commenced treatment within 15 days of the onset of SSNHL (<a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>; <a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a>; <a href="./references#CD008080-bbs2-0010" title="ErmutluG , SüslüN , YılmazT , SaraçS . Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. European Archives of Oto-rhino-laryngology2017;274(10):3585-91. ">Ermutlu 2017</a>; <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>; <a href="./references#CD008080-bbs2-0013" title="HongSM , ParkCH , LeeJH . Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngology - Head and Neck Surgery2009;141(5):579-83. ">Hong 2009</a>; <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>; <a href="./references#CD008080-bbs2-0022" title="QuY , ChenH , ZhangH , GuoM . Analysis the treatment of sudden sensorineural hearing loss with steroid from different administration routes [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery [Chinese]2015;29(4):324-6. ">Qu 2015</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>; <a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a>; <a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a>; <a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>). Five studies permitted enrolment in the study after a longer delay, but most participants were recruited within two weeks (<a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>; <a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>; <a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a>; <a href="./references#CD008080-bbs2-0015" title="KoltsidopoulosP , BibasA , SismanisA , TzonouA , SeggasI . Intratympanic and systemic steroids for sudden hearing loss. Otology &amp; Neurotology2013;34:771-6. ">Koltsidopoulos 2013</a>; <a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>). Four studies did not specify the time from onset of symptoms to treatment as an inclusion criterion. The delay to treatment in three of these studies was a mean of 7 days (<a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a>), 8.4 days (<a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a>), and 5.6 days (<a href="./references#CD008080-bbs2-0020" title="PengY , XiongS , ChengY , QiYF , YangY . Clinical investigation of different routes of administration of dexamethasone on sudden deafness [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery (Chinese)2008;22(10):442-5. ">Peng 2008</a>). One study specifically recruited participants with poor prognostic factors, which may have included a delay in treatment (<a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a>). For this study, 38% of participants had a delay of more than two weeks before receiving their first treatment.  </p> </section> <section id="CD008080-sec-0049"> <h6 class="title">Failure of initial treatment</h6> <p>For studies that were concerned with secondary treatment, participants were recruited based on the failure of initial therapy. Treatment failure was also defined differently across the studies. Two studies based this purely on the improvement in hearing over the course of therapy, with improvement of &lt; 10 dB (<a href="./references#CD008080-bbs2-0017" title="LeeJB , ChoiSJ , ParkK , ParkHY , ChooOS , ChoungYH . The efficiency of intratympanic dexamethasone injection as a sequential treatment after initial systemic steroid therapy for sudden sensorineural hearing loss. European Archives of Oto-rhino-laryngology2011;268(6):833-9. ">Lee 2011</a>) or &lt; 30 dB (<a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a>) regarded as treatment failure. Three studies considered the difference between ears, with or without the absolute hearing threshold: <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a> used a &gt; 20 dB HL difference on PTA when compared to the contralateral (unaffected) ear to define treatment failure, whilst <a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a> and <a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a> both used a &gt; 10 dB HL difference when compared to the contralateral ear or a PTA of &lt; 30 dB. <a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a> required a hearing threshold in the contralateral ear to be at least 20 dB HL better than the affected ear in at least three frequencies between 0.5 kHz and 4 kHz. <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a> considered treatment failure as a change of less than 15 dB in PTA at four frequencies and an increase of &lt; 15% in speech discrimination score after initial therapy. <a href="./references#CD008080-bbs2-0007" title="ChangWX , ZhongHL , CaiX , GanQ . Dexamethasone injection in the middle ear for high altitude refractory sudden deafness. Sichuan Medical Journal2010;31(1):71. ">Chang 2010</a> stated that participants were included if they were refractory to primary therapy after 20 days, but did not describe how this was defined.  </p> </section> </section> <section id="CD008080-sec-0050"> <h5 class="title">Interventions and comparisons</h5> <p>Most of the included studies investigated primary treatment of ISSNHL (<a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a>; <a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a>; <a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>; <a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>; <a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>; <a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a>; <a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a>; <a href="./references#CD008080-bbs2-0010" title="ErmutluG , SüslüN , YılmazT , SaraçS . Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. European Archives of Oto-rhino-laryngology2017;274(10):3585-91. ">Ermutlu 2017</a>; <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>; <a href="./references#CD008080-bbs2-0013" title="HongSM , ParkCH , LeeJH . Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngology - Head and Neck Surgery2009;141(5):579-83. ">Hong 2009</a>; <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>; <a href="./references#CD008080-bbs2-0015" title="KoltsidopoulosP , BibasA , SismanisA , TzonouA , SeggasI . Intratympanic and systemic steroids for sudden hearing loss. Otology &amp; Neurotology2013;34:771-6. ">Koltsidopoulos 2013</a>; <a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>; <a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a>; <a href="./references#CD008080-bbs2-0020" title="PengY , XiongS , ChengY , QiYF , YangY . Clinical investigation of different routes of administration of dexamethasone on sudden deafness [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery (Chinese)2008;22(10):442-5. ">Peng 2008</a>; <a href="./references#CD008080-bbs2-0022" title="QuY , ChenH , ZhangH , GuoM . Analysis the treatment of sudden sensorineural hearing loss with steroid from different administration routes [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery [Chinese]2015;29(4):324-6. ">Qu 2015</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>; <a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a>; <a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a>; <a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>).  </p> <p>For primary treatment, 12 studies compared intratympanic treatment to systemic steroids, which were predominantly administered orally (<a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a>; <a href="./references#CD008080-bbs2-0010" title="ErmutluG , SüslüN , YılmazT , SaraçS . Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. European Archives of Oto-rhino-laryngology2017;274(10):3585-91. ">Ermutlu 2017</a>; <a href="./references#CD008080-bbs2-0013" title="HongSM , ParkCH , LeeJH . Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngology - Head and Neck Surgery2009;141(5):579-83. ">Hong 2009</a>; <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>; <a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>; <a href="./references#CD008080-bbs2-0020" title="PengY , XiongS , ChengY , QiYF , YangY . Clinical investigation of different routes of administration of dexamethasone on sudden deafness [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery (Chinese)2008;22(10):442-5. ">Peng 2008</a>; <a href="./references#CD008080-bbs2-0022" title="QuY , ChenH , ZhangH , GuoM . Analysis the treatment of sudden sensorineural hearing loss with steroid from different administration routes [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery [Chinese]2015;29(4):324-6. ">Qu 2015</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>; <a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a>; <a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a>; <a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a>). Six studies compared combined treatment (intratympanic plus systemic corticosteroids) with systemic corticosteroids alone (<a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a>; <a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a>; <a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>; <a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a>; <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>; <a href="./references#CD008080-bbs2-0015" title="KoltsidopoulosP , BibasA , SismanisA , TzonouA , SeggasI . Intratympanic and systemic steroids for sudden hearing loss. Otology &amp; Neurotology2013;34:771-6. ">Koltsidopoulos 2013</a>). Four studies included three treatment arms (intratympanic treatment alone, intratympanic plus systemic treatment and systemic treatment alone) and therefore contributed data to both of these comparisons (<a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>; <a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>; <a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>). </p> <p>A small number of studies investigated secondary treatment, after the failure of initial therapy (<a href="./references#CD008080-bbs2-0007" title="ChangWX , ZhongHL , CaiX , GanQ . Dexamethasone injection in the middle ear for high altitude refractory sudden deafness. Sichuan Medical Journal2010;31(1):71. ">Chang 2010</a>; <a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a>; <a href="./references#CD008080-bbs2-0017" title="LeeJB , ChoiSJ , ParkK , ParkHY , ChooOS , ChoungYH . The efficiency of intratympanic dexamethasone injection as a sequential treatment after initial systemic steroid therapy for sudden sensorineural hearing loss. European Archives of Oto-rhino-laryngology2011;268(6):833-9. ">Lee 2011</a>; <a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a>; <a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>; <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>; <a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a>; <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>). The type of initial (primary) treatment that participants had received varied, with three studies using intravenous steroids (<a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>; <a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a>; <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>), three studies using a 10‐ to 14‐day course of oral steroids (<a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a>; <a href="./references#CD008080-bbs2-0017" title="LeeJB , ChoiSJ , ParkK , ParkHY , ChooOS , ChoungYH . The efficiency of intratympanic dexamethasone injection as a sequential treatment after initial systemic steroid therapy for sudden sensorineural hearing loss. European Archives of Oto-rhino-laryngology2011;268(6):833-9. ">Lee 2011</a>; <a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a>), and one study using an initial dose of intravenous steroids, followed by a tapered oral dose (<a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>). One study did not describe the primary therapy that had been used (<a href="./references#CD008080-bbs2-0007" title="ChangWX , ZhongHL , CaiX , GanQ . Dexamethasone injection in the middle ear for high altitude refractory sudden deafness. Sichuan Medical Journal2010;31(1):71. ">Chang 2010</a>).  </p> <p>Most studies that considered secondary treatment compared intratympanic steroids to either no treatment (<a href="./references#CD008080-bbs2-0007" title="ChangWX , ZhongHL , CaiX , GanQ . Dexamethasone injection in the middle ear for high altitude refractory sudden deafness. Sichuan Medical Journal2010;31(1):71. ">Chang 2010</a>; <a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a>; <a href="./references#CD008080-bbs2-0017" title="LeeJB , ChoiSJ , ParkK , ParkHY , ChooOS , ChoungYH . The efficiency of intratympanic dexamethasone injection as a sequential treatment after initial systemic steroid therapy for sudden sensorineural hearing loss. European Archives of Oto-rhino-laryngology2011;268(6):833-9. ">Lee 2011</a>; <a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a>; <a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a>), or to placebo (<a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>; <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>). A single study compared intratympanic plus systemic corticosteroids to systemic corticosteroids alone (<a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>).  </p> <p>The nature of the intratympanic injection varied between studies. Most studies used an intratympanic delivery of either dexamethasone or methylprednisolone, administered as a short course of three to four injections, typically over 7 to 14 days. Two studies used notably different methods of administration. One involved daily injections for 10 days, followed by alternate day injections for a further 20 days and ongoing injections twice a week for five months (<a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>). One further study used a catheter to provide continuous infusion of dexamethasone over 14 days, rather than intermittent injections (<a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>). In one study the duration of systemic treatment (15 days) was much shorter than that of the intratympanic treatment (six months) (<a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>).  </p> </section> <section id="CD008080-sec-0051"> <h5 class="title">Outcomes</h5> <p>Duration of follow‐up varied across the studies. Four studies followed participants for 15 days or less (<a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a>; <a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>; <a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>; <a href="./references#CD008080-bbs2-0022" title="QuY , ChenH , ZhangH , GuoM . Analysis the treatment of sudden sensorineural hearing loss with steroid from different administration routes [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery [Chinese]2015;29(4):324-6. ">Qu 2015</a>). Six studies followed participants for between 16 and 30 days (<a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>; <a href="./references#CD008080-bbs2-0007" title="ChangWX , ZhongHL , CaiX , GanQ . Dexamethasone injection in the middle ear for high altitude refractory sudden deafness. Sichuan Medical Journal2010;31(1):71. ">Chang 2010</a>; <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>; <a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a>; <a href="./references#CD008080-bbs2-0020" title="PengY , XiongS , ChengY , QiYF , YangY . Clinical investigation of different routes of administration of dexamethasone on sudden deafness [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery (Chinese)2008;22(10):442-5. ">Peng 2008</a>; <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>). The remaining studies followed participants for over one month, with a range of 38 days (<a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a>) to 204 days (<a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a>). <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a> followed participants for 90 days, but we extracted data for change in hearing thresholds from an interim analysis at 12 days because the comparison of interest (intratympanic versus systemic corticosteroid) was administered only up to that point in time. All other outcome data were reported at the longest follow‐up point for each study, except instances where there was very high dropout at the final time point (as described in <a href="#CD008080-sec-0044">Included studies</a>). </p> <section id="CD008080-sec-0052"> <h6 class="title">Change in hearing threshold with pure tone audiometry (pure tone average)</h6> <p>Most studies assessed hearing thresholds with a pure tone average based on four frequencies, either 0.5 kHz, 1 kHz, 2 kHz or 4 kHz (<a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>; <a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a>; <a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a>; <a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>; <a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a>; <a href="./references#CD008080-bbs2-0020" title="PengY , XiongS , ChengY , QiYF , YangY . Clinical investigation of different routes of administration of dexamethasone on sudden deafness [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery (Chinese)2008;22(10):442-5. ">Peng 2008</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>; <a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>; <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>; <a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a>; <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>), or 0.5 kHz, 1 kHz, 2 kHz and 3 kHz (<a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a>; <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>; <a href="./references#CD008080-bbs2-0013" title="HongSM , ParkCH , LeeJH . Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngology - Head and Neck Surgery2009;141(5):579-83. ">Hong 2009</a>; <a href="./references#CD008080-bbs2-0017" title="LeeJB , ChoiSJ , ParkK , ParkHY , ChooOS , ChoungYH . The efficiency of intratympanic dexamethasone injection as a sequential treatment after initial systemic steroid therapy for sudden sensorineural hearing loss. European Archives of Oto-rhino-laryngology2011;268(6):833-9. ">Lee 2011</a>; <a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a>; <a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>). Two studies used the average of three frequencies (0.5 kHz, 1 kHz, 2 kHz, <a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>; <a href="./references#CD008080-bbs2-0010" title="ErmutluG , SüslüN , YılmazT , SaraçS . Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. European Archives of Oto-rhino-laryngology2017;274(10):3585-91. ">Ermutlu 2017</a>), two studies used five frequencies (0.25 kHz, 0.5 kHz, 1 kHz, 2 kHz and 4kHz) (<a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a>; <a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>), and four studies used six or more frequencies (<a href="./references#CD008080-bbs2-0007" title="ChangWX , ZhongHL , CaiX , GanQ . Dexamethasone injection in the middle ear for high altitude refractory sudden deafness. Sichuan Medical Journal2010;31(1):71. ">Chang 2010</a>; <a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a>; <a href="./references#CD008080-bbs2-0015" title="KoltsidopoulosP , BibasA , SismanisA , TzonouA , SeggasI . Intratympanic and systemic steroids for sudden hearing loss. Otology &amp; Neurotology2013;34:771-6. ">Koltsidopoulos 2013</a>; <a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a>). Two studies did not describe the frequencies used (<a href="./references#CD008080-bbs2-0022" title="QuY , ChenH , ZhangH , GuoM . Analysis the treatment of sudden sensorineural hearing loss with steroid from different administration routes [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery [Chinese]2015;29(4):324-6. ">Qu 2015</a>; <a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a>).  </p> </section> <section id="CD008080-sec-0053"> <h6 class="title">Proportion of patients whose hearing is improved</h6> <p>We included data for this outcome regardless of the definition of 'improvement' used in the individual studies. However, this definition was not consistent across the different studies. A number of studies used the criterion of a specific change in hearing threshold to identify those who had improved. This was typically a change of at least 10 dB (<a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>; <a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a>; <a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a>; <a href="./references#CD008080-bbs2-0017" title="LeeJB , ChoiSJ , ParkK , ParkHY , ChooOS , ChoungYH . The efficiency of intratympanic dexamethasone injection as a sequential treatment after initial systemic steroid therapy for sudden sensorineural hearing loss. European Archives of Oto-rhino-laryngology2011;268(6):833-9. ">Lee 2011</a>; <a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a>; <a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>; <a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a>; <a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a>; <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>; <a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a>), or 15 dB (<a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a>; <a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>; <a href="./references#CD008080-bbs2-0020" title="PengY , XiongS , ChengY , QiYF , YangY . Clinical investigation of different routes of administration of dexamethasone on sudden deafness [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery (Chinese)2008;22(10):442-5. ">Peng 2008</a>; <a href="./references#CD008080-bbs2-0022" title="QuY , ChenH , ZhangH , GuoM . Analysis the treatment of sudden sensorineural hearing loss with steroid from different administration routes [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery [Chinese]2015;29(4):324-6. ">Qu 2015</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>; <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>), over the follow‐up period. Four studies used Siegel's criteria to assess improvement (<a href="./references#CD008080-bbs2-0142" title="SiegelLG . The treatment of idiopathic sudden sensorineural hearing loss. Otolaryngologic Clinics of North America1975;8(2):467-73.">Siegel 1975</a>), where 'any' improvement is considered to be &gt; 15 dB change in hearing threshold and final hearing threshold ≥ 75 dB (<a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a>; <a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a>; <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>; <a href="./references#CD008080-bbs2-0013" title="HongSM , ParkCH , LeeJH . Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngology - Head and Neck Surgery2009;141(5):579-83. ">Hong 2009</a>). Four studies considered both the change in hearing threshold and improvement in word recognition scores (WRS) or speech discrimination scores (SDS) when assessing improvement: <a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a> (&gt; 10 dB decrease in PTA or &gt; 15% improvement in SDS), <a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a> (&gt; 15 dB decrease in PTA or &gt; 25% improvement in SDS), <a href="./references#CD008080-bbs2-0010" title="ErmutluG , SüslüN , YılmazT , SaraçS . Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. European Archives of Oto-rhino-laryngology2017;274(10):3585-91. ">Ermutlu 2017</a> (&gt; 10 dB decrease in PTA or &gt; 10% improvement in WRS) and <a href="./references#CD008080-bbs2-0015" title="KoltsidopoulosP , BibasA , SismanisA , TzonouA , SeggasI . Intratympanic and systemic steroids for sudden hearing loss. Otology &amp; Neurotology2013;34:771-6. ">Koltsidopoulos 2013</a> (&gt; 10 dB decrease in PTA and 15% improvement in SDS). One study used a decrease of &gt; 30 dB in PTA, or an assessment of recovery to 50% of maximum possible (as compared to the unaffected ear) to indicate improvement (<a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>). One study reported on improvement in hearing, but did not describe the criteria (<a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a>). Two studies did not assess improvement (<a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0007" title="ChangWX , ZhongHL , CaiX , GanQ . Dexamethasone injection in the middle ear for high altitude refractory sudden deafness. Sichuan Medical Journal2010;31(1):71. ">Chang 2010</a>).  </p> </section> <section id="CD008080-sec-0054"> <h6 class="title">Final hearing threshold with pure tone audiometry</h6> <p>Frequencies used to assess this outcome were identical to those used for change in hearing threshold (see above).  </p> </section> <section id="CD008080-sec-0055"> <h6 class="title">Change in hearing threshold with speech audiometry</h6> <p>This outcome was only reported by a small number of studies, and was assessed with a variety of instruments, including speech discrimination scores, speech reception thresholds and word recognition scores. Considering the different metrics used to measure this outcome, and a concern that assessment conducted in different languages may not be directly comparable, we did not conduct any meta‐analyses. Six studies reported changes from baseline or final values for speech discrimination score (<a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>; <a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>; <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>; <a href="./references#CD008080-bbs2-0015" title="KoltsidopoulosP , BibasA , SismanisA , TzonouA , SeggasI . Intratympanic and systemic steroids for sudden hearing loss. Otology &amp; Neurotology2013;34:771-6. ">Koltsidopoulos 2013</a>; <a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>; <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>). Two studies reported changes from baseline in speech reception threshold (<a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>; <a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>), and one study reported change from baseline in the word recognition score (<a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>).  </p> </section> <section id="CD008080-sec-0056"> <h6 class="title">Frequency‐specific changes with pure tone audiometry</h6> <p>Again, few studies reported on frequency‐specific changes with pure tone audiometry. There was also inconsistency in the frequencies that were assessed, and some studies presented pooled data across a small number of frequencies (low, mid and high), rather than reporting individual frequencies. Therefore we did not conduct any meta‐analyses for this outcome. The only studies assessing this were: <a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a>; <a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>; <a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a>; <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>; <a href="./references#CD008080-bbs2-0013" title="HongSM , ParkCH , LeeJH . Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngology - Head and Neck Surgery2009;141(5):579-83. ">Hong 2009</a>; <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>; <a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a> <a href="./references#CD008080-bbs2-0017" title="LeeJB , ChoiSJ , ParkK , ParkHY , ChooOS , ChoungYH . The efficiency of intratympanic dexamethasone injection as a sequential treatment after initial systemic steroid therapy for sudden sensorineural hearing loss. European Archives of Oto-rhino-laryngology2011;268(6):833-9. ">Lee 2011</a>; <a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a> and <a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a>.  </p> </section> <section id="CD008080-sec-0057"> <h6 class="title">Mean level of improvement in those whose hearing is improved</h6> <p>This outcome was not assessed or reported by any of the included studies. </p> </section> <section id="CD008080-sec-0058"> <h6 class="title">Percentage of patients reaching serviceable hearing (for those with profound pre‐treatment hearing loss) </h6> <p>This outcome was not assessed or reported by any of the included studies. </p> </section> <section id="CD008080-sec-0059"> <h6 class="title">Effect on tinnitus and vertigo</h6> <p>This outcome was not assessed or reported by any of the included studies. Some studies reported on tinnitus and vertigo, but as adverse effects of the intervention, rather than assessing whether the intervention may have a beneficial effect on existing symptoms.  </p> </section> <section id="CD008080-sec-0060"> <h6 class="title">Minor and serious adverse effects</h6> <p>As described in <a href="#CD008080-sec-0037">Data synthesis</a>, the adverse effects reported by the individual studies were wide‐ranging. The only adverse effects that were consistently reported across a large number of studies were those directly related to intratympanic injection (including persistent tympanic membrane perforation, pain or dizziness/vertigo at the time of the injection). However, as these events were clearly related to the intratympanic injection, and would not occur if participants received no treatment or systemic steroids, we considered it inappropriate to report a risk ratio comparing the intervention and comparator groups. Instead we have reported the rate of these complications for those individuals who received intratympanic injections. Specific details on other adverse events are included in the <a href="#CD008080-sec-0069">Effects of interventions</a> and <a href="./full#CD008080-tbl-0002">Table 1</a>; <a href="./full#CD008080-tbl-0004">Table 2</a>; <a href="./full#CD008080-tbl-0006">Table 3</a> and <a href="./full#CD008080-tbl-0008">Table 4</a>.  </p> </section> </section> </section> <section id="CD008080-sec-0061"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD008080-sec-0168" title="">Characteristics of excluded studies</a>. </p> <p>Five randomised controlled trials compared the efficacy of intratympanic corticosteroid therapy in combination with hyperbaric oxygen therapy (HBO) (<a href="./references#CD008080-bbs2-0032" title="AttanasioG , CovelliE , CagnoniL , MasciE , FerraroD , ManciniP , et al. Does the addition of a second daily session of hyperbaric oxygen therapy to intratympanic steroid influence the outcomes of sudden hearing loss?Acta Otorhinolaryngologica Italica2015;35(4):272-6. ">Attanasio 2015</a>; <a href="./references#CD008080-bbs2-0036" title="ChoI , LeeHM , ChoiSW , KongSK , LeeIW , GohEK , et al. Comparison of two different treatment protocols using systemic and intratympanic steroids with and without hyperbaric oxygen therapy in patients with severe to profound idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Audiology &amp; Neuro-otology2018;23(4):199-207. ">Cho 2018</a>; <a href="./references#CD008080-bbs2-0041" title="XuG , LinD , LinQ . Clinical observations of glucocorticoid combined with hyperbaric oxygen on patients with sudden sensorineural hearing loss. Chinese Scientific Journal of Hearing and Speech Rehabilitation2018;16(1):22-5. ">Gui‐li 2018</a>; <a href="./references#CD008080-bbs2-0047" title="SevilE , BercinS , MuderrisT , GulF , KirisM . Comparison of two different steroid treatments with hyperbaric oxygen for idiopathic sudden sensorineural hearing loss. European Archives of Oto-rhino-laryngology2016;273(9):2419-26. ">Sevil 2016</a>; <a href="./references#CD008080-bbs2-0050" title="ZhouXY , TaoQ , LvLY . The treatment for sudden deafness with intratympanic dexamethasone injection. Chinese Journal of Otorhinolaryngology - Skull Base Surgery2006;12(1):47-8. ">Zhou 2006</a>), and one study used HBO treatment as a comparator (<a href="./references#CD008080-bbs2-0038" title="CvorovicL , JovanovicMB , MilutinovicZ , ArsovicN , DjericD . Randomized prospective trial of hyperbaric oxygen therapy and intratympanic steroid injection as salvage treatment of sudden sensorineural hearing loss. Otology &amp; Neurotology2013;34(6):1021-6. ">Cvorovic 2013</a>). Since data suggest that HBO itself might have an effect on hearing recovery (<a href="./references#CD008080-bbs2-0061" title="BennettMH , KerteszT , PerlethM , YeungP , LehmJP . Hyperbaric oxygen for idiopathic sudden sensorineural hearing loss and tinnitus. Cochrane Database of Systematic Reviews2012, Issue 10. Art. No: CD004739. [DOI: 10.1002/14651858.CD004739.pub4]">Bennett 2012</a>), and since the addition of HBO was not part of the interventions to be studied in this review (see methods), we excluded these studies. </p> <p><a href="./references#CD008080-bbs2-0031" title="AmizadehM , MozafarniaK , MoslemikiaJ , Naghibzadeh-TahamiA . Combination of pulse steroid with intratympanic injections in sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2021;33(1):9-13. [CENTRAL: CN-02287535] [EMBASE: 2012412644]">Amizadeh 2021</a> compared combined corticosteroid treatment and systemic corticosteroid treatment as primary intervention. The study was excluded because the route of administration and dosage of systemic corticosteroid differed between groups. </p> <p>The study <a href="./references#CD008080-bbs2-0046" title="RoghaM , KalkooA . Therapeutic effect of intra-tympanic dexamethasone-hyaluronic acid combination in sudden sensorineural hearing loss. Iran Journal of Otorhinolaryngology2017;29(94):255-60. ">Rogha 2017</a> and the trial registration <a href="./references#CD008080-bbs2-0044" title="NCT04766853. Verification of the efficacy/safety of the dual drug delivery for hearing loss [Verification of the efficacy / safety of the dual drug injectable delivery vehicle for treating intractable hearing loss (pilot study)]. https://clinicaltrials.gov/show/NCT04766853 (first received 23 February 2021). [CENTRAL: CN-02249206] ">NCT04766853</a> compared corticosteroid treatment by intratympanic injection of dexamethasone with intratympanic injection of dexamethasone mixed with hyaluronic acid. This type of comparison was not part of the review. </p> <p><a href="./references#CD008080-bbs2-0034" title="ChangWT , ZeeB , LeeHSH , TongMCF . Dexamethasone eardrop with grommet placement vs intratympanic steroid injection for sudden sensorineural hearing loss: a randomized prospective clinical trial. American Journal of Otolaryngology2020;41(4):102515. ">Chang 2020</a> compared intratympanic corticosteroid treatment with ear drop corticosteroid treatment as a primary intervention. This type of comparison was not part of the review. </p> <p><a href="./references#CD008080-bbs2-0042" title="HanX , WangB , LiC , WangX , ZhangH , YangQ , et al. Observation on the efficacy of Eustachian tube dilation hormone under the guidance of endoscope in the treatment of sudden deafness. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke za Zhi [Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery]2021;35(5):424-7. [CENTRAL: CN-02296088] [PMID: 34304467]">Han 2021</a> compared intratympanic injection of corticosteroid versus corticosteroid administered via endoscopic tympanoplasty. This type of comparison was not part of the review. </p> <p>We excluded the randomised controlled studies <a href="./references#CD008080-bbs2-0033" title="BerjisN , SoheilipourS , MusaviA , HashemiSM . Intratympanic dexamethasone injection vs methylprednisolone for the treatment of refractory sudden sensorineural hearing loss. Advanced Biomedical Research2016;5:111. ">Berjis 2016</a> and <a href="./references#CD008080-bbs2-0049" title="SunRX . Intratympatic budesonide injection for treatment of refractory sudden sensorineural hearing loss. Lin chuang er bi yan hou tou jing wai ke za zhi [Journal of Clinical Otorhinolaryngology, Head and Neck Surgery]2016;30(12):972-7. ">Sun 2016</a> because two intratympanic treatment protocols using two different intratympanically applied corticosteroids were compared. This type of comparison was not part of the review. </p> <p>We excluded <a href="./references#CD008080-bbs2-0043" title="ZhengLI , ChenYAO , XiaohangCAI . To study the effect of intratympanic injection with mouse nerve growth factor and methylprednisolone on sudden deafness. Lin Chuang er bi yan hou tou Jing wai ke za zhi [Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery]2016;30(21):1728-31. ">Li 2016</a> because it compared intratympanic corticosteroid treatment with intratympanic corticosteroid plus mouse nerve growth factor treatment. This type of comparison was not part of the review. </p> <p><a href="./references#CD008080-bbs2-0048" title="SongJ , ZhangL , ChenY . Analysis of the treatment effects of refractory sudden total frequency deafness with steroid from different topical administration routes. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi2018;22(24):1897-9. ">Song 2018</a> compared intratympanic corticosteroid treatment with postauricular injection of corticosteroid as primary Intervention. This type of comparison was not part of the review. </p> <p>In the study <a href="./references#CD008080-bbs2-0045" title="ParkMK , LeeCK , ParkKH , LeeJD , LeeCG , LeeBD . Simultaneous versus subsequent intratympanic dexamethasone for idiopathic sudden sensorineural hearing loss. Otolaryngology - Head &amp; Neck Surgery2011;145(6):1016-21. ">Park 2011</a>, two methods of combination (intratympanic and systemic) therapy were compared. In the simultaneous intratympanic dexamethasone group, local drug application was given initially (as primary therapy for ISSNHL) with systemic steroids (intravenous dexamethasone followed by oral prednisolone). In the other "subsequent intratympanic dexamethasone group", intratympanic dexamethasone was given seven days after systemic treatment. There was no control group for the intratympanic salvage situation without local application. This type of comparison was not part of the review. </p> <p><a href="./references#CD008080-bbs2-0040" title="FilipoR , AttanasioG , RussoFY , ViccaroM , ManciniP , CovelliE . Intratympanic steroid therapy in moderate sudden hearing loss: a randomized, triple-blind, placebo-controlled trial. Laryngoscope2013;123(3):774-8. ">Filipo 2013</a> compared intratympanic corticosteroid treatment with intratympanic placebo as a primary intervention. The study endpoint was seven days after the start of treatment. Studies with a study endpoint of seven days or less after start of treatment were excluded from the review. </p> <p><a href="./references#CD008080-bbs2-0037" title="ChooOS , YangSM , ParkHY , LeeJB , JangJH , ChoiSJ , et al. Differences in clinical characteristics and prognosis of sudden low- and high-frequency hearing loss. Laryngoscope2017;127(8):1878-84. ">Choo 2017</a> compared intratympanic corticosteroid treatment, oral corticosteroid treatment and combined corticosteroid treatment as a primary intervention separated by low‐ or high‐frequency hearing loss. A comparison of hearing improvement in ISSNHL patients with low‐ and high‐frequency hearing loss was not part of the review. </p> <p>We excluded <a href="./references#CD008080-bbs2-0035" title="ChenJ , YangJ , JiaH , ShiJ , LiY , WuH . Efficacy of intratympanic steroid injection as supplementary or initial treatment for sudden sensorineural hearing loss. Lin chuang er bi yan hou tou jing wai ke za zhi [Journal of Clinical Otorhinolaryngology, Head and Neck Surgery]2015;29(19):1691-4. ">Chen 2015</a> because the comparison group in this study included a mixture of patients receiving treatments with systemic steroids or systemic steroids plus intratympanic steroids. </p> <p>We excluded <a href="./references#CD008080-bbs2-0039" title="DiaoY , DongM . The observation on curative effect of 90 cases of sudden hearing loss. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery [Chinese]2012;26(7):306-8. ">Diao 2012</a> because the study population included a high proportion of patients with bilateral sudden hearing loss that raises doubt about whether they represented people with ISSNHL. Further, the unit of analysis in this study was ears instead of participants, as is used in this review. </p> </section> <section id="CD008080-sec-0062"> <h4 class="title">Ongoing studies</h4> <p><a href="./references#CD008080-bbs2-0051" title="ChiCTR2000036382. Clinical study of oral prednisone vs intratympanic injection of dexamethasone as initial treatment for sudden hearing loss. http://www.chictr.org.cn/hvshowproject.aspx?id=53824 (first received 22 August 2020). ">Wang 2021</a> is a non‐blinded, parallel‐group randomised controlled trial that is being carried out in China, from October 2020. It compares nine intratympanic injections of dexamethasone over 14 days with daily oral prednisolone over 14 days for the primary treatment of ISSNHL. Pure tone thresholds, speech recognition, vestibular evoked myogenic potentials (VEMPs), Dizziness Handicap Inventory (DHI) and Tinnitus Handicap Inventory (THI) will be measured before treatment and one month after termination of treatment. </p> <p>The study <a href="./references#CD008080-bbs2-0052" title="ChiCTR1800015954. A prospective study on the treatment of patients with sudden deafness and diabetes with two different ways of administration. http://www.chictr.org.cn/showproj.aspx?proj=25326 (first received 2 May 2018). ">Yang 2020</a> is a non‐blinded, parallel‐group, randomised superiority trial that is being carried out in China, from January 2018. It compares four intratympanic injections of methylprednisolone over one week with daily intravenous methylprednisolone over five days for the primary treatment of ISSNHL in patients with diabetes mellitus. Pure tone thresholds will be measured before treatment and one month after termination of treatment. Secondary outcome measures will include the pure tone average at three months after treatment and blood glucose changes during treatment. </p> </section> </section> <section id="CD008080-sec-0063"> <h3 class="title">Risk of bias in included studies</h3> <p>We deemed the risk of bias to be generally rather high in most of the included studies. We assigned only four of the 30 included studies an overall low risk of bias (<a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>; <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>). An overview of the risk of bias for each included study is provided in <a href="#CD008080-fig-0002">Figure 2</a>. <a href="#CD008080-fig-0003">Figure 3</a> presents the proportion of each risk of bias domain that we found to be high risk/low risk/unclear risk across the whole review.  </p> <div class="figure" id="CD008080-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008080-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD008080-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008080-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD008080-sec-0064"> <h4 class="title">Allocation</h4> <p>Randomisation was adequate in nine studies (<a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a>; <a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>; <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>; <a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>; <a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>; <a href="./references#CD008080-bbs2-0022" title="QuY , ChenH , ZhangH , GuoM . Analysis the treatment of sudden sensorineural hearing loss with steroid from different administration routes [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery [Chinese]2015;29(4):324-6. ">Qu 2015</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>; <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>). <a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a> also used computerised random allocation, but patients who refused the allocated therapy were excluded. Twelve studies stated that they were randomised without details concerning the methods of randomisation (<a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>; <a href="./references#CD008080-bbs2-0007" title="ChangWX , ZhongHL , CaiX , GanQ . Dexamethasone injection in the middle ear for high altitude refractory sudden deafness. Sichuan Medical Journal2010;31(1):71. ">Chang 2010</a>; <a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a>; <a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a>; <a href="./references#CD008080-bbs2-0010" title="ErmutluG , SüslüN , YılmazT , SaraçS . Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. European Archives of Oto-rhino-laryngology2017;274(10):3585-91. ">Ermutlu 2017</a>; <a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a>; <a href="./references#CD008080-bbs2-0013" title="HongSM , ParkCH , LeeJH . Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngology - Head and Neck Surgery2009;141(5):579-83. ">Hong 2009</a>; <a href="./references#CD008080-bbs2-0017" title="LeeJB , ChoiSJ , ParkK , ParkHY , ChooOS , ChoungYH . The efficiency of intratympanic dexamethasone injection as a sequential treatment after initial systemic steroid therapy for sudden sensorineural hearing loss. European Archives of Oto-rhino-laryngology2011;268(6):833-9. ">Lee 2011</a>; <a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a>; <a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a>; <a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a>). Eight studies used inadequate randomisation methods (randomisation according to sequence of admission or actual date) (<a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>; <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>; <a href="./references#CD008080-bbs2-0015" title="KoltsidopoulosP , BibasA , SismanisA , TzonouA , SeggasI . Intratympanic and systemic steroids for sudden hearing loss. Otology &amp; Neurotology2013;34:771-6. ">Koltsidopoulos 2013</a>; <a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a>; <a href="./references#CD008080-bbs2-0020" title="PengY , XiongS , ChengY , QiYF , YangY . Clinical investigation of different routes of administration of dexamethasone on sudden deafness [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery (Chinese)2008;22(10):442-5. ">Peng 2008</a>; <a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a>; <a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a>; <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>).  </p> <p>Allocation concealment was adequate in only five studies (<a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>; <a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>; <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>). The other studies reported either an inadequate method of concealment or it was not mentioned at all. In studies that used sequence of admission or actual date for randomisation adequate allocation concealment is not possible (<a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>; <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>; <a href="./references#CD008080-bbs2-0015" title="KoltsidopoulosP , BibasA , SismanisA , TzonouA , SeggasI . Intratympanic and systemic steroids for sudden hearing loss. Otology &amp; Neurotology2013;34:771-6. ">Koltsidopoulos 2013</a>; <a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a>; <a href="./references#CD008080-bbs2-0020" title="PengY , XiongS , ChengY , QiYF , YangY . Clinical investigation of different routes of administration of dexamethasone on sudden deafness [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery (Chinese)2008;22(10):442-5. ">Peng 2008</a>; <a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a>; <a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a>; <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>). </p> </section> <section id="CD008080-sec-0065"> <h4 class="title">Blinding</h4> <p>Only four studies used placebo therapy with blinding of participants and personnel during their trials (<a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>; <a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>; <a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>; <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>). Twenty‐six studies were not placebo‐controlled. In one, it was explicitly stated that participants and personnel were not blinded (<a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>); in the others we assumed that neither were blinded. We judged the risk of bias in non‐placebo‐controlled studies to be generally 'low' assuming that the outcomes were not influenced by open administration of study therapy. In two studies patients in the intratympanic treatment group could refuse the therapy after allocation, so we deemed the risk of bias to be high (<a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a>; <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>).  </p> <p>In 13 studies, we considered the risk of detection bias to be low because they were either placebo‐controlled, or there was blinding of outcome assessment (<a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a>; <a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>; <a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>; <a href="./references#CD008080-bbs2-0013" title="HongSM , ParkCH , LeeJH . Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngology - Head and Neck Surgery2009;141(5):579-83. ">Hong 2009</a>; <a href="./references#CD008080-bbs2-0015" title="KoltsidopoulosP , BibasA , SismanisA , TzonouA , SeggasI . Intratympanic and systemic steroids for sudden hearing loss. Otology &amp; Neurotology2013;34:771-6. ">Koltsidopoulos 2013</a>; <a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>; <a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>; <a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>; <a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>; <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>). Seventeen studies gave no information on blinding of outcome assessment and the risk of bias was unclear. </p> </section> <section id="CD008080-sec-0066"> <h4 class="title">Incomplete outcome data</h4> <p>Fourteen studies reported results for all randomised participants. The study <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a> reported a low dropout rate below 5%. We classified six studies as high risk of bias because the dropout rate was higher than 10% (<a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>; <a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>; <a href="./references#CD008080-bbs2-0010" title="ErmutluG , SüslüN , YılmazT , SaraçS . Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. European Archives of Oto-rhino-laryngology2017;274(10):3585-91. ">Ermutlu 2017</a>; <a href="./references#CD008080-bbs2-0013" title="HongSM , ParkCH , LeeJH . Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngology - Head and Neck Surgery2009;141(5):579-83. ">Hong 2009</a>; <a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>), and we classified three studies as high risk because dropouts were not balanced across treatment arms (<a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a>) or were related to the therapy (<a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>; <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>). The studies <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>, <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>, <a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a> and <a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a> reported a moderate rate of dropout (5% to 10%) but it was balanced across treatment arms. <a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a> and <a href="./references#CD008080-bbs2-0007" title="ChangWX , ZhongHL , CaiX , GanQ . Dexamethasone injection in the middle ear for high altitude refractory sudden deafness. Sichuan Medical Journal2010;31(1):71. ">Chang 2010</a> gave insufficient information to permit judgement as they did not report the number of participants that were analysed. </p> </section> <section id="CD008080-sec-0067"> <h4 class="title">Selective reporting</h4> <p>Twenty‐one studies specified and reported the main outcome measures (<a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a>; <a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>; <a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>; <a href="./references#CD008080-bbs2-0007" title="ChangWX , ZhongHL , CaiX , GanQ . Dexamethasone injection in the middle ear for high altitude refractory sudden deafness. Sichuan Medical Journal2010;31(1):71. ">Chang 2010</a>; <a href="./references#CD008080-bbs2-0010" title="ErmutluG , SüslüN , YılmazT , SaraçS . Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. European Archives of Oto-rhino-laryngology2017;274(10):3585-91. ">Ermutlu 2017</a>; <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>; <a href="./references#CD008080-bbs2-0013" title="HongSM , ParkCH , LeeJH . Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngology - Head and Neck Surgery2009;141(5):579-83. ">Hong 2009</a>; <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>; <a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>; <a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a>; <a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a>; <a href="./references#CD008080-bbs2-0020" title="PengY , XiongS , ChengY , QiYF , YangY . Clinical investigation of different routes of administration of dexamethasone on sudden deafness [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery (Chinese)2008;22(10):442-5. ">Peng 2008</a>; <a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>; <a href="./references#CD008080-bbs2-0022" title="QuY , ChenH , ZhangH , GuoM . Analysis the treatment of sudden sensorineural hearing loss with steroid from different administration routes [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery [Chinese]2015;29(4):324-6. ">Qu 2015</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>; <a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a>; <a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>; <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>; <a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a>). There was no indication of selective reporting in these studies. Four studies failed to report the standard deviation for change in hearing threshold (<a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a>; <a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>; <a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a>; <a href="./references#CD008080-bbs2-0017" title="LeeJB , ChoiSJ , ParkK , ParkHY , ChooOS , ChoungYH . The efficiency of intratympanic dexamethasone injection as a sequential treatment after initial systemic steroid therapy for sudden sensorineural hearing loss. European Archives of Oto-rhino-laryngology2011;268(6):833-9. ">Lee 2011</a>). Some studies included several follow‐up time points but results were only shown for the last time point (<a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a>; <a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a>; <a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a>; <a href="./references#CD008080-bbs2-0017" title="LeeJB , ChoiSJ , ParkK , ParkHY , ChooOS , ChoungYH . The efficiency of intratympanic dexamethasone injection as a sequential treatment after initial systemic steroid therapy for sudden sensorineural hearing loss. European Archives of Oto-rhino-laryngology2011;268(6):833-9. ">Lee 2011</a>; <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>). In two studies contradictions were present between pre‐specified outcome parameters in the methods section and the presented outcomes in the results: in <a href="./references#CD008080-bbs2-0015" title="KoltsidopoulosP , BibasA , SismanisA , TzonouA , SeggasI . Intratympanic and systemic steroids for sudden hearing loss. Otology &amp; Neurotology2013;34:771-6. ">Koltsidopoulos 2013</a> a 7PTA was defined as the primary outcome parameter but the reported hearing loss before treatment and hearing improvement were both based on a 4PTA. In the study <a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a>, a decrease in PTA of &gt; 30 dB HL was a criterion for successful treatment, but a &gt; 10 dB HL decrease was actually used. In <a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a>, the criteria for hearing improvement were not reported. </p> </section> <section id="CD008080-sec-0068"> <h4 class="title">Other potential sources of bias</h4> <p>A common source of bias was imbalance between groups for a number of factors: there were often unexplained differences in the number of participants in each group (<a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a>; <a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>; <a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a>; <a href="./references#CD008080-bbs2-0017" title="LeeJB , ChoiSJ , ParkK , ParkHY , ChooOS , ChoungYH . The efficiency of intratympanic dexamethasone injection as a sequential treatment after initial systemic steroid therapy for sudden sensorineural hearing loss. European Archives of Oto-rhino-laryngology2011;268(6):833-9. ">Lee 2011</a>; <a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a>; <a href="./references#CD008080-bbs2-0022" title="QuY , ChenH , ZhangH , GuoM . Analysis the treatment of sudden sensorineural hearing loss with steroid from different administration routes [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery [Chinese]2015;29(4):324-6. ">Qu 2015</a>; <a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a>), and differences between groups in the delay before commencing treatment (<a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>; <a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a>; <a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a>; <a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a>; <a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a>). In two studies there was a difference between groups in the length of treatment (<a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>; <a href="./references#CD008080-bbs2-0020" title="PengY , XiongS , ChengY , QiYF , YangY . Clinical investigation of different routes of administration of dexamethasone on sudden deafness [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery (Chinese)2008;22(10):442-5. ">Peng 2008</a>). In one study, follow‐up was longer in the intervention group than in the comparator group (<a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a>). Only the studies <a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>, <a href="./references#CD008080-bbs2-0015" title="KoltsidopoulosP , BibasA , SismanisA , TzonouA , SeggasI . Intratympanic and systemic steroids for sudden hearing loss. Otology &amp; Neurotology2013;34:771-6. ">Koltsidopoulos 2013</a>, <a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a>, <a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a> and <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a> performed a sample size determination. Other studies either did not do so (<a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a>; <a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a>; <a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>; <a href="./references#CD008080-bbs2-0007" title="ChangWX , ZhongHL , CaiX , GanQ . Dexamethasone injection in the middle ear for high altitude refractory sudden deafness. Sichuan Medical Journal2010;31(1):71. ">Chang 2010</a>; <a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a>; <a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a>; <a href="./references#CD008080-bbs2-0010" title="ErmutluG , SüslüN , YılmazT , SaraçS . Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. European Archives of Oto-rhino-laryngology2017;274(10):3585-91. ">Ermutlu 2017</a>; <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>; <a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a>; <a href="./references#CD008080-bbs2-0013" title="HongSM , ParkCH , LeeJH . Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngology - Head and Neck Surgery2009;141(5):579-83. ">Hong 2009</a>; <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>; <a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>; <a href="./references#CD008080-bbs2-0017" title="LeeJB , ChoiSJ , ParkK , ParkHY , ChooOS , ChoungYH . The efficiency of intratympanic dexamethasone injection as a sequential treatment after initial systemic steroid therapy for sudden sensorineural hearing loss. European Archives of Oto-rhino-laryngology2011;268(6):833-9. ">Lee 2011</a>; <a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a>; <a href="./references#CD008080-bbs2-0020" title="PengY , XiongS , ChengY , QiYF , YangY . Clinical investigation of different routes of administration of dexamethasone on sudden deafness [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery (Chinese)2008;22(10):442-5. ">Peng 2008</a>; <a href="./references#CD008080-bbs2-0022" title="QuY , ChenH , ZhangH , GuoM . Analysis the treatment of sudden sensorineural hearing loss with steroid from different administration routes [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery [Chinese]2015;29(4):324-6. ">Qu 2015</a>; <a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a>; <a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a>; <a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a>; <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>; <a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a>; <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>), or terminated recruitment before reaching a sufficient number of participants based on sample size calculation (<a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>). In consequence, the number of included participants per treatment arm was small in most studies. Studies without sample size determination are prone to type II errors. This is not discussed in any of these studies. Small study populations are also prone to imbalances between treatment arms in terms of potential confounding factors, including the propensity in some patients with ISSNHL towards spontaneous hearing recovery. </p> <p>A broad range of delay between the onset of symptoms and the start of treatment was evident in some studies (<a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a>; <a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>; <a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>; <a href="./references#CD008080-bbs2-0020" title="PengY , XiongS , ChengY , QiYF , YangY . Clinical investigation of different routes of administration of dexamethasone on sudden deafness [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery (Chinese)2008;22(10):442-5. ">Peng 2008</a>; <a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a>). Treatment delay is recognised as one of the main factors that influences the observed hearing improvement (<a href="./references#CD008080-bbs2-0107" title="LiebauA , PogorzelskiO , SaltAN , PlontkeSK . Hearing changes after intratympanically applied steroids for primary therapy of sudden hearing loss: a meta-analysis using mathematical simulations of drug delivery protocols. Otology &amp; Neurotology2017;38(1):19-30.">Liebau 2017</a>). When there is a small number of participants per group, studies may differ in this respect across treatment arms. As noted above, a noticeable difference in treatment delay was evident in a number of studies (<a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>; <a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a>; <a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a>; <a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a>; <a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a>). This could have influenced the reported difference in outcome between treatment arms. </p> <p>The main baseline parameter that influences the observed hearing improvement is the level of hearing loss of the patient at the beginning of the observation period (<a href="./references#CD008080-bbs2-0107" title="LiebauA , PogorzelskiO , SaltAN , PlontkeSK . Hearing changes after intratympanically applied steroids for primary therapy of sudden hearing loss: a meta-analysis using mathematical simulations of drug delivery protocols. Otology &amp; Neurotology2017;38(1):19-30.">Liebau 2017</a>). Although a balanced hearing loss before treatment between intervention arms is extremely important, in two studies hearing loss before treatment differed by more than 10 dB HL across groups (<a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a>; <a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a>). The differences in hearing loss before treatment between the intervention arms may have influenced the reported difference in outcome. </p> <p>Many studies did not report the baseline characteristics of their treatment arms, or reported them inadequately. In 13 studies the treatment delay in each treatment arm was not reported (<a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>; <a href="./references#CD008080-bbs2-0007" title="ChangWX , ZhongHL , CaiX , GanQ . Dexamethasone injection in the middle ear for high altitude refractory sudden deafness. Sichuan Medical Journal2010;31(1):71. ">Chang 2010</a>; <a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a>; <a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>; <a href="./references#CD008080-bbs2-0017" title="LeeJB , ChoiSJ , ParkK , ParkHY , ChooOS , ChoungYH . The efficiency of intratympanic dexamethasone injection as a sequential treatment after initial systemic steroid therapy for sudden sensorineural hearing loss. European Archives of Oto-rhino-laryngology2011;268(6):833-9. ">Lee 2011</a>; <a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a>; <a href="./references#CD008080-bbs2-0022" title="QuY , ChenH , ZhangH , GuoM . Analysis the treatment of sudden sensorineural hearing loss with steroid from different administration routes [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery [Chinese]2015;29(4):324-6. ">Qu 2015</a>; <a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a>; <a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a>; <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>; <a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a>; <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>), or a standard deviation is missing in that parameter (<a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a>; <a href="./references#CD008080-bbs2-0013" title="HongSM , ParkCH , LeeJH . Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngology - Head and Neck Surgery2009;141(5):579-83. ">Hong 2009</a>). In the study <a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a>, the hearing thresholds before treatment in participants per group are not reported and <a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a> omitted the standard deviation for that parameter. The studies <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a> and <a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a> reported the mean hearing loss before treatment in the intervention group but not in the control group. </p> <p>The studies <a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>, <a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>, <a href="./references#CD008080-bbs2-0022" title="QuY , ChenH , ZhangH , GuoM . Analysis the treatment of sudden sensorineural hearing loss with steroid from different administration routes [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery [Chinese]2015;29(4):324-6. ">Qu 2015</a> and <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a> conducted a very short follow‐up (two weeks or less), which could result in a bias in the estimation of treatment effects. In <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>, the comparison of interest for this review (intratympanic corticosteroid versus systemic corticosteroid) was observed for only 12 days from the start of treatment, the comparator group receiving systemic treatment then switching to intratympanic corticosteroid. As noted above, in <a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a> the duration of follow‐up was longer in the intervention group in comparison to the control group (21 versus 17 days). This could underestimate the treatment effect in the control group. In <a href="./references#CD008080-bbs2-0020" title="PengY , XiongS , ChengY , QiYF , YangY . Clinical investigation of different routes of administration of dexamethasone on sudden deafness [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery (Chinese)2008;22(10):442-5. ">Peng 2008</a>, the duration of treatment differed between treatment arms  (17 versus 27 days). This was also true of <a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a> (six months versus 15 days). In each case, the discrepancy in the duration of treatment could bias the estimate of effect. <a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a> included patients with very mild hearing loss (&gt; 10 dB HL) and <a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a> included only mild cases of ISSNHL. By contrast, <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a> included only patients with poor prognosis (see the inclusion criteria of the study for details). All three studies risk bias due to selection of the study population. In <a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a>, the omission of overall hearing improvement in the control group is unlike the other studies but is not discussed by the authors. </p> </section> </section> <section id="CD008080-sec-0069"> <h3 class="title" id="CD008080-sec-0069">Effects of interventions</h3> <p>See: <a href="./full#CD008080-tbl-0001"><b>Summary of findings 1</b> Intratympanic corticosteroids versus systemic corticosteroids as primary therapy</a>; <a href="./full#CD008080-tbl-0003"><b>Summary of findings 2</b> Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as primary therapy</a>; <a href="./full#CD008080-tbl-0005"><b>Summary of findings 3</b> Intratympanic corticosteroids versus no treatment or versus placebo as secondary therapy</a>; <a href="./full#CD008080-tbl-0007"><b>Summary of findings 4</b> Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as secondary therapy</a> </p> <section id="CD008080-sec-0070"> <h4 class="title">Intratympanic corticosteroids versus no treatment or versus placebo as primary therapy</h4> <p>No study compared the effects of intratympanic corticosteroids versus no treatment or placebo on hearing improvement for primary therapy of ISSNHL. </p> </section> <section id="CD008080-sec-0071"> <h4 class="title">Intratympanic corticosteroids versus systemic corticosteroids as primary therapy</h4> <p>Sixteen studies compared the efficacy of a primary intratympanic corticosteroid treatment with systemic corticosteroid treatment (<a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>; <a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>; <a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a>; <a href="./references#CD008080-bbs2-0010" title="ErmutluG , SüslüN , YılmazT , SaraçS . Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. European Archives of Oto-rhino-laryngology2017;274(10):3585-91. ">Ermutlu 2017</a>; <a href="./references#CD008080-bbs2-0013" title="HongSM , ParkCH , LeeJH . Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngology - Head and Neck Surgery2009;141(5):579-83. ">Hong 2009</a>; <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>; <a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>; <a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a>; <a href="./references#CD008080-bbs2-0020" title="PengY , XiongS , ChengY , QiYF , YangY . Clinical investigation of different routes of administration of dexamethasone on sudden deafness [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery (Chinese)2008;22(10):442-5. ">Peng 2008</a>; <a href="./references#CD008080-bbs2-0022" title="QuY , ChenH , ZhangH , GuoM . Analysis the treatment of sudden sensorineural hearing loss with steroid from different administration routes [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery [Chinese]2015;29(4):324-6. ">Qu 2015</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>; <a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a>; <a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a>; <a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>).  </p> <section id="CD008080-sec-0072"> <h5 class="title">Change in hearing threshold with pure tone audiometry (pure tone average)</h5> <p>Ten studies (701 participants) were included in the meta‐analysis. <a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a> could not be included as no variance was reported. The mean change in PTA between baseline and 17 to 182 days (range) after start of therapy in participants with intratympanic therapy was ‐5.93 dB (95% confidence interval (CI) ‐7.61 to ‐4.26; 701 participants; 10 studies; I<sup>2</sup> = 80%; low‐certainty evidence) (<a href="./references#CD008080-fig-0007" title="">Analysis 1.1</a>). The point estimate of effect did not exceed the minimally important difference of ‐10 dB, however. Primary intratympanic therapy may result, therefore, in little to no improvement in hearing threshold compared to systemic steroids.  </p> <p>Although we noted high heterogeneity, we considered this unlikely to affect the conclusion of the analysis, as most studies resulted in an estimated effect size that was of borderline clinical significance (did not exceed the minimally important difference). <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a> and <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a> were included in the pre‐planned sensitivity analysis. These two studies (319 participants) found that the mean change of PTA in participants with intratympanic treatment was lower compared with the systemic treatment group but did not exceed the minimally important difference of 10 dB (mean difference (MD) 2.00, 95% CI ‐2.79 to 6.79; 319 participants; 2 studies; I<sup>2</sup> = 0%). The sensitivity analysis therefore confirmed the result from our primary analysis. As the treatment regime for <a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a> was extremely different from all other studies (six months of intratympanic corticosteroid), and as the duration of treatment differed so markedly between treatment arms (the comparator group receiving only 15 days of systemic corticosteroid), we conducted an additional sensitivity analysis to investigate the degree to which excluding this study would impact the pooled estimate. After its exclusion, the pooled mean difference again only indicated a trivial effect in favour of intratympanic therapy (MD ‐2.81, 95% CI ‐4.49 to ‐0.66; 651 participants; 9 studies; I<sup>2</sup> =67%; low‐certainty evidence). We concluded that the inclusion of this study in the meta‐analysis did not affect the pooled effect estimate to any serious degree.  </p> </section> <section id="CD008080-sec-0073"> <h5 class="title">Proportion of patients whose hearing is improved</h5> <p>Fourteen studies (972 participants) were included in the meta‐analysis. In one study there was high (35.1%) loss to follow‐up at the final (three‐month) assessment (<a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a>). We therefore extracted outcome data from the penultimate assessment at one month. A slightly higher proportion of participants with intratympanic therapy had improved hearing at 10 to 182 days (range) after the start of treatment compared with the systemic treatment group. The point estimate of effect did not, however, exceed the minimally important difference of 25% and the 95% confidence interval included no difference between groups (risk ratio (RR) 1.04, 95% CI 0.97 to 1.12; 972 participants; 14 studies; I<sup>2</sup> = 16%) (<a href="./references#CD008080-fig-0008" title="">Analysis 1.2</a>). Primary intratympanic therapy, therefore, probably results in little to no difference in the proportion of patients whose hearing is improved compared to systemic corticosteroids.  </p> <p>The studies <a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>, <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a> and <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a> were included in the sensitivity analysis. The three studies (396 participants) found that fewer participants with intratympanic treatment had improvement of hearing compared with the systemic treatment group but the difference did not exceed the minimally important difference of 25% (RR 0.96, 95% CI 0.86 to 1.07; 396 participants; 3 studies; I<sup>2</sup> = 16%). The sensitivity analysis therefore confirmed the result from our primary analysis. </p> </section> <section id="CD008080-sec-0074"> <h5 class="title">Final hearing threshold with pure tone audiometry (pure tone average)</h5> <p>Seven studies (516 participants) were included in the meta‐analysis. The study <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a> could not be included as no variance was reported. The final PTA at 17 to 183 days (range) after the start of therapy in participants with intratympanic therapy was lower (better) compared with the systemic treatment group. The point estimate of effect did not, however, exceed the minimally important difference of 10 dB HL (MD ‐3.31, 95% CI ‐6.16 to ‐0.47; 516 participants; 7 studies; I<sup>2</sup> = 41%; low‐certainty evidence) (<a href="./references#CD008080-fig-0009" title="">Analysis 1.3</a>). Primary intratympanic therapy may result, therefore, in little to no difference in the final hearing threshold compared to systemic corticosteroids. The study <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a> was included in the sensitivity analysis and confirmed this result (MD 1.60, 95% CI ‐5.75 to 8.95; 250 participants; 1 study). </p> </section> <section id="CD008080-sec-0075"> <h5 class="title">Change in hearing threshold with speech audiometry</h5> <p>Only one study reported on the change in hearing threshold with speech audiometry (<a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>). The speech reception threshold may be lower (better) in the group who received intratympanic corticosteroids compared to those who received systemic corticosteroids, although the confidence interval crosses unity (MD ‐8.85 dB, 95% CI ‐19.58 to 1.88; 98 participants; 1 study) (<a href="./references#CD008080-fig-0010" title="">Analysis 1.4</a>).  </p> <p>Three further studies used methods other than hearing threshold to assess speech audiometry (<a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>; <a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>). These studies reported on the change in speech recognition or discrimination, using either a speech discrimination score (SDS) or a word recognition score (WRS). Although these did not relate to our pre‐specified outcome (change in hearing threshold with speech audiometry) we considered that they were assessing the same underlying outcome (speech audiometry), therefore we have included them for completeness. Due to the different assessment tools used, inconsistency in terminology (making it unclear whether measures were comparable), and the different languages in which these were conducted, we considered that it was not appropriate to pool the data. The results of these additional measures are presented in <a href="./references#CD008080-fig-0011" title="">Analysis 1.5</a>.  </p> <p>The study <a href="./references#CD008080-bbs2-0010" title="ErmutluG , SüslüN , YılmazT , SaraçS . Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. European Archives of Oto-rhino-laryngology2017;274(10):3585-91. ">Ermutlu 2017</a> performed speech audiometry (speech recognition threshold, word recognition score) but did not report results separately for these tests ‐ they were instead reported as part of a composite outcome for 'recovery'. Therefore this study was not included for this outcome.  </p> </section> <section id="CD008080-sec-0076"> <h5 class="title">Frequency‐specific changes with pure tone audiometry</h5> <p>Five studies reported on frequency‐specific changes with pure tone audiometry (<a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a>; <a href="./references#CD008080-bbs2-0013" title="HongSM , ParkCH , LeeJH . Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngology - Head and Neck Surgery2009;141(5):579-83. ">Hong 2009</a>; <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>; <a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a>; <a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a>). Due to the different frequencies assessed in the studies, and heterogeneity in the effect estimates where studies did assess the same frequency, we did not meta‐analyse these data. Instead the results from each study are shown in <a href="./references#CD008080-fig-0012" title="">Analysis 1.6</a>. </p> </section> <section id="CD008080-sec-0077"> <h5 class="title">Mean level of improvement, in those whose hearing is improved</h5> <p>This outcome was not reported by any of the included studies. </p> </section> <section id="CD008080-sec-0078"> <h5 class="title">Percentage of patients reaching serviceable hearing</h5> <p>This outcome was not reported by any of the included studies. </p> </section> <section id="CD008080-sec-0079"> <h5 class="title">Effect on tinnitus and vertigo</h5> <p>This outcome was not reported by any of the included studies. </p> </section> <section id="CD008080-sec-0080"> <h5 class="title">Minor and serious adverse events</h5> <p>For this comparison, 12 studies provided information about adverse events (<a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a>; <a href="./references#CD008080-bbs2-0010" title="ErmutluG , SüslüN , YılmazT , SaraçS . Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. European Archives of Oto-rhino-laryngology2017;274(10):3585-91. ">Ermutlu 2017</a>; <a href="./references#CD008080-bbs2-0013" title="HongSM , ParkCH , LeeJH . Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngology - Head and Neck Surgery2009;141(5):579-83. ">Hong 2009</a>; <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>;  <a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>; <a href="./references#CD008080-bbs2-0022" title="QuY , ChenH , ZhangH , GuoM . Analysis the treatment of sudden sensorineural hearing loss with steroid from different administration routes [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery [Chinese]2015;29(4):324-6. ">Qu 2015</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>; <a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a>; <a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a>; <a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>). In four studies, reporting was incomplete, either because a rate was not provided for both randomised groups (<a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>; <a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a>), or because it was unclear in which group (or groups) events were observed (<a href="./references#CD008080-bbs2-0022" title="QuY , ChenH , ZhangH , GuoM . Analysis the treatment of sudden sensorineural hearing loss with steroid from different administration routes [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery [Chinese]2015;29(4):324-6. ">Qu 2015</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>). In one additional study adverse event data were not reported specifically for the period of follow‐up during which the allocated interventions matched the comparison of interest for this review (<a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>). Despite these limitations in the reporting of adverse events, meta‐analysis was possible for some adverse event outcomes (<a href="./references#CD008080-fig-0013" title="">Analysis 1.7</a>). </p> <section id="CD008080-sec-0081"> <h6 class="title">Persistent tympanic membrane perforation</h6> <p>Four studies reported a rate of tympanic membrane perforation of between 0% (0/30) and 3.9% (5/129) for those who received an intratympanic corticosteroid injection (<a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>; <a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>; <a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a>). Note that in one study both groups received intratympanic injection: one group received intratympanic corticosteroid, and the other received intravenous followed by intratympanic corticosteroid (<a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>). We concluded that the evidence is very uncertain regarding the risk of tympanic membrane perforation for those who received intratympanic corticosteroid as primary treatment (463 participants; 4 studies; very low‐certainty evidence). </p> </section> <section id="CD008080-sec-0082"> <h6 class="title">Vertigo/dizziness, timing not reported</h6> <p>A single study provided a comparison between intratympanic and systemic corticosteroid, resulting in a risk ratio of 2.53 (95% CI 1.41 to 4.54) (<a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>). It is not specified whether all of the patients in the intratympanic corticosteroid group experiencing vertigo did so at the time of injection. We concluded that intratympanic therapy may increase the risk of vertigo/dizziness of unspecified timing as compared to systemic corticosteroid (250 participants; 1 study; low‐certainty evidence). </p> </section> <section id="CD008080-sec-0083"> <h6 class="title">Vertigo/dizziness at the time of intratympanic injection</h6> <p>Four studies reported a rate of vertigo/dizziness of between 1.5% (1/67) and 21% (4/19) for those who received an intratympanic injection (<a href="./references#CD008080-bbs2-0010" title="ErmutluG , SüslüN , YılmazT , SaraçS . Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. European Archives of Oto-rhino-laryngology2017;274(10):3585-91. ">Ermutlu 2017</a>; <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>; <a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>). We have included in this analysis all participants who received an intratympanic injection in these studies. For two studies, this included participants in another treatment arm. In <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>, participants in the control arm also received intratympanic injection at a later point in the trial. In <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>, data were reported for participants who received intratympanic corticosteroids alone, and combined therapy with intratympanic corticosteroids and systemic corticosteroids. We concluded that the evidence is very uncertain regarding the risk of vertigo/dizziness at the time of intratympanic corticosteroid treatment as primary therapy (301 participants; 4 studies; very low‐certainty evidence).  </p> </section> <section id="CD008080-sec-0084"> <h6 class="title">Ear pain, timing not reported</h6> <p>Two studies contributed data to a meta‐analysis (<a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>). The risk ratio was 15.68 (95% CI 6.22 to 39.49), favouring systemic corticosteroid. In each study, the number of participants with ear pain/earache was presented separately from the numbers with ear pain at intratympanic injection. It was assumed, therefore, that those participants with pain at injection were not included among those with ear pain/earache. We concluded that intratympanic corticosteroid injection probably increases the risk of ear pain as compared to systemic corticosteroid when used as primary treatment (289 participants; 2 studies; moderate‐certainty evidence). </p> </section> <section id="CD008080-sec-0085"> <h6 class="title">Ear pain at the time of injection</h6> <p>Three studies reported a rate of ear pain from 4.8% (5/104) to 27.1% (35/129) (<a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>). In <a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a> and <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>, the number of participants with ear pain/earache was presented separately from the numbers with ear pain at intratympanic injection. It was assumed, therefore, that those participants with pain at injection were not included among those with ear pain/earache. The evidence suggests that there is a risk of ear pain at the time of intratympanic injection of corticosteroid as primary treatment (393 participants; 3 studies; low‐certainty evidence). </p> </section> <section id="CD008080-sec-0086"> <h6 class="title">Mood change</h6> <p>Two studies contributed data to a meta‐analysis (<a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>). The risk ratio was 0.22 (95% CI 0.13 to 0.37), favouring intratympanic corticosteroid. We concluded that intratympanic corticosteroid likely results in a large reduction in risk compared to systemic corticosteroids (289 participants; 2 studies; moderate‐certainty evidence). </p> </section> <section id="CD008080-sec-0087"> <h6 class="title">Blood glucose problems</h6> <p>Two studies contributed data to a meta‐analysis (<a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>). The risk ratio was 0.54 (95% CI 0.35 to 0.85), favouring intratympanic corticosteroid. We concluded that intratympanic corticosteroid may result in a reduction in risk compared to systemic corticosteroid (289 participants; 2 studies; low‐certainty evidence). </p> </section> <section id="CD008080-sec-0088"> <h6 class="title">Sleep change</h6> <p>Two studies contributed data to a meta‐analysis (<a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>). The risk ratio was 0.19 (95% CI 0.10 to 0.36), favouring intratympanic corticosteroid. We concluded that intratympanic corticosteroid likely results in a large reduction in risk compared to systemic corticosteroid (289 participants; 2 studies; moderate‐certainty evidence). </p> </section> <section id="CD008080-sec-0089"> <h6 class="title">Appetite change</h6> <p>Two studies contributed data to a meta‐analysis (<a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>). The risk ratio was 0.20 (95% CI 0.09 to 0.44), favouring intratympanic corticosteroid. We concluded that intratympanic corticosteroid likely results in a large reduction in risk compared to systemic corticosteroid (289 participants; 2 studies; moderate‐certainty evidence). </p> </section> <section id="CD008080-sec-0090"> <h6 class="title">Weight change</h6> <p>Two studies contributed data to a meta‐analysis (<a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>). The risk ratio was 0.28 (95% CI 0.13 to 0.61), favouring intratympanic corticosteroid. We concluded that intratympanic corticosteroid likely results in a large reduction in risk compared to systemic corticosteroid (289 participants; 2 studies; moderate‐certainty evidence). </p> </section> <section id="CD008080-sec-0091"> <h6 class="title">Dry mouth</h6> <p>Two studies contributed data to a meta‐analysis (<a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a>; <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>). The risk ratio was 0.15 (95% CI 0.06 to 0.35), favouring intratympanic corticosteroid. We concluded that intratympanic corticosteroid likely results in a large reduction in risk compared with systemic corticosteroids (289 participants; 2 studies; moderate‐certainty evidence). </p> </section> <section id="CD008080-sec-0092"> <h6 class="title">Otitis media</h6> <p>One study reported a rate for each group (<a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>). The risk ratio was 3.28 (95% CI 0.70 to 15.49), favouring systemic corticosteroid. We concluded that intratympanic corticosteroid may result in a large increase in risk compared to systemic corticosteroid (250 participants; 1 study; low‐certainty evidence). </p> <p><a href="./full#CD008080-tbl-0002">Table 1</a> provides details of the more limited data on other reported adverse events.  </p> </section> </section> </section> <section id="CD008080-sec-0093"> <h4 class="title">Intratympanic plus systemic corticosteroids (combined therapy) versus no treatment or versus placebo as primary therapy </h4> <p>No study compared the effects of intratympanic corticosteroids plus systemic corticosteroids (combined therapy) versus no treatment or versus placebo on hearing improvement for primary therapy of ISSNHL. </p> </section> <section id="CD008080-sec-0094"> <h4 class="title">Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as primary therapy </h4> <p>Ten studies compared the efficacy of a primary combined therapy with a systemic corticosteroid therapy (<a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a>; <a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a>; <a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>; <a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>; <a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>; <a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a>; <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>; <a href="./references#CD008080-bbs2-0015" title="KoltsidopoulosP , BibasA , SismanisA , TzonouA , SeggasI . Intratympanic and systemic steroids for sudden hearing loss. Otology &amp; Neurotology2013;34:771-6. ">Koltsidopoulos 2013</a>; <a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>). Three of our secondary outcome measures were not reported by any of the included studies. </p> <section id="CD008080-sec-0095"> <h5 class="title">Change in hearing threshold with pure tone audiometry (pure tone average)</h5> <p>Six studies (435 participants) were included in the meta‐analysis. The study <a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a> could not be included as no variance was reported. The mean change in PTA between baseline and 15 to 91 days (range) after start of therapy improved more in participants with combined therapy. The point estimate of effect did not exceed the minimally important difference of ‐10 dB (MD ‐8.55, 95% CI ‐12.48 to ‐4.61; 435 participants; 6 studies; I<sup>2</sup> = 32%; low‐certainty evidence) (<a href="./references#CD008080-fig-0014" title="">Analysis 2.1</a>). Primary combined therapy may result, therefore, in a slight improvement in hearing threshold compared to systemic corticosteroids alone, but it is not certain whether the extent of improvement would be meaningful to people with ISSNHL. The study <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a> was included in the sensitivity analysis and confirmed this result (MD 0.80, 95% CI ‐8.41 to 10.01; 68 participants; 1 study). </p> </section> <section id="CD008080-sec-0096"> <h5 class="title">Proportion of patients whose hearing is improved</h5> <p>Ten studies (788 participants) were included in the meta‐analysis. A higher proportion of participants with combined therapy had improvement of hearing at 15 to 91 days (range) after start of treatment. The point estimate of effect exceeded the minimally important difference of 25% (RR 1.27, 95% CI 1.15 to 1.41; 788 participants; 10 studies; I<sup>2</sup> = 47%) (<a href="./references#CD008080-fig-0015" title="">Analysis 2.2</a>). Primary combined therapy may, therefore, increase the proportion of patients whose hearing is improved compared to systemic corticosteroids alone (low‐certainty evidence). The studies <a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a> and <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a> were included in the sensitivity analysis and found that more participants with combined therapy had improvement of hearing but this did not exceed the minimally important difference of 25% (RR 1.08, 95% CI 0.88 to 1.33; 148 participants; 2 studies; I<sup>2</sup> = 0%). </p> </section> <section id="CD008080-sec-0097"> <h5 class="title">Final hearing threshold with pure tone audiometry (pure tone average)</h5> <p>Three studies (194 participants) were included in the meta‐analysis. The studies <a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a> and <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a> could not be included since no variance was reported. The final PTA at 15 to 56 days (range) after start of therapy in participants with combined therapy was lower (more favourable) when compared with the systemic treatment group but the point estimate of effect did not exceed the minimally important difference of ‐10 dB (MD ‐9.11, 95% CI ‐1.67 to ‐16.56; 194 participants; 3 studies; I<sup>2</sup> = 35%; very low‐certainty evidence) (<a href="./references#CD008080-fig-0016" title="">Analysis 2.3</a>). Primary combined therapy may result, therefore, in slightly lower (better) final hearing thresholds compared to systemic corticosteroids alone, but the evidence is very uncertain. No eligible studies could be identified for a sensitivity analysis.  </p> </section> <section id="CD008080-sec-0098"> <h5 class="title">Change in hearing threshold with speech audiometry</h5> <p>One study reported on the change in speech recognition threshold (<a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>). The speech reception threshold may be lower (better) in the group who received combination treatment compared to those who received systemic corticosteroids, although the confidence interval crosses unity (mean difference ‐7.59 dB; 95% CI ‐20.22 to 5.04; 98 participants; 1 study) (<a href="./references#CD008080-fig-0017" title="">Analysis 2.4</a>).  </p> <p>Four studies reported on alternative measures of speech audiometry (<a href="./references#CD008080-bbs2-0005" title="AshtianiMK , FirouziF , BastaninejadS , DabiriS , NasirmohtaramS , SaeediN , et al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Archives of Oto-rhino-laryngology2018;275(1):89-97. ">Ashtiani 2018</a>; <a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>; <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>; <a href="./references#CD008080-bbs2-0015" title="KoltsidopoulosP , BibasA , SismanisA , TzonouA , SeggasI . Intratympanic and systemic steroids for sudden hearing loss. Otology &amp; Neurotology2013;34:771-6. ">Koltsidopoulos 2013</a>). The results of these additional measures are presented in <a href="./references#CD008080-fig-0018" title="">Analysis 2.5</a>. All had an effect direction that favoured combined treatment. <a href="./references#CD008080-bbs2-0015" title="KoltsidopoulosP , BibasA , SismanisA , TzonouA , SeggasI . Intratympanic and systemic steroids for sudden hearing loss. Otology &amp; Neurotology2013;34:771-6. ">Koltsidopoulos 2013</a> reported on the change in speech discrimination score using medians and an interquartile range, therefore these data are not portrayed in <a href="./references#CD008080-fig-0018" title="">Analysis 2.5</a>. The authors reported that the results favoured combined therapy, but the difference was not statistically significant (median change in combined group 32% (interquartile range (IQR) 8.5 to 60.5%), median change in systemic group 18% (IQR 2.0 to 50.5%)).  </p> </section> <section id="CD008080-sec-0099"> <h5 class="title">Frequency‐specific changes with pure tone audiometry</h5> <p>Four studies assessed changes in hearing level at specific frequencies (<a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a>; <a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>; <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>; <a href="./references#CD008080-bbs2-0019" title='LimHJ , KimYT , ChoiSJ , LeeJB , ParkHY , ParkK , et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngology - Head &amp; Neck Surgery2013;148(1):121-7. LimHJ , KimYT , ParkHY , ParkK , ChoungYH , ChoiSJ , et al. Response to: "Possible errors in hearing recovery results" from Kai-Min Fang. Otolaryngology - Head &amp; Neck Surgery2013;148(6):1063. [DOI: 10.1177/0194599813486090]'>Lim 2013</a>). Due to the different frequencies assessed in the studies, and heterogeneity in the effect estimates where studies did assess the same frequency, we did not meta‐analyse these data. Instead the results from each study are shown in <a href="./references#CD008080-fig-0019" title="">Analysis 2.6</a>.  </p> </section> <section id="CD008080-sec-0100"> <h5 class="title">Mean level of improvement, in those whose hearing is improved</h5> <p>This outcome was not reported by any of the included studies. </p> </section> <section id="CD008080-sec-0101"> <h5 class="title">Percentage of patients reaching serviceable hearing</h5> <p>This outcome was not reported by any of the included studies. </p> </section> <section id="CD008080-sec-0102"> <h5 class="title">Effect on tinnitus and vertigo</h5> <p>This outcome was not reported by any of the included studies. </p> </section> <section id="CD008080-sec-0103"> <h5 class="title">Minor and serious adverse events</h5> <p>For this comparison, eight studies provided information pertaining to adverse events (<a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a>; <a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a>; <a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>; <a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a>; <a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a>; <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>; <a href="./references#CD008080-bbs2-0015" title="KoltsidopoulosP , BibasA , SismanisA , TzonouA , SeggasI . Intratympanic and systemic steroids for sudden hearing loss. Otology &amp; Neurotology2013;34:771-6. ">Koltsidopoulos 2013</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>). In three studies reporting was incomplete for one or more adverse event outcomes, because it was unclear in which group (or groups) events were observed (<a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a>; <a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>). There were insufficient data for meta‐analysis. </p> <section id="CD008080-sec-0104"> <h6 class="title">Persistent tympanic membrane perforation</h6> <p>Five studies reported a rate of perforation between 0% (0/85) and 5.5% (2/36) for those who received an intratympanic injection (<a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a>; <a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a>; <a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>; <a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a>; <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>). We concluded that the evidence is very uncertain regarding the risk of tympanic membrane perforation for those who received intratympanic corticosteroid combined with systemic corticosteroid as primary treatment (474 participants; 5 studies; very low‐certainty evidence). </p> </section> <section id="CD008080-sec-0105"> <h6 class="title">Vertigo/dizziness at the time of injection</h6> <p>Four studies reported a rate between 0% (0/60) and 8.1% (3/37) for those who received an intratympanic injection (<a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a>; <a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a>; <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>; <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>). Note that in one study, two groups received intratympanic injection: one group received intratympanic corticosteroid, and the other received intratympanic and systemic corticosteroid (<a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>). We concluded that the evidence is very uncertain regarding the risk of vertigo/dizziness at the time of intratympanic injection for those who received intratympanic corticosteroid as primary treatment (341 participants; 4 studies; very low‐certainty evidence). </p> </section> <section id="CD008080-sec-0106"> <h6 class="title">Ear pain at the time of injection</h6> <p>One study reported a rate of 5/37 (13.5%) for those who received an intratympanic corticosteroid injection (<a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a>). All recovered within one hour. We concluded that the evidence is very uncertain regarding the risk of ear pain at the time of intratympanic injection for those who received combined treatment as primary treatment (73 participants; 1 study; very low‐certainty evidence). </p> <p><a href="./full#CD008080-tbl-0004">Table 2</a> provides details of the more limited data on other reported adverse events.  </p> </section> </section> </section> <section id="CD008080-sec-0107"> <h4 class="title">Intratympanic corticosteroids versus no treatment or versus placebo as secondary therapy</h4> <p>There were five studies comparing the efficacy of a secondary intratympanic corticosteroid with no therapy (<a href="./references#CD008080-bbs2-0007" title="ChangWX , ZhongHL , CaiX , GanQ . Dexamethasone injection in the middle ear for high altitude refractory sudden deafness. Sichuan Medical Journal2010;31(1):71. ">Chang 2010</a>; <a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a>; <a href="./references#CD008080-bbs2-0017" title="LeeJB , ChoiSJ , ParkK , ParkHY , ChooOS , ChoungYH . The efficiency of intratympanic dexamethasone injection as a sequential treatment after initial systemic steroid therapy for sudden sensorineural hearing loss. European Archives of Oto-rhino-laryngology2011;268(6):833-9. ">Lee 2011</a>; <a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a>; <a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a>), and two studies comparing intratympanic corticosteroid with intratympanic placebo (<a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>; <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>).  </p> <section id="CD008080-sec-0108"> <h5 class="title">Change in hearing threshold with pure tone audiometry (pure tone average)</h5> <p>Seven studies (280 participants) were included in the meta‐analysis. The mean change in PTA between baseline and 20 to 60 days (range) after the start of therapy showed more improvement in participants with intratympanic treatment but the point estimate of effect did not exceed the minimally important difference of ‐10 dB (MD ‐9.07 dB, 95% CI ‐11.47 to ‐6.66; 280 participants; 7 studies; I<sup>2</sup> = 23%; low‐certainty evidence) (<a href="./references#CD008080-fig-0020" title="">Analysis 3.1</a>). Secondary (rescue) intratympanic therapy may therefore result in a small benefit compared to no treatment or placebo, but it is not clear whether this would be important to patients. The studies <a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a> and <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a> were included in a sensitivity analysis and confirmed the result of our primary analysis (MD ‐5.45 dB, 95% CI ‐9.30 to ‐1.59; 76 participants; 2 studies; I<sup>2</sup> = 0%). </p> </section> <section id="CD008080-sec-0109"> <h5 class="title">Proportion of patients whose hearing is improved</h5> <p>Six studies (232 participants) were included in the meta‐analysis. The study <a href="./references#CD008080-bbs2-0007" title="ChangWX , ZhongHL , CaiX , GanQ . Dexamethasone injection in the middle ear for high altitude refractory sudden deafness. Sichuan Medical Journal2010;31(1):71. ">Chang 2010</a> could not be included since this parameter was not reported. A higher proportion of participants with intratympanic therapy had improved hearing at 29 to 79 days (range) after the start of treatment (RR 5.55, 95% CI 2.89 to 10.68; 232 participants; 6 studies; I<sup>2</sup> = 0%; low‐certainty evidence) (<a href="./references#CD008080-fig-0021" title="">Analysis 3.2</a>). Secondary (rescue) intratympanic therapy may therefore result in a much higher proportion of patients whose hearing is improved, compared to no treatment or placebo. The studies <a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a> and <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a> were included in the sensitivity analysis and confirmed this result (RR 4.21, 95% CI 1.44 to 12.31; 76 participants; 2 studies; I<sup>2</sup> = 0%). </p> </section> <section id="CD008080-sec-0110"> <h5 class="title">Final hearing threshold with pure tone audiometry (pure tone average)</h5> <p>Five studies (203 participants) were included in the meta‐analysis. The studies <a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a> and <a href="./references#CD008080-bbs2-0007" title="ChangWX , ZhongHL , CaiX , GanQ . Dexamethasone injection in the middle ear for high altitude refractory sudden deafness. Sichuan Medical Journal2010;31(1):71. ">Chang 2010</a> could not be included since they did not report a final PTA. The mean final PTA at 29 to 61 days (range) after the start of therapy was lower (better) in participants with intratympanic therapy, and the point estimate of effect exceeded the minimally important difference of ‐10 dB HL (MD ‐11.09, 95% CI ‐17.46 to ‐4.72; 203 participants; 5 studies; I<sup>2</sup> = 0%; low‐certainty evidence) (<a href="./references#CD008080-fig-0022" title="">Analysis 3.3</a>). Secondary intratympanic therapy may result, therefore, in lower (improved) final hearing thresholds compared to no treatment or placebo. The studies <a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a> and <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a> were included in the sensitivity analysis and confirmed the result of the primary analysis (MD ‐10.20 dB, 95% CI ‐19.64 to ‐0.77; 76 participants; 2 studies; I<sup>2</sup> = 0%). </p> </section> <section id="CD008080-sec-0111"> <h5 class="title">Change in hearing threshold with speech audiometry</h5> <p>One study reported on this outcome (<a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>). The speech reception threshold may be lower (better) in the group who received intratympanic treatment compared to those who received placebo, although the confidence interval crosses unity (MD ‐12.80 dB, 95% CI ‐30.17 to 4.57; 21 participants; 1 study; <a href="./references#CD008080-fig-0023" title="">Analysis 3.4</a>).  </p> <p>The same study also reported on the change in maximum speech discrimination, measured as the number of monosyllables understood. Again, this outcome appeared to favour intratympanic treatment (<a href="./references#CD008080-fig-0024" title="">Analysis 3.5</a>).  </p> </section> <section id="CD008080-sec-0112"> <h5 class="title">Frequency‐specific changes with pure tone audiometry</h5> <p>A single study reported on frequency‐specific changes with pure tone audiometry. The results are shown in <a href="./references#CD008080-fig-0025" title="">Analysis 3.6</a>.  </p> </section> <section id="CD008080-sec-0113"> <h5 class="title">Mean level of improvement, in those whose hearing is improved</h5> <p>This outcome was not reported by any of the included studies. </p> </section> <section id="CD008080-sec-0114"> <h5 class="title">Percentage of patients reaching serviceable hearing</h5> <p>This outcome was not reported by any of the included studies. </p> </section> <section id="CD008080-sec-0115"> <h5 class="title">Effect on tinnitus and vertigo</h5> <p>This outcome was not reported by any of the included studies. </p> </section> <section id="CD008080-sec-0116"> <h5 class="title">Minor and serious adverse events</h5> <p>For this comparison, five studies provided information about adverse events (<a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a>; <a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a>; <a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>; <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>; <a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a>). There were insufficient data for meta‐analysis. In all studies, reporting was incomplete for one or more adverse event outcomes, either because a rate was not provided for both randomised groups, or because it was unclear in which group (or groups) events were observed.  </p> <p><b>Persistent tympanic membrane perforation</b> </p> <p>Five studies reported a rate of tympanic membrane perforation of between 0% (0/19) and 4.2% (1/24) for those who received an intratympanic injection (<a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a>; <a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a>; <a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>; <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>; <a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a>). This includes participants who received placebo intratympanic injection. We concluded that the evidence is very uncertain regarding the risk of tympanic membrane perforation for those who received intratympanic injection (either corticosteroid or placebo) as secondary treatment (185 participants; 5 studies; very low‐certainty evidence).  </p> <p><b>Vertigo/dizziness at the time of intratympanic injection</b> </p> <p>Three studies reported a rate of vertigo/dizziness of between 6.7% (1/15) and 33% (number not reported) for those who received an intratympanic injection (<a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a>; <a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a>; <a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a>). This includes participants who received placebo intratympanic injection. We concluded that the evidence is very uncertain regarding the risk of vertigo/dizziness at the time of intratympanic injection (either corticosteroid or placebo) as secondary treatment (118 participants; 3 studies; very low‐certainty evidence). </p> <p><b>Ear pain at the time of intratympanic injection</b> </p> <p>One study reported no participants with ear pain at the time of intratympanic injection (0/24) (<a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a>). The evidence is very uncertain regarding the risk of ear pain at the time of intratympanic corticosteroid injection as secondary treatment (44 participants; 1 study; very low‐certainty evidence). </p> <p><a href="./full#CD008080-tbl-0006">Table 3</a> provides details of the more limited data on other reported adverse events.  </p> </section> </section> <section id="CD008080-sec-0117"> <h4 class="title">Intratympanic corticosteroids versus systemic corticosteroids as secondary therapy</h4> <p>No study compared the effects of intratympanic corticosteroids versus systemic corticosteroids on hearing improvement for secondary therapy of ISSNHL. </p> </section> <section id="CD008080-sec-0118"> <h4 class="title">Intratympanic plus systemic corticosteroids (combined therapy) versus no treatment or versus placebo as secondary therapy </h4> <p>No study compared the effects of intratympanic corticosteroids plus systemic corticosteroids (combined therapy) versus no treatment or versus placebo on hearing improvement for secondary therapy of ISSNHL. </p> </section> <section id="CD008080-sec-0119"> <h4 class="title">Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as secondary therapy </h4> <p>One study compared the effects of a secondary systemic versus a secondary combined intratympanic and systemic corticosteroid treatment (<a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>).  </p> <section id="CD008080-sec-0120"> <h5 class="title">Change in hearing threshold with pure tone audiometry (pure tone average)</h5> <p>Change in hearing threshold (PTA change) was not reported in the study <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>. </p> </section> <section id="CD008080-sec-0121"> <h5 class="title">Proportion of patients whose hearing is improved</h5> <p>One study (76 participants) explored this outcome. A higher proportion of participants with combined therapy had improved hearing at 56 days after the start of treatment compared with the systemic treatment group. The point estimate of effect exceeded the minimally important difference of 25% (RR 2.24, 95% CI 1.10 to 4.55; 76 participants; 1 study; very low‐certainty evidence) (<a href="./references#CD008080-fig-0026" title="">Analysis 4.1</a>). Secondary combined therapy may therefore increase the proportion of patients whose hearing is improved compared to systemic corticosteroids alone, but the evidence is very uncertain. </p> </section> <section id="CD008080-sec-0122"> <h5 class="title">Final hearing threshold with pure tone audiometry (pure tone average)</h5> <p>This outcome was not reported by <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>. </p> </section> <section id="CD008080-sec-0123"> <h5 class="title">Change in hearing threshold with speech audiometry</h5> <p><a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a> did not assess hearing thresholds, but did report the proportion of participants who achieved an improvement of at least 15% in their speech discrimination score (see <a href="./references#CD008080-fig-0027" title="">Analysis 4.2</a>).  </p> <section id="CD008080-sec-0124"> <h6 class="title">Change in speech discrimination scores</h6> <p>This outcome was not reported by <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>. </p> </section> </section> <section id="CD008080-sec-0125"> <h5 class="title">Frequency‐specific changes with pure tone audiometry</h5> <p>This outcome was not reported by <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>. </p> </section> <section id="CD008080-sec-0126"> <h5 class="title">Mean level of improvement, in those whose hearing is improved</h5> <p>This outcome was not reported by <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>. </p> </section> <section id="CD008080-sec-0127"> <h5 class="title">Percentage of patients reaching serviceable hearing</h5> <p>This outcome was not reported by <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>. </p> </section> <section id="CD008080-sec-0128"> <h5 class="title">Effect on tinnitus and vertigo</h5> <p>This outcome was not reported by <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>. </p> </section> <section id="CD008080-sec-0129"> <h5 class="title">Minor and serious adverse events</h5> <p><a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a> provided data for this comparison.  </p> <p><b>Persistent tympanic membrane perforation</b> </p> <p><b>T</b>he rate of tympanic membrane perforation in the intervention group was 8.1% (3/37). We concluded that the risk of tympanic membrane perforation among those who receive intratympanic corticosteroid combined with systemic corticosteroid as primary treatment is very uncertain (76 participants; 1 study; very low‐certainty evidence).  </p> <p><a href="./full#CD008080-tbl-0008">Table 4</a> provides details of the more limited data on other reported adverse events.  </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008080-sec-0130" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008080-sec-0130"></div> <section id="CD008080-sec-0131"> <h3 class="title" id="CD008080-sec-0131">Summary of main results</h3> <p>We identified data for four of our proposed comparisons, from a total of 30 randomised controlled trials (RCTs) that analysed 2133 participants. No data were found for the comparisons of intratympanic corticosteroids versus no treatment/placebo as primary therapy, intratympanic corticosteroids versus systemic corticosteroids as secondary therapy, or intratympanic corticosteroids plus systemic corticosteroids versus placebo/no treatment as either primary or secondary therapy.   </p> <p>The following is a summary of the key findings for each comparison:</p> <section id="CD008080-sec-0132"> <h4 class="title">Intratympanic corticosteroids versus systemic corticosteroids as primary therapy</h4> <p>We identified 16 studies and analysed 1108 patients for this comparison (<a href="./full#CD008080-tbl-0001">summary of findings Table 1</a>). Intratympanic corticosteroids may result in a trivial or no difference in the change in hearing threshold, as compared with systemic steroids (low‐certainty evidence). They probably also result in little to no difference in the number of participants whose hearing improves, and may result in little to no difference in the final hearing threshold. The confidence intervals of all outcomes do not overlap the thresholds for clinical relevance, and these results persisted after sensitivity analysis. Overall, vertigo and dizziness may be increased, and ear pain is probably more common for those who receive intratympanic corticosteroids. However, adverse effects commonly associated with steroid use (such as blood glucose problems) may be reduced among those who receive intratympanic steroids. Persistent tympanic membrane perforation, ear pain at the time of the injection and vertigo/dizziness at the time of the injection were noted among those who received intratympanic injection, but we could not be certain how often these effects would occur. </p> </section> <section id="CD008080-sec-0133"> <h4 class="title">Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as primary therapy </h4> <p>We identified 10 studies and analysed 788 patients for this comparison (<a href="./full#CD008080-tbl-0003">summary of findings Table 2</a>). The change in hearing threshold may be slightly increased (better) among those who received combined therapy, but it is unclear whether this increase would be noticeable and important to patients (low‐certainty evidence). The evidence regarding the number of patients whose hearing improved, and the final hearing threshold, was very uncertain, although both outcomes favoured the combined treatment group. Adverse effects were only reported for those who received combined therapy, therefore we were unable to compare the intervention to systemic corticosteroids. Persistent tympanic membrane perforation, vertigo/dizziness at the time of the injection and ear pain at the time of the injection were all reported in the intervention group, but we could not be certain how often these effects would be seen.  </p> </section> <section id="CD008080-sec-0134"> <h4 class="title">Intratympanic corticosteroids versus no treatment or versus placebo as secondary therapy</h4> <p>Seven studies were included for this comparison (<a href="./full#CD008080-tbl-0005">summary of findings Table 3</a>). Five studies compared the efficacy of a secondary intratympanic corticosteroid with no therapy and two studies compared intratympanic corticosteroid with intratympanic placebo. Intratympanic therapy may result in a small improvement in the change in hearing threshold (low‐certainty evidence) although the mean difference was just below the threshold for clinical relevance (PTA change ‐9.07 dB). In addition, intratympanic corticosteroids may result in a much higher proportion of patients achieving an improvement in their hearing (absolute effect of 315 more patients per 1000 having improved hearing) and a small, but clinically important, effect on the final hearing threshold (decrease of 11.09 dB HL, low‐certainty). The clinically relevant effects persisted after sensitivity analysis. Adverse effects were only reported for those who received intratympanic corticosteroids, therefore we were unable to compare the intervention to placebo or no treatment. Persistent tympanic membrane perforation, vertigo/dizziness at the time of the injection and ear pain at the time of the injection were all reported in the intervention group, but we could not be certain how often these effects would be seen. The results indicate that there may be a small improvement in hearing with the use of intratympanic corticosteroids, but it is unclear whether this would be a noticeable or important difference.  </p> </section> <section id="CD008080-sec-0135"> <h4 class="title">Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as secondary therapy </h4> <p>We identified one study and analysed 76 patients for this comparison (<a href="./full#CD008080-tbl-0007">summary of findings Table 4</a>). Combined therapy may increase the proportion of patients whose hearing is improved, but the evidence is very uncertain. No data were available for the remaining efficacy outcomes for this comparison (change in hearing threshold or final hearing threshold, determined by PTA). The study did report that a number of participants had a persistent tympanic membrane perforation, but the evidence was very uncertain.  </p> </section> </section> <section id="CD008080-sec-0136"> <h3 class="title" id="CD008080-sec-0136">Overall completeness and applicability of evidence</h3> <p>The available evidence included all corticosteroids known to be used for intratympanic applications. All studies only included participants with sudden idiopathic sensorineural hearing loss (without alternative diagnoses) and most studies included adults. As participants included in the studies were predominantly adults, it is not clear whether these results also apply to  children. However, ISSNHL in children is rare. The available evidence included patients mostly treated in secondary and tertiary care settings. In summary, we conclude that the ISSNHL patients included in the review cover the patient population seen in clinical practice. </p> <p>The included studies showed variability in their treatment protocols. The glucocorticoids used in the included RCTs were either methylprednisolone or dexamethasone preparations. The methylprednisolone concentrations used were usually 40 mg/mL with only very few studies using higher concentrations (62.5 mg/mL or 125 mg/mL). The dexamethasone concentrations used were usually 4 mg/mL to 5 mg/mL with only one study using a higher concentration (12 mg/mL). We are aware that in clinical practice, other (higher) concentrations of corticosteroids might be used or recommended (<a href="./references#CD008080-bbs2-0067" title="ChandrasekharSS , Tsai DoBS , SchwartzSR , BontempoLJ , FaucettEA , FinestoneSA , et al. Clinical practice guideline: sudden hearing loss (Update). Otolaryngology - Head and Neck Surgery2019;161(1 Suppl):S1-S45. [PMID: 31369359]">Chandrasekhar 2019</a>). In addition, other types of corticosteroids (e.g. triamcinolone acetonide), other forms of corticosteroids (e.g. dexamethasone phosphate versus dexamethasone base) and other drug delivery systems different from intratympanic injections of solutions, including wicks, gels, catheters or biodegradable controlled‐release implants, may be used (reviewed in: <a href="./references#CD008080-bbs2-0074" title="El KechaiN , AgnelyF , MamelleE , NguyenY , FerraryE , BochotA . Recent advances in local drug delivery to the inner ear. International journal of pharmaceutics2015;494(1):83-101. [PMID: 26260230]">El Kechai 2015</a>; <a href="./references#CD008080-bbs2-0110" title="MäderK , LehnerE , LiebauA , PlontkeSK . Controlled drug release to the inner ear: concepts, materials, mechanisms, and performance. Hearing Research2018;368:49-66. [PMID: 29576310]">Mäder 2018</a>; <a href="./references#CD008080-bbs2-0135" title="SaltAN , PlontkeSK . Principles of local drug delivery to the inner ear. Audiology &amp; Neuro-otology2009;14(6):350-60.">Salt 2009</a>; <a href="./references#CD008080-bbs2-0136" title="SaltAN , PlontkeSK . Pharmacokinetic principles in the inner ear: influence of drug properties on intratympanic applications. Hearing Research2018;368:28-40. [PMID: 29551306]">Salt 2018</a>; <a href="./references#CD008080-bbs2-0162" title="ZhangZ , LiX , ZhangW , KohaneDS . Drug delivery across barriers to the middle and inner ear. Advanced Functional Materials2021;31(44):2008701. [DOI: 10.1002/adfm.202008701] [PMID: 34795553]">Zhang 2021</a>). However, we did not find any further RCTs that have addressed therapeutic strategies using intratympanic application of corticosteroids for ISSNHL, other than those included in this systematic review. </p> <p>Three outcome parameters for the evaluation of the treatment effect could be used for statistical analysis (the primary outcome parameter and two secondary outcome parameters). The primary outcome parameter (change in pure tone average (PTA)) is widely used in studies on the treatment of ISSNHL. The proportion of patients whose hearing is improved (one of the secondary outcome parameters) is also a widely used outcome parameter in studies. However, in the view of the authors, this type of outcome parameter is not very reliable because 1) it is a dichotomous parameter, which gives only a little information about the absolute hearing improvement in patients and within‐study group variance and 2) it is highly dependent on the definition of hearing improvement, which is inconsistent between studies. As a further outcome parameter we included the final PTA in patients at the study endpoint. Although this outcome parameter is not widely used in studies, it has been shown to depend less upon baseline characteristics (such as initial hearing loss or treatment delay), and is therefore more robust against distortions due to differences in baseline characteristics between treatment arms (<a href="./references#CD008080-bbs2-0107" title="LiebauA , PogorzelskiO , SaltAN , PlontkeSK . Hearing changes after intratympanically applied steroids for primary therapy of sudden hearing loss: a meta-analysis using mathematical simulations of drug delivery protocols. Otology &amp; Neurotology2017;38(1):19-30.">Liebau 2017</a>; <a href="./references#CD008080-bbs2-0108" title="LiebauA , PogorzelskiO , SaltAN , PlontkeSK . Hearing changes after intratympanic steroids for secondary (salvage) therapy of sudden hearing loss: a meta-analysis using mathematical simulations of drug delivery protocols. Otology &amp; Neurotology2018;39(7):803-15.">Liebau 2018</a>). </p> <p>In this review, the wording of the comments in the summary of findings tables and, thus, in the abstract, results and authors’ conclusions sections is based on the <i>"GRADE guidelines informative statements to communicate the findings of systematic reviews of interventions"</i> (<a href="./references#CD008080-bbs2-0138" title="SantessoN , GlentonC , DahmP , GarnerP , AklEA , AlperB , et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. Journal of Clinical Epidemiology2020;119:126-35. [PMID: 31711912]">Santesso 2020</a>). In this guideline, producers and users of systematic reviews found statements to communicate findings that combine the size and certainty of an effect to be acceptable. The final list of informative statements to communicate the results of systematic reviews combines the effect size (1) large effect, 2) moderate effect, 3) small important effect, 4) trivial, small unimportant effect or no effect) and the certainty of the evidence (high, moderate, low, very low) (<a href="./references#CD008080-bbs2-0138" title="SantessoN , GlentonC , DahmP , GarnerP , AklEA , AlperB , et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. Journal of Clinical Epidemiology2020;119:126-35. [PMID: 31711912]">Santesso 2020</a>). The <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Chapter 15.6.4) also suggests using these narrative statements to draw conclusions based on the effect estimate from the meta‐analysis and the certainty of the evidence (<a href="./references#CD008080-bbs2-0088" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Handbook 2021</a>). The clinicians amongst the authors initially tried to define the effect sizes in detail (1) large effect, 2) moderate effect, 3) small important effect, 4) trivial, small, unimportant effect or no effect) for both change in hearing threshold and proportion of patients whose hearing improved. However, we could not agree on a uniform statement for this. Thus, we agreed on a 'minimally important difference' (MID). </p> <p>Determining a relevant and important change in hearing is challenging. In this review we have taken a change in hearing threshold of 10 dB HL to represent the MID. However, we acknowledge that this may not be universally agreed. The decision to choose 10 dB as a MID was based on the test‐retest reliability of pure tone audiometric measurements, established minimal criteria for improvement in individual patients (<a href="./references#CD008080-bbs2-0067" title="ChandrasekharSS , Tsai DoBS , SchwartzSR , BontempoLJ , FaucettEA , FinestoneSA , et al. Clinical practice guideline: sudden hearing loss (Update). Otolaryngology - Head and Neck Surgery2019;161(1 Suppl):S1-S45. [PMID: 31369359]">Chandrasekhar 2019</a>; <a href="./references#CD008080-bbs2-0083" title="GurgelRK , JacklerRK , DobieRA , PopelkaGR . A new standardized format for reporting hearing outcome in clinical trials. Otolaryngology--Head and Neck Surgery2012;147(5):803-7. [PMID: 22931898]">Gurgel 2012</a>; <a href="./references#CD008080-bbs2-0145" title="StachlerRJ , ChandrasekharSS , ArcherSM , RosenfeldRM , SchwartzSR , BarrsDM , et al. Clinical practice guideline: sudden hearing loss. Otolaryngology - Head and Neck Surgery2012;146(3 Suppl):1-35.">Stachler 2012</a>), and on a large RCT on this topic with low bias (<a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>). For dichotomous outcomes (e.g. the proportion of patients with hearing improvement), we used a threshold of 25% or more in RR increase for appreciable benefit as suggested in the GRADE guideline (<a href="./references#CD008080-bbs2-0084" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93. [PMID: 21839614]">Guyatt 2011</a>). The 10 dB difference and the 25% criteria were agreed upon by all authors. Many of the mean differences reported in this review were close to this MID, therefore it is uncertain whether the detectable change from the interventions would be of importance to patients. </p> <p>Some studies used different thresholds to define 'improvement' of hearing. This may result in different conclusions to this review. If, for example, a change of 5 dB HL (or 3 dB, 6 dB or 9 dB) was deemed to be the MID then we would have concluded that some interventions were of more certain benefit. This may also partly explain apparent discrepancies in our findings where the mean difference was found not to be clinically relevant, and yet a higher proportion of patients 'improved' when assigned to the intervention group. When interpreting the findings, it is important to consider both the mean change in hearing and how many people improved. Although the mean change for the whole group may not be especially strong, there may still be a greater number of people who improve. </p> <p>The estimation of whether an effect size is "1. large", "2. moderate", "3. small important" or "4. trivial, small unimportant effect or no effect" (<a href="./references#CD008080-bbs2-0138" title="SantessoN , GlentonC , DahmP , GarnerP , AklEA , AlperB , et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. Journal of Clinical Epidemiology2020;119:126-35. [PMID: 31711912]">Santesso 2020</a>) also depends on the degree of initial hearing loss (i.e. moderate, severe, profound hearing loss) and whether the patients had serviceable hearing before and/or after therapy (<a href="./references#CD008080-bbs2-0067" title="ChandrasekharSS , Tsai DoBS , SchwartzSR , BontempoLJ , FaucettEA , FinestoneSA , et al. Clinical practice guideline: sudden hearing loss (Update). Otolaryngology - Head and Neck Surgery2019;161(1 Suppl):S1-S45. [PMID: 31369359]">Chandrasekhar 2019</a>). For example, a 10 dB change might not be useful in severe or profound hearing loss if the patient (or the ear) would remain at a cochlear implant candidate level after therapy. The current US guideline therefore correctly recommends that future studies should report the number of patients reaching serviceable hearing: "For ears that were rendered nonserviceable by the episode of SSNHL, return to serviceable hearing should be considered a significant improvement, and whether or not this level of recovery occurs should be recorded. Recovery to a serviceable level typically indicates that after recovery, the ear would be a candidate for traditional hearing amplification. Recovery to less‐than‐serviceable levels indicates an ear that would, in most circumstances, not benefit from traditional amplification. For ears with SSNHL to hearing levels that are still in the serviceable range, an improvement of &gt; 10 dB in pure tone thresholds (accounting for test‐retest variability in audiometry) or an improvement in WRS of &gt; 10% (approximate lower limit for a statistically significant change based on binomial tables for WRS of &gt;50% at baseline) should be considered partial recovery and recorded." (<a href="./references#CD008080-bbs2-0067" title="ChandrasekharSS , Tsai DoBS , SchwartzSR , BontempoLJ , FaucettEA , FinestoneSA , et al. Clinical practice guideline: sudden hearing loss (Update). Otolaryngology - Head and Neck Surgery2019;161(1 Suppl):S1-S45. [PMID: 31369359]">Chandrasekhar 2019</a>). </p> <p>We think that the criteria with high patient relevance are: how many patients (ears) reach levels where they are not a cochlear implant candidate anymore ("serviceable hearing", as stated above) or even reach levels where a hearing aid would not be necessary any more? Such criteria mainly depend on word recognition tests, which were not sufficiently reported in the RCTs in our review. However, speech audiometry results are difficult to compare due to different test strategies and different languages. The criteria for candidacy for a cochlear implant or a hearing aid may also differ between countries or even between audiologists. </p> <p>Data for many of the outcomes were missing. The length of follow‐up in studies was less than a year, meaning that there was limited evidence regarding the long‐term effectiveness of the therapies. However, a stable hearing threshold is considered to occur several weeks after treatment of ISSNHL and long‐term follow‐up may increase the likelihood of occurrence of other causes of hearing loss, which would confound any long‐term analysis.  </p> <p>Important or key outcome criteria missing in this review are quality of life and patient‐reported outcome measures. These measures should ideally have been defined in the protocol version of this review. Possible tools for measuring quality of life or patient‐reported outcomes might be the Hearing Handicap Inventory for the Elderly (<a href="./references#CD008080-bbs2-0154" title="VentryIM , WeinsteinBE . The hearing handicap inventory for the elderly: a new tool. Ear and Hearing1982;3(3):128-34. [PMID: 7095321]">Ventry 1982</a>), the Short Form (12) Health Survey (SF‐12) (<a href="./references#CD008080-bbs2-0094" title="JenkinsonC , LayteR , JenkinsonD , LawrenceK , PetersenS , PaiceC , et al. A shorter form health survey: can the SF-12 replicate results from the SF-36 in longitudinal studies?Journal of Public Health Medicine1997;19(2):179-86. [PMID: 9243433]">Jenkinson 1997</a>), or the Core Rehabilitation Outcome Set for Single Sided Deafness (CROSSSD) (<a href="./references#CD008080-bbs2-0095" title="KatiriR , HallDA , BuggyN , HoganN , HorobinA , vande HeyningP , et al. Core Rehabilitation Outcome Set for Single Sided Deafness (CROSSSD) study: protocol for an international consensus on outcome measures for single sided deafness interventions using a modified Delphi survey. Trials2020;21(1):238. [PMID: 32131880]">Katiri 2020</a>). However, quality of life measures had not been reported in any of the RCTs included in this systematic review. </p> </section> <section id="CD008080-sec-0137"> <h3 class="title" id="CD008080-sec-0137">Quality of the evidence</h3> <p>We largely assessed the certainty of the evidence in this review as low or very low. There was moderate‐certainty evidence for a small number of outcomes, but we identified no high‐certainty evidence. The main reasons for the uncertainty were a serious risk of bias in the included studies and imprecision in the effect estimates ‐ either due to a small number of included participants or few events, or because the wide confidence intervals overlapped the threshold for clinical relevance.  </p> <p>Nearly all the included studies had a small number of participants. This increases the risk that randomisation does not achieve balance across groups for important prognostic characteristics (both known and unknown) that may confound outcome estimates. One such characteristic is the propensity towards spontaneous recovery. This can have a large impact on pooled estimates for hearing threshold, and imbalance across groups may not be detected by a comparison of baseline parameters such as pre‐treatment hearing loss and delay between the onset of symptoms and the start of treatment. It is important, therefore, to make sure that trials have enough participants to achieve a balance across groups for the propensity towards spontaneous recovery, as well as other important prognostic factors. This is supported by meta‐analyses (<a href="./references#CD008080-bbs2-0107" title="LiebauA , PogorzelskiO , SaltAN , PlontkeSK . Hearing changes after intratympanically applied steroids for primary therapy of sudden hearing loss: a meta-analysis using mathematical simulations of drug delivery protocols. Otology &amp; Neurotology2017;38(1):19-30.">Liebau 2017</a>; <a href="./references#CD008080-bbs2-0108" title="LiebauA , PogorzelskiO , SaltAN , PlontkeSK . Hearing changes after intratympanic steroids for secondary (salvage) therapy of sudden hearing loss: a meta-analysis using mathematical simulations of drug delivery protocols. Otology &amp; Neurotology2018;39(7):803-15.">Liebau 2018</a>), which demonstrated (in primary and secondary treatment respectively) that variation in outcome estimates is reduced when there is a larger number of participants. </p> <p>These observations are reflected in the meta‐analysis as well. In many included studies a high within‐group variance was seen that might be the consequence of the heterogeneous impact of spontaneous recovery on total hearing improvement among patients, in combination with a low number of included participants per treatment arm. In addition, heterogeneous results were found in outcome parameters between studies, especially in studies with a small number of included participants. However, due to the high imprecision of the results in these studies statistical heterogeneity might be underestimated by the Chi² test and I² statistic. </p> <p>We created funnel plots for outcomes including 10 or more studies (<a href="#CD008080-fig-0004">Figure 4</a>; <a href="#CD008080-fig-0005">Figure 5</a>; <a href="#CD008080-fig-0006">Figure 6</a>). These did not indicate the presence of publication bias. However, this is not proof that no publication bias exists. It is noteworthy that we found some high‐quality studies with larger sample sizes indicating no differences between treatment modalities and smaller studies with higher risk of bias indicating large differences in treatment effects. High‐quality studies with large sample sizes imply more investment of time, work and money. It is very likely that these studies will be published afterwards. In smaller studies, a higher risk exists that the results of those studies will not be published if the conclusion differs from current concepts or expectations. </p> <div class="figure" id="CD008080-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="original image" data-id="CD008080-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <div class="figure" id="CD008080-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="original image" data-id="CD008080-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <div class="figure" id="CD008080-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="original image" data-id="CD008080-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>The overall methodological and reporting quality of the studies was disappointing. This leads to an overall high risk of bias in most of the included studies and reduces the certainty of the evidence. It seems that 20 years after CONSORT (<a href="./references#CD008080-bbs2-0059" title="BeggC , ChoM , EastwoodS , HortonR , MoherD , OlkinI , et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA1996;276(8):637-9.">Begg 1996</a>), authors and journals in the field of otolaryngology still do not adhere to these guidelines and most of the publications of RCTs were accepted without fulfilling essential methodological and reporting criteria. Further, only very few included studies were reported to be pre‐registered. Without publishing a pre‐specified study protocol, uncertainty remains about whether study methods may have changed after data synthesis and before publishing the study results. </p> <p>Many studies did not report their method of randomisation. It was therefore not possible to justify whether an adequate randomisation method was used in these studies. Similarly, almost no study reported their method for concealment of allocation. However, the randomisation principle is only guaranteed if ‐ in addition to a robust method of randomisation ‐ a plausible method was used that prevents manipulation of the allocation process. Without this information the randomisation procedure remains questionable. In addition, some studies reported an inadequate method of randomisation in which the allocation of patients could be predicted (such as alternate allocation). </p> <p>It is also mandatory to give a clear statement about which persons in the study are blinded and which are not. Blinding of outcome assessment is possible even in non‐placebo‐controlled studies. Without a clear statement of blinding a judgement on the risk of bias is not possible and remains unclear. </p> <p>In some of the included studies, treatment arms actually differed considerably in their baseline parameters and these imbalances between groups may have influenced the reported outcomes. In addition, many studies have not reported important baseline parameters, or reported them in an inadequate way. In two studies the reporting of baseline parameters even differed between treatment arms. Such inconsistent reporting of data raises doubts about the transparency of studies. We also noted a number of studies where measures of variance (such as standard deviations or standard errors) were missing. A variance element is an essential component when reporting the mean.  </p> </section> <section id="CD008080-sec-0138"> <h3 class="title" id="CD008080-sec-0138">Potential biases in the review process</h3> <p>The included studies used a broad range of different treatment protocols and follow‐up times for final hearing evaluation. No specific conclusions can thus be drawn on the effectiveness of a particular corticosteroid treatment protocol for ISSNHL. However, this only marginally influences the general conclusions on the comparison of treatment modalities (i.e. systemic, intratympanic or combined treatment). </p> <p>The included studies also cover a broad range of baseline characteristics (e.g. degree of hearing loss, treatment delay, type of primary treatment for comparisons using intratympanic corticosteroids as secondary treatments, and accompanying symptoms such as vertigo). </p> <p>There are differences between studies concerning hearing evaluation (different frequencies used for calculating PTA) and different definitions of positive response to treatment (proportion of patients whose hearing is improved). It has previously been shown that the frequencies chosen for calculating the PTA influence the estimation of hearing loss in patients and thus can influence the outcome in clinical trials (<a href="./references#CD008080-bbs2-0128" title="PlontkeSK , BauerM , MeisnerC . Comparison of pure tone audiometry analysis in sudden hearing loss studies: lack of agreement for different outcome measures. Otology &amp; Neurotology2007;28(6):753-63.">Plontke 2007</a>). Different definitions of positive response to treatment can present a risk of bias when pooling the outcome parameter 'proportion of patients improved' (<a href="./references#CD008080-bbs2-0089" title="HaynesDS , O'MalleyM , CohenS , WatfordK , LabadieRF . Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope2007;117(1):3-15.">Haynes 2007</a>). </p> <p>There are many included studies with a high risk of bias and major methodological weaknesses. We therefore performed a sensitivity analysis, which takes into account only studies with high quality and low risk of bias. </p> <p>One included study was performed by authors of the review (SKP and CM) (<a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a>). These authors were therefore not involved in data extraction or risk of bias assessment for this study.  </p> <p>The outcome parameter 'final PTA' after treatment was added after the publication of the protocol. This was based on conclusions drawn from a different meta‐analysis (<a href="./references#CD008080-bbs2-0107" title="LiebauA , PogorzelskiO , SaltAN , PlontkeSK . Hearing changes after intratympanically applied steroids for primary therapy of sudden hearing loss: a meta-analysis using mathematical simulations of drug delivery protocols. Otology &amp; Neurotology2017;38(1):19-30.">Liebau 2017</a>; <a href="./references#CD008080-bbs2-0108" title="LiebauA , PogorzelskiO , SaltAN , PlontkeSK . Hearing changes after intratympanic steroids for secondary (salvage) therapy of sudden hearing loss: a meta-analysis using mathematical simulations of drug delivery protocols. Otology &amp; Neurotology2018;39(7):803-15.">Liebau 2018</a>), and was independent from the data processing in the present meta‐analysis. </p> <p>Some of the planned secondary outcomes could not be assessed due to the lack of available data. Due to missing individual patient data in almost all studies and the limited number of studies per type of comparison, intended subgroup analyses could not be performed either. However, this has no influence on the conclusions drawn from the overall analysis. </p> </section> <section id="CD008080-sec-0139"> <h3 class="title" id="CD008080-sec-0139">Agreements and disagreements with other studies or reviews</h3> <p>A number of meta‐analyses on local corticosteroid treatment of ISSNHL have already been published. There is much variation concerning included studies, defined types of comparisons and evaluated outcome parameters within these reviews. However, the primary outcome parameter was either mean hearing gain (change in hearing threshold with pure tone audiometry) or recovery rate (proportion of patients whose hearing is improved). Many studies included both outcome parameters. </p> <section id="CD008080-sec-0140"> <h4 class="title">Intratympanic corticosteroids versus no treatment or versus placebo as primary therapy</h4> <p>We identified no data of relevance for this comparison because of the lack of studies that fulfilled the inclusion criteria. Despite that, the meta‐analysis <a href="./references#CD008080-bbs2-0054" title="AhmadzaiN , KiltyS , ChengW , EsmaeilisarajiL , WolfeD , BonaparteJP , et al. A systematic review and network metaanalysis of existing pharmacologic therapies in patients with idiopathic sudden sensorineural hearing loss. PLOS One2019;14(9):e0221713.">Ahmadzai 2019</a> reports a significant benefit of intratympanic treatment over placebo in hearing gain and recovery rate. They did not perform pair‐wise comparisons in their meta‐analysis but pooled single treatment arms from different trials instead. Besides inclusion of the study <a href="./references#CD008080-bbs2-0040" title="FilipoR , AttanasioG , RussoFY , ViccaroM , ManciniP , CovelliE . Intratympanic steroid therapy in moderate sudden hearing loss: a randomized, triple-blind, placebo-controlled trial. Laryngoscope2013;123(3):774-8. ">Filipo 2013</a> with an early salvage therapy at day seven, they further included the placebo groups from the studies <a href="./references#CD008080-bbs2-0093" title="HultcrantzE , Nosrati-ZarenoeR . Corticosteroid treatment of idiopathic sudden sensorineural hearing loss: analysis of an RCT and material drawn from the Swedish national database. European Archives of Oto-rhino-laryngology2015;272(11):3169-75.">Hultcrantz 2014</a> and <a href="./references#CD008080-bbs2-0121" title="Nosrati-ZarenoeR , HultcrantzE . Corticosteroid treatment of idiopathic sudden sensorineural hearing loss: randomized triple-blind placebo-controlled trial. Otology &amp; Neurotology2012;33(4):523-31.">Nosrati‐Zarenoe 2012</a>, although these studies compared the efficacy of systemic corticosteroids versus placebo instead of local treatment. This may lead to a greater risk of bias because effect evaluation is not based on a randomised process. </p> </section> <section id="CD008080-sec-0141"> <h4 class="title">Intratympanic corticosteroids versus systemic corticosteroids as primary therapy</h4> <p>A large number of meta‐analyses have examined the difference in effectiveness of intratympanic and systemic treatment as primary therapy. Most of them are in accordance with our finding of no important difference between the two treatment modalities (<a href="./references#CD008080-bbs2-0054" title="AhmadzaiN , KiltyS , ChengW , EsmaeilisarajiL , WolfeD , BonaparteJP , et al. A systematic review and network metaanalysis of existing pharmacologic therapies in patients with idiopathic sudden sensorineural hearing loss. PLOS One2019;14(9):e0221713.">Ahmadzai 2019</a>; <a href="./references#CD008080-bbs2-0071" title="CraneRA , CamilonM , NguyenS , MeyerTA . Steroids for treatment of sudden sensorineural hearing loss: a meta-analysis of randomized controlled trials. Laryngoscope2015;125(1):209-17.">Crane 2015</a>; <a href="./references#CD008080-bbs2-0075" title="El SabbaghNG , SewitchMJ , BezdjianA , DanielSJ . Intratympanic dexamethasone in sudden sensorineural hearing loss: a systematic review and meta-analysis. Laryngoscope2017;127(8):1897–908.">El Sabbagh 2016</a>; <a href="./references#CD008080-bbs2-0078" title="GaravelloW , GalluzziF , GainiRM , ZanettiD . Intratympanic steroid treatment for sudden deafness: a meta-analysis of randomized controlled trials. Otology &amp; Neurotology2012;33(5):724-9.">Garavello 2012</a>; <a href="./references#CD008080-bbs2-0102" title="LaiD , ZhaoF , JalalN , ZhengY . Intratympanic glucocorticosteroid therapy for idiopathic sudden hearing loss: meta-analysis of randomized controlled trials. Medicine (Baltimore)2017;96(50):e8955.">Lai 2017</a>; <a href="./references#CD008080-bbs2-0115" title="MirianC , OvesenT . Intratympanic vs systemic corticosteroids in first-line treatment of idiopathic sudden sensorineural hearing loss: a systematic review and meta-analysis. JAMA Otolaryngology--Head &amp; Neck Surgery2020;146(5):421-8.">Mirian 2020</a>). However, the meta‐analysis <a href="./references#CD008080-bbs2-0071" title="CraneRA , CamilonM , NguyenS , MeyerTA . Steroids for treatment of sudden sensorineural hearing loss: a meta-analysis of randomized controlled trials. Laryngoscope2015;125(1):209-17.">Crane 2015</a> included studies by <a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a> and <a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>, which compared combined rather than local treatment. The review <a href="./references#CD008080-bbs2-0078" title="GaravelloW , GalluzziF , GainiRM , ZanettiD . Intratympanic steroid treatment for sudden deafness: a meta-analysis of randomized controlled trials. Otology &amp; Neurotology2012;33(5):724-9.">Garavello 2012</a> included the study <a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a> in this comparison. The meta‐analysis <a href="./references#CD008080-bbs2-0075" title="El SabbaghNG , SewitchMJ , BezdjianA , DanielSJ . Intratympanic dexamethasone in sudden sensorineural hearing loss: a systematic review and meta-analysis. Laryngoscope2017;127(8):1897–908.">El Sabbagh 2016</a> did not separate conditions of primary and secondary therapy and pooled studies of both types of treatment. They also included studies with combined treatment in the intervention group in this type of comparison. The meta‐analyses <a href="./references#CD008080-bbs2-0115" title="MirianC , OvesenT . Intratympanic vs systemic corticosteroids in first-line treatment of idiopathic sudden sensorineural hearing loss: a systematic review and meta-analysis. JAMA Otolaryngology--Head &amp; Neck Surgery2020;146(5):421-8.">Mirian 2020</a> and <a href="./references#CD008080-bbs2-0102" title="LaiD , ZhaoF , JalalN , ZhengY . Intratympanic glucocorticosteroid therapy for idiopathic sudden hearing loss: meta-analysis of randomized controlled trials. Medicine (Baltimore)2017;96(50):e8955.">Lai 2017</a> did not include some of the trials included in our analysis. The meta‐analysis <a href="./references#CD008080-bbs2-0054" title="AhmadzaiN , KiltyS , ChengW , EsmaeilisarajiL , WolfeD , BonaparteJP , et al. A systematic review and network metaanalysis of existing pharmacologic therapies in patients with idiopathic sudden sensorineural hearing loss. PLOS One2019;14(9):e0221713.">Ahmadzai 2019</a> pooled single treatment arms from different studies and therefore included the systemic treatment groups of <a href="./references#CD008080-bbs2-0073" title="EftekharianA , AmizadehM . Pulse steroid therapy in idiopathic sudden sensorineural hearing loss: a randomized controlled clinical trial. Laryngoscope2016;126(1):150-5.">Eftekharian 2016</a>, <a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a> and <a href="./references#CD008080-bbs2-0093" title="HultcrantzE , Nosrati-ZarenoeR . Corticosteroid treatment of idiopathic sudden sensorineural hearing loss: analysis of an RCT and material drawn from the Swedish national database. European Archives of Oto-rhino-laryngology2015;272(11):3169-75.">Hultcrantz 2014</a>, as well as the local treatment group from <a href="./references#CD008080-bbs2-0040" title="FilipoR , AttanasioG , RussoFY , ViccaroM , ManciniP , CovelliE . Intratympanic steroid therapy in moderate sudden hearing loss: a randomized, triple-blind, placebo-controlled trial. Laryngoscope2013;123(3):774-8. ">Filipo 2013</a> with early salvage therapy in this comparison. </p> <p>The meta‐analysis <a href="./references#CD008080-bbs2-0132" title="QuiangQ , WuX , YangT , YangC , SunH . A comparison between systemic and intratympanic steroid therapies as initial therapy for idiopathic sudden sensorineural hearing loss: a meta-analysis. Acta Oto-laryngologica2017;137(6):598-605.">Quiang 2016</a> found a significantly greater benefit of intratympanic therapy over systemic therapy as a primary intervention when assessed with mean hearing gain as well as recovery rate. This meta‐analysis, however, did not include the large clinical trial with low bias <a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>, in which there were a high number of included participants finding no significant difference in outcomes between treatment modalities. The meta‐analysis <a href="./references#CD008080-bbs2-0163" title="ZhaoD , TongB , WangQ , HellstromS , DuanM . A comparison of effects of systemic and intratympanic steroid therapies for sudden sensorineural hearing loss: a meta-analysis. Journal of Otology2016;11:18-23.">Zhao 2016</a> found a significant difference in the rate of complete hearing recovery, but not in the general recovery rate, termed as significant hearing improvement. However, this review included the studies <a href="./references#CD008080-bbs2-0111" title="MaoHJ , LuZM , ZahngHR . Comparison of the effects of two different administration routes with hormone on sudden hearing loss. Chinese Journal of Misdiagnostics2005;5(12):2203-4.">Mao 2005</a>, <a href="./references#CD008080-bbs2-0160" title="YiJC , ChenS , HuangCY . Observation on the therapeutic effect of Eustachian tube injection of dexamethasone in treatment of sudden deafness. Guangxi Medical Journal2011;33(2):179-80.">Yi 2011</a>, <a href="./references#CD008080-bbs2-0161" title="YouXL , LinX , ZhuBC . Local and systemic glucocorticoid treatment for sudden hearing loss. China Practical Medical2008;3(28):125-7.">You 2008</a> and <a href="./references#CD008080-bbs2-0050" title="ZhouXY , TaoQ , LvLY . The treatment for sudden deafness with intratympanic dexamethasone injection. Chinese Journal of Otorhinolaryngology - Skull Base Surgery2006;12(1):47-8. ">Zhou 2006</a>. The studies <a href="./references#CD008080-bbs2-0160" title="YiJC , ChenS , HuangCY . Observation on the therapeutic effect of Eustachian tube injection of dexamethasone in treatment of sudden deafness. Guangxi Medical Journal2011;33(2):179-80.">Yi 2011</a> and <a href="./references#CD008080-bbs2-0111" title="MaoHJ , LuZM , ZahngHR . Comparison of the effects of two different administration routes with hormone on sudden hearing loss. Chinese Journal of Misdiagnostics2005;5(12):2203-4.">Mao 2005</a> investigated the injection of corticosteroids through the Eustachian tube. <a href="./references#CD008080-bbs2-0161" title="YouXL , LinX , ZhuBC . Local and systemic glucocorticoid treatment for sudden hearing loss. China Practical Medical2008;3(28):125-7.">You 2008</a> is a non‐randomised study, while <a href="./references#CD008080-bbs2-0050" title="ZhouXY , TaoQ , LvLY . The treatment for sudden deafness with intratympanic dexamethasone injection. Chinese Journal of Otorhinolaryngology - Skull Base Surgery2006;12(1):47-8. ">Zhou 2006</a> included hyperbaric oxygen therapy in treatment arms. The meta‐analysis <a href="./references#CD008080-bbs2-0106" title="LiJ , DingL . Effectiveness of steroid treatment for sudden sensorineural hearing loss: a meta-analysis of randomized controlled trials. Annals of Pharmacotherapy2020;54(10):949-57.">Li 2020</a> reported a significant difference in mean hearing gain but not in recovery rate. However, they did not include a number of trials that were included in our analysis. </p> </section> <section id="CD008080-sec-0142"> <h4 class="title">Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as primary therapy </h4> <p>Other meta‐analyses about the effectiveness of combined therapy over systemic corticosteroids as primary therapy found heterogeneous results. This is consistent with our conclusion that there is uncertainty in the evidence. <a href="./references#CD008080-bbs2-0054" title="AhmadzaiN , KiltyS , ChengW , EsmaeilisarajiL , WolfeD , BonaparteJP , et al. A systematic review and network metaanalysis of existing pharmacologic therapies in patients with idiopathic sudden sensorineural hearing loss. PLOS One2019;14(9):e0221713.">Ahmadzai 2019</a> and <a href="./references#CD008080-bbs2-0115" title="MirianC , OvesenT . Intratympanic vs systemic corticosteroids in first-line treatment of idiopathic sudden sensorineural hearing loss: a systematic review and meta-analysis. JAMA Otolaryngology--Head &amp; Neck Surgery2020;146(5):421-8.">Mirian 2020</a> concluded that combined therapy is not superior to systemic therapy as primary treatment. On the other hand, the meta‐analyses <a href="./references#CD008080-bbs2-0077" title="GaoY , LiuD . Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss: a meta-analysis. European Archives of Oto-rhino-laryngology2016;273(11):3699-711.">Gao 2016</a>, <a href="./references#CD008080-bbs2-0086" title="HanX , YinX , DuX , SunC . Combined intratympanic and systemic use of steroids as a first-line treatment for sudden sensorineural hearing loss: a meta-analysis of randomized, controlled trials. Otology &amp; Neurotology2017;38(4):487-95.">Han 2017</a> and <a href="./references#CD008080-bbs2-0106" title="LiJ , DingL . Effectiveness of steroid treatment for sudden sensorineural hearing loss: a meta-analysis of randomized controlled trials. Annals of Pharmacotherapy2020;54(10):949-57.">Li 2020</a> showed a significant difference in the effectiveness of combined and systemic therapy (favouring combined therapy) and concluded that combined therapy might be superior to systemic therapy. <a href="./references#CD008080-bbs2-0077" title="GaoY , LiuD . Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss: a meta-analysis. European Archives of Oto-rhino-laryngology2016;273(11):3699-711.">Gao 2016</a>, however, included two non‐randomised trials (<a href="./references#CD008080-bbs2-0058" title="BattagliaA , LualhatiA , LinH , BurchetteR , CuevaR . A prospective, multi-centered study of the treatment of idiopathic sudden sensorineural hearing loss with combination therapy versus high-dose prednisone alone: a 139 patient follow-up. Otology &amp; Neurotology2014;35(6):1091-8.">Battaglia 2014</a>; <a href="./references#CD008080-bbs2-0082" title="GünelC , BaşalY , TokaA , EryılmazA , Kurt ÖmürlüI . Efficacy of low-dose intratympanic dexamethasone for sudden hearing loss. Auris Nasus Larynx2015;42(4):284-7.">Günel 2015</a>). In <a href="./references#CD008080-bbs2-0082" title="GünelC , BaşalY , TokaA , EryılmazA , Kurt ÖmürlüI . Efficacy of low-dose intratympanic dexamethasone for sudden hearing loss. Auris Nasus Larynx2015;42(4):284-7.">Günel 2015</a>, the control group was a retrospective cohort. <a href="./references#CD008080-bbs2-0086" title="HanX , YinX , DuX , SunC . Combined intratympanic and systemic use of steroids as a first-line treatment for sudden sensorineural hearing loss: a meta-analysis of randomized, controlled trials. Otology &amp; Neurotology2017;38(4):487-95.">Han 2017</a> also included the study <a href="./references#CD008080-bbs2-0056" title="Khorsandi AshtianiMT , BorgheieP , YazdaniN , MaghsoudS . The effect of intratympanic dexamethasone with oral prednisolone as a primary treatment in idiopathic sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2012;24(66):19-22.">Ashtiani 2012</a>, a study with a very uncertain randomisation process, which is only mentioned in the abstract, not in the full text of their publication. They also included the non‐randomised trial <a href="./references#CD008080-bbs2-0058" title="BattagliaA , LualhatiA , LinH , BurchetteR , CuevaR . A prospective, multi-centered study of the treatment of idiopathic sudden sensorineural hearing loss with combination therapy versus high-dose prednisone alone: a 139 patient follow-up. Otology &amp; Neurotology2014;35(6):1091-8.">Battaglia 2014</a> and the trial <a href="./references#CD008080-bbs2-0035" title="ChenJ , YangJ , JiaH , ShiJ , LiY , WuH . Efficacy of intratympanic steroid injection as supplementary or initial treatment for sudden sensorineural hearing loss. Lin chuang er bi yan hou tou jing wai ke za zhi [Journal of Clinical Otorhinolaryngology, Head and Neck Surgery]2015;29(19):1691-4. ">Chen 2015</a>, in which the control group included a mixture of patients receiving combined or systemic treatment. <a href="./references#CD008080-bbs2-0106" title="LiJ , DingL . Effectiveness of steroid treatment for sudden sensorineural hearing loss: a meta-analysis of randomized controlled trials. Annals of Pharmacotherapy2020;54(10):949-57.">Li 2020</a> also included the non‐randomised trials <a href="./references#CD008080-bbs2-0058" title="BattagliaA , LualhatiA , LinH , BurchetteR , CuevaR . A prospective, multi-centered study of the treatment of idiopathic sudden sensorineural hearing loss with combination therapy versus high-dose prednisone alone: a 139 patient follow-up. Otology &amp; Neurotology2014;35(6):1091-8.">Battaglia 2014</a> and <a href="./references#CD008080-bbs2-0056" title="Khorsandi AshtianiMT , BorgheieP , YazdaniN , MaghsoudS . The effect of intratympanic dexamethasone with oral prednisolone as a primary treatment in idiopathic sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2012;24(66):19-22.">Ashtiani 2012</a> (very uncertain randomisation process). Further, they included the trial <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>, which investigated the efficacy of combined therapy against systemic treatment as a secondary intervention. </p> </section> <section id="CD008080-sec-0143"> <h4 class="title">Intratympanic corticosteroids versus no treatment or versus placebo as secondary therapy</h4> <p>In accordance with our meta‐analysis, other reviews also found that intratympanic salvage therapy might be more effective than no therapy or placebo therapy. The meta‐analyses <a href="./references#CD008080-bbs2-0118" title="NgJH , HoRC , CheongCS , NgA , YuenHW , NgoRY . Intratympanic steroids as a salvage treatment for sudden sensorineural hearing loss? A meta-analysis. European Archives of Oto-rhino-laryngology2015;272(10):2777-82.">Ng 2015</a> and <a href="./references#CD008080-bbs2-0105" title="LiH , FengG , WangH , FengY . Intratympanic steroid therapy as a salvage treatment for sudden sensorineural hearing loss after failure of conventional therapy: a meta-analysis of randomized, controlled trials. Clinical Therapeutics2015;37(1):178-87.">Li 2015</a> found a significantly higher mean change in hearing threshold in patients receiving intratympanic therapy. The meta‐analysis <a href="./references#CD008080-bbs2-0144" title="SpearSA , SchwartzSR . Intratympanic steroids for sudden sensorineural hearing loss: a systematic review. Otolaryngology - Head and Neck Surgery2011;145(4):534-43.">Spear 2011</a> also found a significant difference in mean change in hearing threshold. However, this review also included non‐randomised studies (<a href="./references#CD008080-bbs2-0096" title="KiliçR , SafakMA , OğuzH , KarginS , DemirciM , SamimE , et al. Intratympanic methylprednisolone for sudden sensorineural hearing loss. Otology &amp; Neurotology2007;28(3):312-6.">Kiliç 2007</a>; <a href="./references#CD008080-bbs2-0126" title="PlazaG , HerráizC . Intratympanic steroids for treatment of sudden hearing loss after failure of intravenous therapy. Otolaryngology - Head &amp; Neck Surgery2007;137(1):74-8.">Plaza 2007</a>; <a href="./references#CD008080-bbs2-0141" title="SheW , DaiY , DuX , YuC , ChenF , WangJ , et al. Hearing evaluation of intratympanic methylprednisolone perfusion for refractory sudden sensorineural hearing loss. Otolaryngology - Head &amp; Neck Surgery2010;142(2):266-71.">She 2010</a>). The reviews <a href="./references#CD008080-bbs2-0071" title="CraneRA , CamilonM , NguyenS , MeyerTA . Steroids for treatment of sudden sensorineural hearing loss: a meta-analysis of randomized controlled trials. Laryngoscope2015;125(1):209-17.">Crane 2015</a> and <a href="./references#CD008080-bbs2-0078" title="GaravelloW , GalluzziF , GainiRM , ZanettiD . Intratympanic steroid treatment for sudden deafness: a meta-analysis of randomized controlled trials. Otology &amp; Neurotology2012;33(5):724-9.">Garavello 2012</a> found a significantly higher recovery rate in patients receiving intratympanic therapy. The review <a href="./references#CD008080-bbs2-0071" title="CraneRA , CamilonM , NguyenS , MeyerTA . Steroids for treatment of sudden sensorineural hearing loss: a meta-analysis of randomized controlled trials. Laryngoscope2015;125(1):209-17.">Crane 2015</a>, however, included the study <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a>, which compared combined treatment with systemic therapy. The review <a href="./references#CD008080-bbs2-0078" title="GaravelloW , GalluzziF , GainiRM , ZanettiD . Intratympanic steroid treatment for sudden deafness: a meta-analysis of randomized controlled trials. Otology &amp; Neurotology2012;33(5):724-9.">Garavello 2012</a> also included the study <a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a> and the study <a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a>, which compared combined therapy with systemic treatment as primary therapy. </p> </section> <section id="CD008080-sec-0144"> <h4 class="title">Combined intratympanic plus systemic corticosteroids versus systemic corticosteroids alone as secondary therapy </h4> <p>We found no review addressing this question.</p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008080-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Process of selection of studies for inclusion in the review." data-id="CD008080-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Process of selection of studies for inclusion in the review.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008080-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008080-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-FIG-04" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD008080-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-FIG-05" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD008080-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-FIG-06" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD008080-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intratympanic compared to systemic corticosteroids as primary therapy, Outcome 1: Mean change in pure tone average (PTA)" data-id="CD008080-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Intratympanic compared to systemic corticosteroids as primary therapy, Outcome 1: Mean change in pure tone average (PTA) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intratympanic compared to systemic corticosteroids as primary therapy, Outcome 2: Proportion improved" data-id="CD008080-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Intratympanic compared to systemic corticosteroids as primary therapy, Outcome 2: Proportion improved </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intratympanic compared to systemic corticosteroids as primary therapy, Outcome 3: Final PTA" data-id="CD008080-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Intratympanic compared to systemic corticosteroids as primary therapy, Outcome 3: Final PTA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intratympanic compared to systemic corticosteroids as primary therapy, Outcome 4: Change in hearing threshold with speech audiometry" data-id="CD008080-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Intratympanic compared to systemic corticosteroids as primary therapy, Outcome 4: Change in hearing threshold with speech audiometry </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intratympanic compared to systemic corticosteroids as primary therapy, Outcome 5: Speech audiometry: additional outcomes" data-id="CD008080-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Intratympanic compared to systemic corticosteroids as primary therapy, Outcome 5: Speech audiometry: additional outcomes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intratympanic compared to systemic corticosteroids as primary therapy, Outcome 6: Frequency‐specific changes in PTA" data-id="CD008080-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Intratympanic compared to systemic corticosteroids as primary therapy, Outcome 6: Frequency‐specific changes in PTA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intratympanic compared to systemic corticosteroids as primary therapy, Outcome 7: Adverse events" data-id="CD008080-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Intratympanic compared to systemic corticosteroids as primary therapy, Outcome 7: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined compared to systemic corticosteroids as primary therapy, Outcome 1: Mean change in pure tone average (PTA)" data-id="CD008080-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Combined compared to systemic corticosteroids as primary therapy, Outcome 1: Mean change in pure tone average (PTA) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined compared to systemic corticosteroids as primary therapy, Outcome 2: Proportion improved" data-id="CD008080-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Combined compared to systemic corticosteroids as primary therapy, Outcome 2: Proportion improved </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined compared to systemic corticosteroids as primary therapy, Outcome 3: Final PTA" data-id="CD008080-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Combined compared to systemic corticosteroids as primary therapy, Outcome 3: Final PTA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined compared to systemic corticosteroids as primary therapy, Outcome 4: Change in hearing threshold with speech audiometry" data-id="CD008080-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Combined compared to systemic corticosteroids as primary therapy, Outcome 4: Change in hearing threshold with speech audiometry </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined compared to systemic corticosteroids as primary therapy, Outcome 5: Speech audiometry: additional outcomes" data-id="CD008080-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Combined compared to systemic corticosteroids as primary therapy, Outcome 5: Speech audiometry: additional outcomes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined compared to systemic corticosteroids as primary therapy, Outcome 6: Frequency‐specific changes with PTA" data-id="CD008080-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Combined compared to systemic corticosteroids as primary therapy, Outcome 6: Frequency‐specific changes with PTA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Intratympanic corticosteroids compared to no treatment/placebo as secondary therapy, Outcome 1: Mean change in PTA" data-id="CD008080-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Intratympanic corticosteroids compared to no treatment/placebo as secondary therapy, Outcome 1: Mean change in PTA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Intratympanic corticosteroids compared to no treatment/placebo as secondary therapy, Outcome 2: Proportion improved" data-id="CD008080-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Intratympanic corticosteroids compared to no treatment/placebo as secondary therapy, Outcome 2: Proportion improved </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Intratympanic corticosteroids compared to no treatment/placebo as secondary therapy, Outcome 3: Final PTA" data-id="CD008080-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Intratympanic corticosteroids compared to no treatment/placebo as secondary therapy, Outcome 3: Final PTA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Intratympanic corticosteroids compared to no treatment/placebo as secondary therapy, Outcome 4: Change in hearing threshold with speech audiometry" data-id="CD008080-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Intratympanic corticosteroids compared to no treatment/placebo as secondary therapy, Outcome 4: Change in hearing threshold with speech audiometry </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Intratympanic corticosteroids compared to no treatment/placebo as secondary therapy, Outcome 5: Speech audiometry: additional outcomes" data-id="CD008080-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Intratympanic corticosteroids compared to no treatment/placebo as secondary therapy, Outcome 5: Speech audiometry: additional outcomes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Intratympanic corticosteroids compared to no treatment/placebo as secondary therapy, Outcome 6: Frequency‐specific changes with PTA" data-id="CD008080-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Intratympanic corticosteroids compared to no treatment/placebo as secondary therapy, Outcome 6: Frequency‐specific changes with PTA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Combined compared to systemic corticosteroids as secondary treatment, Outcome 1: Proportion improved" data-id="CD008080-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Combined compared to systemic corticosteroids as secondary treatment, Outcome 1: Proportion improved </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008080-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/urn:x-wiley:14651858:media:CD008080:CD008080-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Combined compared to systemic corticosteroids as secondary treatment, Outcome 2: Speech audiometry: additional outcomes" data-id="CD008080-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_t/tCD008080-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Combined compared to systemic corticosteroids as secondary treatment, Outcome 2: Speech audiometry: additional outcomes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/media/CDSR/CD008080/image_n/nCD008080-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008080-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Intratympanic corticosteroids versus systemic corticosteroids as primary therapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Intratympanic corticosteroids versus systemic corticosteroids as primary therapy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> sudden sensorineural hearing loss </p> <p><b>Settings:</b> initial therapy </p> <p><b>Intervention:</b> intratympanic steroid therapy </p> <p><b>Comparison:</b> systemic steroid therapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Systemic therapy</b> </p> <p><b>(assumed risk)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intratympanic therapy</b> </p> <p><b>(corresponding risk)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in hearing threshold determined by PTA</p> <p> </p> <p>Range 0 dB to 140 dB</p> <p> </p> <p>Negative values represent lowering and positive values represent raising of the hearing threshold. A lower hearing threshold represents hearing improvement). </p> <p> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in PTA ranged across control groups from ‐30.07 dB to ‐15.1 dB</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in PTA in the intervention groups was on average ‐5.93 dB greater (from ‐4.26 greater to ‐7.61 greater) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>701</p> <p>(10 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐5.93  dB</p> <p>(95% CI ‐7.61 to ‐4.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intratympanic therapy may have a trivial/no effect on the change in hearing threshold when compared to systemic steroids (as primary therapy). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of patients whose hearing is improved</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>731 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>760 per 1000 (709 to 818)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>972</p> <p>(14 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04</p> <p>(95% CI 0.97 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intratympanic therapy probably results in little to no difference in the proportion of patients whose hearing is improved compared to systemic corticosteroids (as primary therapy). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final hearing threshold determined by PTA (a lower value represents better hearing)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final PTA ranged across control groups from 25.1 dB to 59 dB </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final PTA in the intervention groups was on average ‐3.31 dB lower (‐6.16 lower to ‐0.47 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>516</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐3.31 dB</p> <p>(95% CI ‐6.16 to ‐0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intratympanic therapy may result in little to no difference in the final hearing threshold (as primary therapy). </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse events<sup>b</sup> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events in control group</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events in intervention group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tympanic membrane perforation</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not applicable<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Ranged from 0% (0/30) to 3.9% (5/129) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>463 (4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain regarding the risk of tympanic membrane perforation for those who received intratympanic corticosteroid as primary treatment.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness: timing not reported<sup>d</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13/121 (10.7%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35/129 (27.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.53 (1.41 to 4.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intratympanic therapy may increase the risk of vertigo/dizziness of unspecified timing as compared to systemic corticosteroid. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness: at the time of injection </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not applicable<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 studies reported a rate between 1.5% (1/67) and 21% (4/19) for those who received an intratympanic injection<sup>e</sup>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301 (4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain regarding the risk of vertigo/dizziness at the time of intratympanic injection of corticosteroid as primary treatment.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain: timing not reported<sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4/141 (2.8%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74/148 (50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>289 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 15.68 (95% CI 6.22 to 39.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intratympanic corticosteroid injection probably increases the risk of ear pain of unspecified timing as compared to systemic corticosteroid when used as primary treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain: at the time of injection<sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not applicable<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 studies reported a rate between 4.8% (5/104) and 27.1% (35/129)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>393 (3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence suggests that there may be a risk of ear pain at the time of intratympanic injection of corticosteroid as primary treatment.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>PTA:</b> pure tone audiometry; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><sup>a</sup>Fourteen studies recruited participants suffering from sudden sensorineural hearing loss. The incidence of improvement for the systemic corticosteroid group in these 14 studies was 73.07%. We have used 731 per 1000 to express the assumed risk. </p> <p><sup>b</sup>Only the most widely reported adverse events are described here. For adverse events that could feasibly occur in either group, we have only included the studies that provided a rate for both groups. For adverse events that could only occur in one group, we have only included the studies that reported the rate in that group, and presented these as a range. A full description of adverse event data is available for reference in <a href="./full#CD008080-tbl-0002">Table 1</a>. </p> <p><sup>c</sup>Comparisons between patients receiving intratympanic therapy and those receiving only systemic therapy were regarded as invalid for the following adverse events: persistent tympanic membrane perforation, vertigo observed at the time of intratympanic injection and ear pain observed at the time of intratympanic injection. This is explained in <a href="#CD008080-sec-0028">Data extraction and management</a>.  </p> <p><sup>d</sup>A single study reported a rate for both intratympanic and systemic corticosteroid (<a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a>). However, it is not specified whether all of the patients in the intratympanic corticosteroid group experiencing vertigo did so at the time of injection. We have therefore reported this outcome separately from vertigo/dizziness interpreted as having occurred specifically at the time of injection. </p> <p><sup>e</sup>In two studies, two groups received intratympanic injection: in <a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>, one group received intratympanic corticosteroid and the other received intratympanic and systemic corticosteroid; in <a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>, one group received intratympanic corticosteroid and the other received intravenous followed by intratympanic corticosteroid. </p> <p><sup>f</sup>In each study contributing data, the number of participants with ear pain/earache was presented separately from the numbers with ear pain at intratympanic injection. It was assumed, therefore that those participants with pain at injection were not included among those with ear pain/earache.  </p> <p> </p> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate.  </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level due to risk of bias: eight studies were at high risk of other bias, three studies were at risk of attrition bias and three studies were at risk of selection bias. Downgraded one level due to inconsistency: the size and direction of effect varied between the studies and the I<sup>2</sup> value was 80%. </p> <p><sup>2</sup>Downgraded one level due to risk of bias: we judged 11 of 14 studies to be at unclear or high risk of selection bias and we judged 12 of 14 studies to be at high risk of other bias. </p> <p><sup>3</sup>Downgraded one level due to risk of bias: we judged six studies to be at high risk of other bias; two studies were at high risk of selection bias. Downgraded one level due to inconsistency: the I<sup>2</sup> value was moderate (41%). </p> <p><sup>4</sup>Downgraded one level due to risk of bias: we judged one study to be at high risk of bias because of concern about random sequence generation and allocation concealment. Downgraded two levels due to imprecision: the number of events is smaller than the optimal information size (taken as 300 events) and an effect estimate could not be calculated. </p> <p><sup>5</sup>Downgraded one level due to imprecision: the number of events is smaller than the optimal information size (taken as 300 events). Downgraded one level because of indirectness: provision of data by only a single study from a single setting, which may not adequately represent all patients with ISSNHL. </p> <p><sup>6</sup>Downgraded two levels due to risk of bias: we judged two studies to be at high risk of bias because of incomplete outcome data; we judged one study to be at high risk of bias because of concern about random sequence generation and allocation concealment. Downgraded two levels due to imprecision: the number of events is smaller than the optimal information size (taken as 300 events) and an effect estimate could not be calculated. </p> <p><sup>7</sup>Downgraded one level due to imprecision: the number of events is smaller than the optimal information size (taken as 300 events). </p> <p><sup>8</sup>Downgraded two levels because of imprecision: the number of events is smaller than the optimal information size (taken as 300 events) and an effect estimate could not be calculated. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Intratympanic corticosteroids versus systemic corticosteroids as primary therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008080-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse events: intratympanic compared to systemic corticosteroids as primary therapy</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse event reported</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>How reported</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Details of recovery</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rate in intervention group (%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rate in comparator group (%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RR (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tympanic membrane (TM) perforation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no cases of [...] perforation of the tympanic membrane</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52 (0)*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No residual TM perforations</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All patients demonstrated a complete healing of TM after the tympanostomy tube removal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/24 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent TM perforation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/129 (3.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No residual tympanic membrane perforations were observed in any of the individuals at their final visit </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/30 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0010" title="ErmutluG , SüslüN , YılmazT , SaraçS . Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. European Archives of Oto-rhino-laryngology2017;274(10):3585-91. ">Ermutlu 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Four patients in the ITS group had transient vertigo during the procedure</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/19 (21)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>[...] complained of brief dizziness after IT injection [...]</p> <p> </p> <p> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No patients stopped the treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/52 (13.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/52 (15.4)*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The intratympanic group experienced adverse effects typical of local injection, most often transient pain at the injection site and brief caloric vertigo. Note, it is unclear whether all reported instances of vertigo in the intervention group occurred at the time of injection. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35/129 (27.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/121 (10.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.53 (1.41 to 4.54); favours systemic corticosteroid; P = 0.002</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temporary adverse events in 22.7% of patients treated with oral prednisolone which included [...] and dizziness. In 35% of patients treated with intratympanic corticosteroid, adverse events occurred including [...] and dizziness. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six of 30 patients in the intratympanic injection group complained of a transient dizziness lasting about a minute during treatment </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/30 (20)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient experienced transient dizziness as a result of caloric stimulation from the injected steroid solution (unclear which of 2 groups receiving intratympanic injection) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptoms resolved completely within 15 minutes and there was no need to discontinue the treatment. The injections that followed caused no further side effect. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinnitus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 35% of patients treated with intratympanic corticosteroid, adverse events occurred including [...] ringing sensation in the ear </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain due to injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/19 (10.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Earache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/19 (21.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.45 (0.54 to 164.49); favours systemic corticosteroid; P = 0.12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>[...] refused repeated IT injections due to unbearable pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/52 (5.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/52 (3.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The intratympanic group experienced adverse effects typical of local injection, most often transient pain at the injection site [...] </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35/129 (27.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Experienced ear pain at least once</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70/129 (54.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/121 (3.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.41 (6.18 to 43.59); favours systemic corticosteroid;  P &lt; 0.00001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 35% of patients treated with intratympanic corticosteroid adverse events occurred including […] mild ear pain, severe ear pain (3 patients) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/20 (15) severe ear pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some patients had a tolerable pain reaction after the injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0002" title="Al-ShehriAMS . Intratympanic vs. oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. British Journal of Medicine &amp; Medical Research2015;11(6):1-6. ">Al‐Shehri 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mood change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/19 (10.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/20 (40)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.26 (0.06 to 1.08); favours IT corticosteroid; P = 0.06</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood glucose problem</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/19 (15.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/20 (30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.53 (0.15 to 1.81); favours IT corticosteroid; P = 0.31</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleep change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/19 (5.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/20 (30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.18 (0.02 to 1.32); favours IT corticosteroid; P = 0.09</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased appetite</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/19 (5.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/20 (25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.21 (0.03 to 1.64); favours IT corticosteroid; P = 0.14  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mouth dryness/thirst</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/20 (25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.10 (0.01 to 1.62); favours IT corticosteroid; P = 0.10</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weight gain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/20 (15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.15 (0.01 to 2.72); favours IT corticosteroid; P = 0.20  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0009" title="DispenzaF , AmodioE , De StefanoA , GallinaS , MarcheseD , MathurN , et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. European Archives of Oto-rhino-laryngology2011;268(9):1273-8. ">Dispenza 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No complications related to the treatment were noted in both the groups</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/21 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0010" title="ErmutluG , SüslüN , YılmazT , SaraçS . Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. European Archives of Oto-rhino-laryngology2017;274(10):3585-91. ">Ermutlu 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No long‐term complications were observed in any of the patients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/16 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0013" title="HongSM , ParkCH , LeeJH . Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngology - Head and Neck Surgery2009;141(5):579-83. ">Hong 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No side effects were observed in either group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/32 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/31 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Apparent bleeding at intratympanic injection site</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>External otitis or myringitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Otitis media</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluctuation of basal blood pressure (&gt; 10 mmHg)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/52 (3.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/52 (13.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluctuation of fasting blood glucose (&gt; 2 mmol/L)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/52 (9.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/52 (23.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Emotional change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/52 (15.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/52 (28.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appetite change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/52 (25.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/52 (48.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dyssomnia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/52 (44.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/52 (73.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Water‐sodium retention</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/52 (17.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/52 (46.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne on face and body</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/52 (3.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/52 (11.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irregular menstruation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/21 (23.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/23 (47.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cushing's syndrome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/52 (1.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Osteoporotic fracture</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0016" title="KosyakovS , AtanesyanA , GunenkovA , AshkhatunyanE , KurlovaA . Intratympanic steroids for sudden sensorineural hearing loss. Journal of International Advanced Otology2011;7(3):323-32. ">Kosyakov 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In one case an acute suppurative otitis media developed that was eliminated by local antibacterial therapy. This patient was excluded from the study. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nine patients in the ST (standard therapy) group and 12 patients in the intravenous corticosteroid group complained of sleep loss </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completely corrected after withdrawal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/24 (37.5) in ST group and 12/25 (48) in intravenous corticosteroid group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No systemic adverse effects related to intratympanic application of steroids were noticed </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/24 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious side effects related to systemic administration of steroids were observed in the study </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/49 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0022" title="QuY , ChenH , ZhangH , GuoM . Analysis the treatment of sudden sensorineural hearing loss with steroid from different administration routes [Lin chuang er bi yan hou tou jing wai ke za zhi]. Journal of Clinical Otorhinolaryngology, Head and Neck Surgery [Chinese]2015;29(4):324-6. ">Qu 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No complications were seen in patients (unclear which group), including those with hypertension or diabetes </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0023" title="RauchSD , HalpinCF , AntonelliPJ , BabuS , CareyJP , GantzBJ , et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA2011;305(20):2071-9. ">Rauch 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mood change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/129 (9.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54/121 (44.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.21 (0.12 to 0.37); favours IT corticosteroid; P &lt; 0.00001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood glucose problem</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/129 (16.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/121 (29.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.55 (0.34 to 0.88); favours IT corticosteroid; P = 0.01</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleep change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/129 (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/121 (36.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19 (0.1 to 0.38); favours IT corticosteroid; P &lt; 0.00001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appetite change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/129 (4.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/121 (23.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 (0.09 to 0.47); favours IT corticosteroid; P = 0.0002</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dry mouth/thirst</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/129 (3.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/121 (24.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.16 (0.06 to 0.39); favours IT corticosteroid; P &lt; 0.0001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weight change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/129 (5.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/121 (18.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 (0.13 to 0.67); favours IT corticosteroid; P = 0.004</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/129 (5.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/121 (1.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.28 (0.7 to 15.49); favours systemic corticosteroid; P = 0.13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse event: "Adverse events were reported by 87.6% (106 of 121) of participants in the oral group and 89.9% (116 of 129) in the intratympanic group." Note: it is unclear whether 'adverse events' refers to those already reported (and listed for this study in this table).  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By the 6‐month follow‐up most adverse events had resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116/129 (89.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106/121 (87.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03 (0.94 to 1.12); favours systemic corticosteroid;</p> <p>P = 0.56 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events: "In the intratympanic treatment group, these included osteomyelitis of the toe, leukemia, myocardial infarction, bladder cancer, chest pain due to possible endocarditis, and exacerbation of pre‐existing chronic obstructive pulmonary disease. In the oral treatment group, the serious adverse events were myocardial infarction, cerebral hemorrhage, hyponatremia, hospitalization for possible transient ischemic attack, and syncope. The case of hyponatremia arose from worsening of pre‐existent mild renal insufficiency in a patient with type 2 diabetes that was deemed study‐related." </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/129 (4.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/121 (4.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.13 (0.35 to 3.59); favours systemic corticosteroid;</p> <p>P = 0.84 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0024" title="RupasingheRAST . Comparison - Effectiveness of oral steroid versus intratympanic dexamethasone for sudden onset sensorineural hearing loss. Ceylon Journal of Otolaryngology2017;5(1):7-13. ">Rupasinghe 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adverse effects were reported in either study group during the study period</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0025" title="SwachiaK , SharmaD , SinghJ . Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. Journal of Basic and Clinical Physiology and Pharmacology2016;27(4):371-7. ">Swachia 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temporary adverse events: temporary adverse events in 22.7% of patients treated with oral prednisolone which included puffiness of face, ulcers in mouth, increased appetite, diarrhea [...] </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/22 (22.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: in 35% of patients treated with intratympanic methylprednisolone adverse events occurred including mild ear pain, severe ear pain (3 patients), ringing sensation in ear and dizziness </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/20 (35)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0026" title="DuanM . Data on frequency specific hearing changes (table 5) [personal communication]. Email to K Webster 9 October 2021. TongB , WangQ , DaiQ , HellstromS , DuanM . Efficacy of various corticosteroid treatment modalities for the initial treatment of idiopathic sudden hearing loss: a prospective randomized controlled trial. Audiology &amp; Neurotology2021;26(1):45-52. ">Tong 2021</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No otitis media […] observed in any of the individuals at their final visit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/30 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/30 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant complications during the intratympanic injections or the follow‐up period </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/33 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Patients in the comparator group for this trial also received intratympanic (IT) corticosteroid at a later time point in the trial, therefore complications of IT treatment are included here (<a href="./references#CD008080-bbs2-0014" title="HuangJ , YangL , CaoX , WangW . Differences in hearing recovery following intratympanic alone or intravenous dexamethasone with rescue intratympanic steroids for sudden sensorineural hearing loss: a randomised trial. Clinical Otolaryngology2021;46(3):546-51. ">Huang 2021</a>). The intervention group received 24 days of IT corticosteroid and the comparator group received 12 days of systemic (intravenous corticosteroid) followed by 12 days of IT corticosteroid. Rate ratios are not presented as they are not applicable to the comparison of interest (IT compared to systemic as primary therapy).  </p> <p>CI: confidence interval; IT: intratympanic; NA: not applicable; NR: not reported; RR: risk ratio; TM: tympanic membrane </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse events: intratympanic compared to systemic corticosteroids as primary therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008080-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as primary therapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as primary therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> sudden sensorineural hearing loss </p> <p><b>Settings:</b> initial therapy </p> <p><b>Intervention:</b> combination of intratympanic and systemic steroid therapy </p> <p><b>Comparison:</b> systemic steroid therapy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants</b> <br/><b>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Systemic therapy</b> </p> <p><b>(assumed risk)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Combined therapy</b> </p> <p><b>(corresponding risk)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in hearing threshold determined by PTA</p> <p>Range 0 dB to 140 dB</p> <p>Negative values represent lowering and positive values represent raising of the hearing threshold. A lower hearing threshold represents hearing improvement. </p> <p> </p> <p> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in PTA ranged across control groups from<br/>‐33.0 dB to ‐13.0 dB </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in PTA in the intervention groups was on average ‐8.55 dB greater (‐4.61 greater to ‐12.48 greater) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>435</p> <p>(6 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐8.55 dB</p> <p>(95% CI ‐12.48 to ‐4.61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The change in hearing threshold may be slightly increased in participants who receive combined therapy. However, it is unclear whether this increase would be noticeable to patients.  </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of patients whose hearing is improved</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>579 per 1000<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>735 per 1000 (666 to 816)<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>788</p> <p>(10 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.27</p> <p>(95% CI 1.15 to 1.41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain as to whether combined therapy changes the proportion of participants whose hearing is improved. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final hearing threshold determined by PTA</p> <p>A lower value represents better hearing</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final PTA ranged across control groups from 39.1 dB to 59 dB </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final PTA in the intervention groups was on average 9.11 dB lower (1.67 lower to 16.56 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> <p>(3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐9.11 dB</p> <p>(95% CI ‐16.56 to ‐1.67)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>3</sup> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combined therapy may result in slightly lower (more favourable) final hearing thresholds compared to systemic corticosteroids alone (as primary therapy) but the evidence is very uncertain, and it is not clear whether the change would be of importance to patients. </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse events<sup>b</sup> </b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events in control group</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events in intervention group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of Participants</b> <br/><b>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent tympanic membrane perforation</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not applicable<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 studies reported a rate between 0% (0/85) and 5.5% (2/36) for those who received an intratympanic injection  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>474 (5 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain regarding the risk of tympanic membrane perforation for those who received intratympanic steroids.  </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness: timing not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No study reported on this outcome for both the intervention and comparator groups. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness: at the time of injection </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not applicable<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 studies reported a rate between 0% (0/60) and 8.1% (3/37) for those who received an intratympanic injection<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341 (4 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain regarding the risk of vertigo/dizziness at the time of intratympanic injection for those who received intratympanic corticosteroid as primary treatment. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain: timing not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No study reported on this outcome for both the intervention and comparator groups. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain: at the time of injection</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not applicable<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>One study reported a rate of 5/37 (13.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain regarding the risk of ear pain at the time of intratympanic injection for those who received combined treatment as primary treatment. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>PTA:</b> pure tone audiometry; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><sup>a</sup>Ten studies recruited participants suffering from sudden sensorineural hearing loss. The incidence of improvement for the 10 studies was 57.86%. We have used 579 per 1000 to express the assumed risk. </p> <p><sup>b</sup>Only the most widely reported adverse events are described here. For adverse events that could feasibly occur in either group, we have only included the studies that provided a rate for both groups. For adverse events that could only occur in one group, we have only included the studies that reported the rate in that group, and presented these as a range. A full description of adverse event data is available for reference in <a href="./full#CD008080-tbl-0004">Table 2</a>. </p> <p><sup>c</sup>Comparisons between patients receiving intratympanic therapy and those receiving only systemic therapy were regarded as invalid for the following adverse events: persistent tympanic membrane perforation, vertigo observed at the time of intratympanic injection and ear pain observed at the time of intratympanic injection. This is explained in <a href="#CD008080-sec-0028">Data extraction and management</a>.  </p> <p><sup>d</sup>In one study, two groups received intratympanic injection: one group received intratympanic corticosteroid and the other received intratympanic and systemic corticosteroid (<a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a>).  </p> <p> </p> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level due to risk of bias: we rated a study contributing moderate weight to the overall effect estimate as high risk of bias due to concern about random sequence generation and allocation concealment. Five studies were at high risk of other bias, and one study was at risk of attrition bias. Downgraded one level due to imprecision: the 95% CI overlaps the threshold for clinical relevance, taken to be 10 dB. </p> <p><sup>2</sup>Downgraded one level due to risk of bias: we judged 8 of 10 studies to be at high or unclear risk of selection bias and at high risk of other bias. Downgraded one level due to imprecision: the 95% CI overlaps the threshold for clinical relevance. Downgraded one level due to inconsistency: the I<sup>2</sup> value was moderate (47%). </p> <p><sup>3</sup>Downgraded two levels due to risk of bias: we judged all three studies to be at high or unclear risk of selection bias and high risk of other bias. We also judged one of three studies to be at high risk of bias for incomplete outcome data and selective reporting. Downgraded one level due to imprecision: the 95% CI overlaps the threshold for clinical relevance and the sample size is smaller than the optimal information size (taken as 400 participants). </p> <p><sup>4</sup>Downgraded two levels due to risk of bias: we judged two studies to be at high risk of bias because of concern about random sequence generation, two studies because of selective reporting, one study because of concern about blinding and one study because of concern about allocation concealment. </p> <p><sup>5</sup>Downgraded two levels due to risk of bias: we judged one study to be at high risk of bias because of concern about random sequence generation and blinding, one study because of selective reporting and one study because of incomplete outcome data. Downgraded two levels due to imprecision: the number of events is smaller than the optimal information size (taken as 300 events) and an effect estimate could not be calculated. </p> <p><sup>6</sup>Downgraded two levels due to imprecision: the number of events is smaller than the optimal information size (taken as 300 events) and an effect estimate could not be calculated. Downgraded one level because of indirectness: provision of data by only a single study from a single setting, which may not adequately represent all patients with ISSNHL. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as primary therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008080-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events: combined compared to systemic as primary therapy</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse event reported</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>How reported</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Details of recovery</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rate in intervention group (%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rate in comparator group (%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RR (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TM perforation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant complications during or after IT dexamethasone, including TM perforation […] </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/60 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0003" title="ArastouS , TajediniA , BorgheiP . Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology2013;25(70):23-8. ">Arastou 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two patients developed tympanic perforation (reported as 2.6% of whole study sample; unclear how many from each group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treated with cauterisation and paper patch (n = 1) and tympanoplasty (n = 1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the patients had an important complication, namely […] TM perforation (unclear which group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant complications during or after IT steroid injection including TM perforation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No case of residual TM perforation […] was noted</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No long‐term complications resulting from either oral steroid or IT steroid in any of the patients </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/37 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant complications during or after IT dexamethasone, including […] vertigo […] </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/60 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the patients had an important complication, namely, […] vertigo […] (unclear which group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant complications during or after IT steroid injection, including […] vertigo […] </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three patients complained of vertigo immediately after injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovered after 2 hours of rest</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/37 (8.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient experienced transient dizziness as a result of caloric stimulation from the injected steroid solution (unclear which of two groups receiving intratympanic injection) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptoms resolved completely within 15 minutes and there was no need to discontinue the treatment. The injections that followed caused no further side effects. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinnitus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant<br/>complications during or after IT dexamethasone, including […] and tinnitus </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/60 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the patients had an important complication, namely, […] tinnitus […] (unclear which group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant complications during or after IT steroid injection, including […] tinnitus […] </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the patients had an important complication, namely, […] otalgia […] (unclear which group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Otalgia occurred in 5 patients after IT corticosteroid injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relieved after 1 hour</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/37 (13.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0001" title="AhnJH , YooMH , YoonTH , ChungJW . Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope2008;118(2):279-82. ">Ahn 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant complications during or after IT dexamethasone, including […] otitis media […] </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/60 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0004" title="ArslanN , OğuzH , DemirciM , ŞafakMA , İslamA , KaytezSK , et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2011;32(3):393-7. ">Arslan 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the patients had an important complication, namely, […]  nystagmus, otitis media […] (unclear which group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0006" title="BattagliaA , BurchetteR , CuevaR . Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology &amp; Neurotology2008;29(4):453-60. ">Battaglia 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No long‐term complications resulted from either the prednisone taper or the IT corticosteroid in any of the patients enrolled in the study </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/16 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/18 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0008" title="ChoiSJ , LeeYH , KimYH . Comparison of the efficacy of systemic and combined highly frequent intratympanic steroid treatment on sudden sensorineural hearing loss. Korean Journal of Audiology2011;15:133-6. ">Choi 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant complications during or after IT steroid injection, including […] otitis media […] </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0011" title="GundoganO , PinarE , ImreA , OzturkcanS , CokmezO , YigiterAC . Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngology - Head &amp; Neck Surgery2013;149:753-8. ">Gundogan 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No case of […] otitis media was noted</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No long‐term complications resulted from either oral steroid or IT steroid in any of the patients </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No long‐ term complications resulted from either oral steroid or IT steroid in any of the patients </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/37 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/36 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0027" title="TsounisM , PsillasG , TsalighopoulosM , VitalV , MaroudiasN , MarkouK . Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. Otorhinolaryngology2018;275(1):103-10. ">Tsounis 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant complications during the intratympanic injections or the follow‐up period </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/33 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0015" title="KoltsidopoulosP , BibasA , SismanisA , TzonouA , SeggasI . Intratympanic and systemic steroids for sudden hearing loss. Otology &amp; Neurotology2013;34:771-6. ">Koltsidopoulos 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant complications occurred during IT injections or the follow‐up period. One case of otitis media was encountered (unclear which group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/46 (0) (significant complications)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>IT: intratympanic; NA: not applicable; NR: not reported; TM: tympanic membrane</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events: combined compared to systemic as primary therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008080-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Intratympanic corticosteroids versus no treatment or versus placebo as secondary therapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Intratympanic corticosteroids versus no treatment or versus placebo as secondary therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> sudden sensorineural hearing loss </p> <p><b>Settings:</b> after treatment failure with systemic steroids </p> <p><b>Intervention:</b> intratympanic steroid therapy </p> <p><b>Comparison:</b> no treatment/placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants</b> <br/><b>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No treatment/placebo</b> </p> <p><b>(assumed risk)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intratympanic therapy</b> </p> <p><b>(corresponding risk)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in hearing threshold determined by PTA</p> <p>Range 0 dB to 140 dB</p> <p>Negative values represent lowering and positive values represent raising of the hearing threshold. A lower hearing threshold represents hearing improvement. </p> <p> </p> <p> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in PTA ranged across control groups from<br/>‐13.21 dB to 0.8 dB </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in PTA in the intervention groups was on average ‐9.07 dB greater (‐6.66 greater to ‐11.47 greater)<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280</p> <p>(7 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐9.07 dB (95% CI ‐11.47 to ‐6.66)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low<sup>1</sup> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intratympanic therapy may have a small effect on hearing threshold compared to no treatment or placebo (as secondary therapy), but it is not clear whether this change would be important to patients. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of patients whose hearing is improved</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>70 per 1000<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>385 per 1000 (203 to 747)<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232</p> <p>(6 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.55</p> <p>(95% CI 2.89 to 10.68)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intratympanic therapy may result in a much higher proportion of patients whose hearing is improved, compared to no treatment or placebo (as secondary therapy). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final hearing threshold determined by PTA (a lower value represents better hearing)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final PTA ranged across control groups from 59.9 to 90.5 dB HL</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final PTA in the intervention groups was on average ‐11.09 dB lower (‐4.72 lower to ‐17.46 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203</p> <p>(5 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐11.09 dB</p> <p>(95% CI ‐17.46 to ‐4.72)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intratympanic therapy may result in lower (more favourable) final hearing thresholds compared to no treatment or placebo (as secondary therapy). </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse events<sup>b</sup> </b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events in control group</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events in intervention group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of Participants (studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent tympanic membrane perforation</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not applicable<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 studies reported a rate between 0% (0/19) and 4.2% (1/24) for those who received an intratympanic injection<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185 (5 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain regarding the risk of tympanic membrane perforation for those who received intratympanic injection (either corticosteroid or placebo) as secondary treatment. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness: timing not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No study reported on this outcome for both the intervention and comparator groups.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness at the time of intratympanic injection</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not applicable<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 studies reported a rate between 6.7% (1/15) and 33% (number not reported) for those who received an intratympanic injection.<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128 (3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low<sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain regarding the risk of vertigo/dizziness at the time of intratympanic injection (either corticosteroid or placebo) as secondary treatment. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain: timing not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No study reported on this outcome for both the intervention and comparator groups.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain at the time of intratympanic injection</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not applicable<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>One study reported no participants with ear pain at the time of intratympanic injection (0/24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (one study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low<sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain regarding the risk of ear pain at the time of intratympanic corticosteroid injection as secondary treatment. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>PTA:</b> pure tone audiometry; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><sup>a</sup>Six studies recruited participants suffering from sudden sensorineural hearing loss after treatment failure with systemic steroids. The incidence of improvement for the control group in these six studies was 6.96%. We have used 70 per 1000 to express the assumed risk. </p> <p><sup>b</sup>Only the most widely reported adverse events are described here. For adverse events that could feasibly occur in either group, we have only included the studies that provided a rate for both groups. For adverse events that could only occur in one group, we have only included the studies that reported the rate in that group, and presented these as a range. A full description of adverse event data is available for reference in <a href="./full#CD008080-tbl-0006">Table 3</a>. </p> <p><sup>c</sup>Comparisons between patients receiving intratympanic therapy and those receiving only systemic therapy were regarded as invalid for the following adverse events: persistent tympanic membrane perforation, vertigo observed at the time of intratympanic injection and ear pain observed at the time of intratympanic injection. This is explained in <a href="#CD008080-sec-0028">Data extraction and management</a>.  </p> <p><sup>d</sup>This includes participants who received placebo intratympanic injection. </p> <p> </p> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level due to risk of bias: we rated one study contributing moderate weight to the overall effect estimate as having high risk of bias due to incomplete outcome data. All studies were at high risk of other bias. Downgraded one level due to imprecision: the 95% CI for the effect overlaps the threshold for clinical relevance and the sample size is smaller than the optimal information size (taken as 400 participants). One study included treatment in the comparator arm with vitamin B, vasodilators and benzodiazepines (<a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a>). However, as the weight of this study in the meta‐analysis was low and exclusion of the study made little difference to the effect estimate we did not downgrade for indirectness. </p> <p><sup>2</sup>Downgraded one level due to risk of bias: we rated two studies as being at high risk of bias due to selective reporting and one study was at high risk of bias for incomplete outcome data. All studies were at high risk of other bias. Downgraded one level due to imprecision: the total number of events is smaller than the optimal information size (taken as 300 events). </p> <p><sup>3</sup>Downgraded one level due to risk of bias: we rated one study contributing moderate weight to the overall effect estimate as high risk of bias due to incomplete outcome data, and one other study as high risk of bias because of selective reporting. All studies were at high risk of other bias. Downgraded one level due to imprecision: the 95% CI for the effect overlaps the threshold for clinical relevance and the sample size is smaller than the optimal information size (taken as 400 participants). </p> <p><sup>4</sup>Downgraded one level due to risk of bias: we rated one study as high risk of bias because of selective reporting; we rated one study as high risk of bias because of incomplete outcome data; we rated three studies as uncertain for random sequence generation, allocation concealment and blinding. Downgraded two levels because of imprecision: the number of events is smaller than the optimal information size (taken as 300 events) and an effect estimate could not be calculated. </p> <p><sup>5</sup>Downgraded one level due to risk of bias: we rated one study as high risk of bias because of selective reporting; we rated one study as high risk of bias because of incomplete outcome data; we rated two studies as uncertain for random sequence generation, allocation concealment and blinding. Downgraded two levels because of imprecision: the number of events is smaller than the optimal information size (taken as 300 events) and an effect estimate could not be calculated. </p> <p><sup>6</sup>Downgraded two levels because of imprecision: the number of events is smaller than the optimal information size (taken as 300 events) and an effect estimate could not be calculated. Downgraded one level due to indirectness: single study from a single setting, which may not adequately represent all patients with ISSNHL. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Intratympanic corticosteroids versus no treatment or versus placebo as secondary therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008080-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse events: intratympanic compared to no treatment/placebo as secondary therapy</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse event reported</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>How reported</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Details of recovery</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rate in intervention group (%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rate in comparator group (%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RR (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TM perforation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No residual TM perforation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/15 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent TM perforation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No hearing loss in the affected ear. The perforation was treated successfully with a paper patch. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/24 (4.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient (unclear which group) had a major catheter dislocation with perforation of ear drum. Note: both groups received IT injection, either corticosteroid or normal saline.   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small ear drum perforation was closed with a myringoplasty</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient TM perforation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healed spontaneously by follow‐up 1 month later</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/27 (3.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No TM perforation was noticed at last visit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complained of vertigo immediately after injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovered after 2 hours of rest</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/15 (6.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three patients complained of vertigo [...] during the injections</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resolved within minutes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/24 (12.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No disequilibrium</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/24 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No dizziness for more than 24 hours</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/24 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient (unclear which group) with increase in vertigo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temporary dizziness experienced by one‐third of subjects (unclear how many each group). Note: both groups received IT injection, either corticosteroid or normal saline. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relieved by resting for a short time. Three participants quit the trial because of uncomfortable dizziness (unclear how many each group). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinnitus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three patients complained of vertigo or an increase in tinnitus during the injections</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resolved within minutes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/24 (12.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hearing loss</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The injection did not induce an increase in […] hearing loss […] for greater than 24 h </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/24 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No participant experienced a decrease in hearing of 10 dB or more</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The injection did not induce an increase in ear pain […]</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/24 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two patients (unclear how many each group) with ear pain. Note: both groups received IT injection, either corticosteroid or normal saline. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A mild ear pain occurring the first hour post‐injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Easily controlled with common analgesics</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0012" title="HoHG , LinHC , ShuMT , YangCC , TsaiHT . Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope2004;114(7):1184-9. ">Ho 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One of 15 patients had acne</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/15 (6.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0018" title="LiP , ZengXL , YeJ , YangQT , ZhangGH , LiY . Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiology &amp; Neurotology2011;16(3):198-202. ">Li 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious complications such as chronic otitis media, disequilibrium or dysgeusia developed </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/24 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0021" title="NCT00335920. Safety and efficacy of intratympanic application of dexamethasone via catheter in patients with sudden hearing loss. https://clinicaltrials.gov/ct2/show/NCT00335920 (first received 12 June 2006). PlontkeSK , LowenheimH , MertensJ , EngelC , MeisnerC , WeidnerA , et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope2009;119(2):359-69. ">Plontke 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient (unclear which group) with each of: ear canal skin defect, steroid acne, nausea after antibiotic intake, gastroenteritis, hypokalaemia, pump battery failure and viral conjunctivitis. Three patients with headache (unclear how many in each group; one considered as 'possibly', 'probably' or 'very likely' related to the study) and 3 (unclear how many each group) with increased liver function tests (probably due to antibiotics). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resolved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0028" title="WuHP , ChouYF , YuSH , WangCP , HsuCJ , ChenPR . Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otology &amp; Neurotology2011;32(5):774-9. ">Wu 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe nausea or vomiting was not experienced by any of the participants after the injection therapy </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0029" title="XenellisJ , PapadimitriouN , NikolopoulosT , MaragoudakisP , SegasJ , TzagaroulakisA , et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngology - Head &amp; Neck Surgery2006;134(6):940-5. ">Xenellis 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No infection was noticed in any of the patients at their last visit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/18 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>TM: tympanic membrane; NA: not applicable; NR: not reported; IT: intratympanic</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse events: intratympanic compared to no treatment/placebo as secondary therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008080-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as secondary therapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as secondary therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> sudden sensorineural hearing loss </p> <p><b>Settings:</b> after treatment failure with systemic steroids </p> <p><b>Intervention:</b> combination of intratympanic and systemic steroid therapy </p> <p><b>Comparison:</b> systemic steroid therapy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants</b> <br/><b>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Systemic therapy</b> </p> <p><b>(assumed risk)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Combined therapy</b> </p> <p><b>(corresponding risk)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in hearing threshold determined by PTA</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of patients whose hearing is improved</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>205 per 1000<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>459 per 1000 (226 to 933)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.24</p> <p>(95% CI 1.10 to 4.55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combined therapy may increase the proportion of patients whose hearing is improved compared to systemic corticosteroids alone (as secondary therapy), but the evidence is very uncertain.  </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final hearing threshold determined by PTA</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse events<sup>b</sup> </b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events in control group</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events in intervention group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants</b> <br/><b>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent tympanic membrane perforation</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not appropriate<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>One study reported a rate of 8.1% (3/37)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The risk of tympanic membrane perforation among those who receive intratympanic corticosteroid combined with systemic corticosteroid as primary treatment is very uncertain.    </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness:</p> <p>timing not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo/dizziness:</p> <p>at the time of injection </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not appropriate<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No study reported a rate in the intervention group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain:</p> <p>timing not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain: </p> <p>at the time of injection</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparison not appropriate<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No study reported a rate in the intervention group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>PTA:</b> pure tone audiometry; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><sup>a</sup>One study recruited participants suffering from sudden sensorineural hearing loss after treatment failure with systemic steroids. The incidence of improvements was 20.51%. We have used 205 per 1000 to express the assumed risk. </p> <p><sup>b</sup>Only the most widely reported adverse events are described here. For adverse events that could feasibly occur in either group, we have only included the studies that provided a rate for both groups. For adverse events that could only occur in one group, we have only included the studies that reported the rate in that group, and presented these as a range. A full description of adverse event data is available for reference in <a href="./full#CD008080-tbl-0008">Table 4</a>. </p> <p><sup>c</sup>Comparisons between patients receiving intratympanic therapy and those receiving only systemic therapy were regarded as invalid for the following adverse events: persistent tympanic membrane perforation, vertigo observed at the time of intratympanic injection and ear pain observed at the time of intratympanic injection. This is explained in <a href="#CD008080-sec-0028">Data extraction and management</a>.  </p> <p> </p> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels due to risk of bias: we judged the study to be at high risk of selection bias, performance bias, incomplete outcome data, selective reporting and other bias. Downgraded two levels due to imprecision: the 95% CI overlaps the threshold for clinical relevance and the total number of events is smaller than the optimal information size (taken as 300 events). </p> <p><sup>2</sup>Downgraded two levels due to risk of bias: we judged the study to be at high risk of bias because of selection bias, concern about blinding, incomplete outcome data and selective reporting. Downgraded two levels due to imprecision: the number of events is smaller than the optimal information size (taken as 300 events) and an effect estimate could not be calculated. Downgraded one level because of indirectness: provision of data by only a single study from a single setting, which may not adequately represent all patients with ISSNHL. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as secondary therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008080-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse events: combined compared to systemic as secondary treatment</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse event reported</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>How reported</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Details of recovery</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rate in intervention group (%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rate in comparator group (%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RR (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TM perforation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three patients had small eardrum perforations</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Successful closure by simple treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/37 (8.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertigo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Second frequent complaint: transient vertigo after the drug had been injected into the ear </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not a severe problem if the drug was heated in 37°C water before injection and the vertigo disappeared after a few minutes or under 30 minutes </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most frequent complaint</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Easily controlled by the oral administration of paracetamol 30 minutes before the local infusion of the methylprednisolone </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hearing loss*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No loss in hearing related to the treatment (in either group)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/37 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/39 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008080-bbs2-0030" title="ZhouY , ZhengH , ZhangQ , CampionePA . Early transtympanic steroid injection in patients with 'poor prognosis' idiopathic sensorineural sudden hearing loss. ORL; Journal for Oto-rhino-laryngology and Its Related Specialties2011;73(1):31-7. ">Zhou 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient had tongue paresthesia (unclear which group)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resolved after 2 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No infections were observed (unclear which group)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term complications did not occur in any patients who received the transtympanic injections </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/37 (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Hearing loss defined as ≥ 15 dB worsening in pure tone audiometry or ≥ 15% worsening of speech discrimination score. </p> <p>NA: not applicable; NR: not reported; TM: tympanic membrane</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse events: combined compared to systemic as secondary treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/full#CD008080-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008080-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intratympanic compared to systemic corticosteroids as primary therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Mean change in pure tone average (PTA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.93 [‐7.61, ‐4.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Proportion improved <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.97, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Final PTA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.31 [‐6.16, ‐0.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Change in hearing threshold with speech audiometry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.85 [‐19.58, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Speech audiometry: additional outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Speech discrimination score: change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.64 [1.57, 29.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Speech discrimination score: endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.00 [‐20.88, 32.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 Word recognition score: change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐9.28, 8.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Frequency‐specific changes in PTA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 0.25 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 0.5 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 1 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.4 2 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.5 3 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.6 4 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.7 8 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.8 Frequency range: low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.9 Frequency range: mid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.10 Frequency range: high</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Ear pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.68 [6.22, 39.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Otitis media</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.28 [0.70, 15.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Vertigo/dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.53 [1.41, 4.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.4 Blood glucose problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.35, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.5 Mood change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.13, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.6 Sleep change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.10, 0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.7 Appetite change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.09, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.8 Weight change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.13, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.9 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.06, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.10 Any adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.94, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.11 Serious adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.35, 3.59]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intratympanic compared to systemic corticosteroids as primary therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008080-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Combined compared to systemic corticosteroids as primary therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Mean change in pure tone average (PTA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.55 [‐12.48, ‐4.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Proportion improved <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.15, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Final PTA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.11 [‐16.56, ‐1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Change in hearing threshold with speech audiometry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.59 [‐20.22, 5.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Speech audiometry: additional outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Speech discrimination score: change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Speech discrimination score: endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Frequency‐specific changes with PTA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 0.25 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 0.5 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.3 1 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.4 2 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.5 3 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.6 4 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.7 8 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.8 Frequency range: low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.9 Frequency range: mid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.10 Frequency range: high</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Combined compared to systemic corticosteroids as primary therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008080-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Intratympanic corticosteroids compared to no treatment/placebo as secondary therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Mean change in PTA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.07 [‐11.47, ‐6.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Proportion improved <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.55 [2.89, 10.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Final PTA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.09 [‐17.46, ‐4.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Change in hearing threshold with speech audiometry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.80 [‐30.17, 4.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Speech audiometry: additional outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.90 [0.41, 39.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Maximum speech discrimination: change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.90 [0.41, 39.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Frequency‐specific changes with PTA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 0.25 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 0.5 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.3 1 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.4 2 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.5 3 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.6 4 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.7 6 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.8 8 kHz</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Intratympanic corticosteroids compared to no treatment/placebo as secondary therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008080-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Combined compared to systemic corticosteroids as secondary treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Proportion improved <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [1.10, 4.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Speech audiometry: additional outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Improvement in speech discrimination score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.41 [1.12, 5.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Combined compared to systemic corticosteroids as secondary treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008080.pub2/references#CD008080-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008080.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD008080-note-0018">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD008080-note-0043">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008080-note-0059">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008080-note-0038">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008080-note-0034">Hrvatski</a> </li> <li class="section-language"> <a class="" href="hu#CD008080-note-0039">Magyar</a> </li> <li class="section-language"> <a class="" href="ja#CD008080-note-0055">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD008080-note-0026">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD008080-note-0030">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD008080-note-0060">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD008080-note-0022">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008080-note-0047">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008080-note-0051">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008080\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008080\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008080\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008080\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008080\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008080\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008080\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008080\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008080\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008080\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008080\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008080\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008080\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008080\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008080\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008080\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008080\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008080\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PMzGcYGP&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008080.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008080.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008080.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008080.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008080.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719264204"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008080.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719264208"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008080.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de47ca9d59368',t:'MTc0MDcxOTI2NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 